Modulators of thr-β and methods of use thereof

THR-β modulators, such as TRα and TRβ receptor agonists/antagonists, address the challenge of halting NAFLD and NASH progression by targeting liver-specific metabolic pathways, offering a therapeutic solution to reverse fibrosis and minimize cardiac side effects.

UA131325C2Active Publication Date: 2026-10-21ALIGOS THERAPEUTICS INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
UA202106384
Authority / Receiving Office
UA · UA
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-04-06
Filing Date
2020-05-07
Publication Date
2026-10-21
Estimated Expiration
2040-05-07

AI Technical Summary

Technical Problem

Current treatments for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) lack effective methods to halt disease progression and reverse fibrosis, which can lead to liver failure and hepatocellular carcinoma.

Method used

Development of THR-β modulators, including compounds that act as agonists or antagonists of thyroid hormone receptors (TRα and/or TRβ), designed to target liver-specific activity and address metabolic disorders.

Benefits of technology

These compounds effectively modulate THR-β activity to treat liver-related disorders, potentially stopping the progression of NAFLD and NASH, and may improve therapeutic indices by minimizing cardiac effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000223_0000
    Figure 00000223_0000
  • Figure 00000224_0000
    Figure 00000224_0000
Patent Text Reader

Abstract

Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds. (IIa) (IIb) (IIIa) (IIIb) (IIIc) (IIId)
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-LINKS TO RELATED APPLICATIONS This application claims priority to prior patent application US No. 63 / 005661, filed 6 April 2020, prior patent application US No. 62 / 944052, filed December 5, 2019, and of the prior patent application US No. 62 / 845252, filed May 8, 2019, a full description of each of which incorporated by reference into this document. ENGINEERING INDUSTRY The present invention relates to the field of pharmaceutical compounds and preparations and a method of their use. in the treatment of diseases. In particular, the present invention relates to the field of THR-β modulators and their application. LEVEL OF TECHNOLOGY In parallel with the global increase in obesity, non-alcoholic fatty liver disease (NAFLD) is becoming a leading cause of chronic liver disease and liver transplantation worldwide [1, 2]. NAFLD is thought to affect 30% of the adult population and 70-80% of those affected obesity and diabetes. NAFLD is defined as excess accumulation of liver fat greater than 5% caused by causes other than alcohol consumption. NAFLD progresses to liver inflammation (nonalcoholic steatohepatitis, NASH) and fibrosis in a different proportion of individuals, which ultimately leads to liver failure and hepatocellular carcinoma (HCC) in susceptible individuals [3]. In the United States alone, NASH is the third most common indication for liver transplantation and is gradually becoming the most common [4]. The most important medical need in patients with NAFLD and NASH is an effective treatment for stopping the progression and possibly reversing fibrosis, which is the main predictor of the development of liver diseases [5, 6]. Thyroid hormone (TH) is essential for normal development, growth, and metabolism of all vertebrates. Its effects are mediated primarily through triiodothyronine (T3), which acts as a ligand for TH receptors (TR, or THR) 1, 2 and α1 [7]. In the absence of ligand, TR initially binds as heterodimer or homodimer with TH response elements (TRE) located in promoter regions regions of target genes where it interacts with corepressors. Upon ligand binding, TR homodimers dissociate in favor of forming a heterodimer with the retinoid-X receptor (RXR), which leads to release of core corepressors and a set of coactivators. This new complex attracts a large the number of proteins that recruit RNA polymerase II to the transcription of target genes. Two different genetic loci, designated THRA and THRB, are responsible for encoding several interrelated TR isoforms that have distinct tissue distributions and biological functions. The two main the isoforms with the widest tissue expression levels are TR1 and TR1 [8]. While initially TR1 is expressed during intrauterine development and is widely expressed in tissues adults, TR1 appears later in development and shows the highest expression in the liver, kidney and in the adult lung [9]. TR1 is a key regulator of cardiac output, while TR1 helps control metabolism in the liver. It is important that the natural thyroid hormone T3 activates both TR1 and TR1 without any significant selectivity. The design of thyromimetic small molecule agents has led to the identification of TR agonists (or THR) with different levels of TR selectivity, despite the high structural similarity between the ligands binding domains for TR and TR. The TR selectivity achieved by some of these compounds has led to to improve the therapeutic index of lipid lowering with respect to cardiac effects such as heart rate heart rate, cardiac hypertrophy and contractility [10-12]. Another strategy to avoid TR activation in cardiac tissue is to develop prodrugs phosphonate-containing TR agonists, which are specifically converted to an active agonist in the liver, but remain stable as inactive prodrugs in the blood and extrahepatic tissues, including the heart

[13] . TR and TR agonists are also used for indications other than disorders related to liver, as was known in the art. ESSENCE OF THE INVENTION This document describes compounds of formula I': (I') TL-La-CE-HD or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, wherein i) TL represents a fragment of formula IIa, IIb, IIIa, IIIb, IIIc or IIId; ii) La independently represents a bond; -(C(Ra)2)n-; oxygen; sulfur; -NRa-iii) CE represents a fragment of formula IV; iv) HD represents a fragment Formula V or VI; wherein the substituents are as defined herein. Also described are pharmaceutical compositions containing the above-mentioned compounds, and methods of treating disease by administration or contact of a patient with one or more of the above-mentioned compounds. (IIa) (IIb) (IIIa) (IIIb) (IIIc) (IIId) (IV) (V) (VI) BRIEF DESCRIPTION OF GRAPHIC MATERIALS Fig. 1 shows the chemical structure of compound 67, confirmed by X-ray crystallography. Fig. 2 shows the chemical structure of compound 67-A, confirmed by X-ray diffraction. crystallography. DETAILED DESCRIPTION OF IMPLEMENTATION OPTIONS This document describes new compounds that are effective modulators of THR-β activity, which can be used to treat various disorders related to THR-β. Below in detail compounds and methods of their use are discussed. Some of the compounds described in this document are agonists, while others are antagonists of TRα and / or TRβ receptors and are used to treat liver-related disorders and other indications known in the art that mediated by TRα and / or TRβ receptors. DEFINITION The various implementation options are described below. It should be noted that specific implementation options are not are intended as an exhaustive description or as a limitation to the broader aspects discussed in This document. One aspect described in conjunction with a specific implementation is not is necessarily limited to this implementation option and can be applied in practice with any another implementation option. As used herein, the term "close" will be understood by those skilled in the art to mean field of technology and will vary to some extent depending on the context in which it is used. If there are uses of a term that are not clear to those skilled in the art, given the context, in In the context in which it is used, "about" means within plus or minus 10% of a particular term. Use of subject terms and similar references in the context of describing elements (especially in the context of the following claims) should be construed both for the singular and the plural, unless otherwise stated in this document or clearly contradicted by the context. Repeating ranges values ​​in this document is only intended to shorten the way to refer to each separately a single value falling within a range, unless otherwise stated in this document, and each a separate value is included in the specification as if it were separately stated in this document. All methods described in this document can be performed in any appropriate order, as long as the unless otherwise stated in this document or clearly contradicted by the context. The use of any and all examples, or examples of language (e.g., "such as") given in this document, are intended only to better illustrate implementation options and does not limit the scope of the claims, unless unless otherwise stated. No wording in the specification should be construed as an indication of any an unexplained element as essential. In the definition of chemical substituents, each of Rx and Ry is independently hydrogen, alkyl, carbocyclic ring, heterocyclic ring, aryl or heteroaryl, all of which, except hydrogen, are optional substituted. Unless otherwise noted, the abbreviations "TR" and "THR" refer to thyroid hormone receptors. glands. As used herein, "pharmaceutically acceptable salt" refers to a salt a compound that does not cause significant irritation in the patient to whom it is administered and does not reverse biological activity and properties of the compound. Pharmaceutical salts can be prepared by reacting a compound, described herein, with an acid or base. Salts formed with a base include, but are not limited to limitation, ammonium salt (NH4+); alkali metal salts such as, without limitation, sodium or potassium; salts alkaline earth metals such as, without limitation, calcium or magnesium; salts of organic bases such as, without limitation, dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine; and salts with amino group of amino acids such as, but not limited to, arginine and lysine. Useful salts are formed with the acid include, without limitation, hydrochlorides, hydrobromides, sulfates, nitrates, phosphates, methanesulfonates, ethanesulfonates, p-toluenesulfonates and salicylates. As used herein, "pharmaceutically acceptable ester" refers to an ester of a compound that does not cause significant irritation in the patient to whom it is administered. Ester metabolized in the body to form the parent compound, e.g., the claimed compound. Accordingly, the ester does not cancel the biological activity and properties of the compound. Pharmaceutical esters can be obtained by reacting a compound described in this document with an alcohol. Common esters, which are to be obtained are methyl, ethyl and isopropyl esters. Other suitable esters are well known. to those skilled in the art (see, for example, Wuts, PGM, Greene's Protective Groups in Organic Synthesis, 5th Ed., John Wiley & Sons, New York, NY, 2014, which is incorporated herein by reference. link in its entirety). If the compounds described in this document have at least one chiral center, they may exist as a racemate or as individual enantiomers. It should be noted that all such isomers and their mixtures are included within the scope of this invention. Thus, an illustration of a chiral center without the designation R or S means that the scope of the description includes the R-isomer, the sec-isomer, the racemic mixture of isomers or mixtures, where one isomer is present in greater quantities than the other. If the processes for preparing the compounds described in this document result in the formation of mixtures stereoisomers, such isomers can be separated by conventional methods such as preparative chiral chromatography. Compounds can be obtained in racemic form or separated Enantiomers can be obtained by stereoselective synthesis or separation. Compounds can be separated into their component enantiomers by standard methods, such as the formation of diastereomeric pairs by forming a salt with an optically active acid, such as (-)-di-p-toluoyl- d-tartaric acid and / or (+)-di-p-toluoyl-1-tartaric acid followed by fractional crystallization and by regeneration of the free base. Compounds can also be separated by the formation of diastereomeric esters or amides with subsequent chromatographic separation and removal of the chiral auxiliary substances. Unless otherwise specified, when a substituent is considered to be "optionally substituted", it is meant that, that the substituent represents a group which may be substituted by one or more groups separately and independently selected, without limitation, from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amide, N-amide, sec- sulfanilamide, N-sulfonamide, C-carboxy, O-carboxy, O-cyanate, thiocyanate, isothiocyanate, nitro, silyl, trihalomethanesulfonyl and amine, including mono- and disubstituted amino groups and their protected forms derivatives. Protecting groups that can form protective derivatives of the above substituents are known. to those skilled in the art and can be found in references such as Wuts, above. As used herein, a "carbocyclic ring" is a ring structure in which all the atoms in the ring are carbon atoms. If any of the atoms in the ring are anything other than a carbon atom, then it is ring is a "heterocyclic ring." Examples of atoms found in the ring include sulfur, oxygen and nitrogen. The carbocyclic ring or heterocyclic ring may be polycyclic, for example, a fused ring system, a spirocyclic ring system, or a bridged ring system. These polycyclic rings include, for example, adamantyl, norbornyl (i.e. bicyclo[2.2.1]heptanyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, etc. Additional non-limiting examples include: , , , , and . As used herein, "aryl" refers to a carbocyclic (fully carbon) ring that has a completely delocalized pi-electron system. The "aryl" group can consist of two or more fused rings (rings that share two adjacent carbon atoms). If the aryl is a fused ring system, then the ring that is connected to the rest of the molecule is has a completely delocalized pi-electron system. Other rings in a condensed ring system may or may not have a fully delocalized pi electron system. Examples of aryl groups include, without limitation, benzene, naphthalene, and azulene radicals. Additional non-limiting examples include: , , and . As used herein, the term "heteroaryl" refers to a ring having a completely a delocalized pi-electron system and contains one or more heteroatoms selected from the group consisting of consists of nitrogen, oxygen and sulfur in a ring. A "heteroaryl" group can consist of two or more fused rings (rings that share two adjacent carbon atoms). If the heteroaryl is a condensed ring system, then the ring connected to the rest of the molecule has a completely delocalized pi-electron system. Other rings in the condensed ring system may have either not have a fully delocalized pi electron system. Examples of heteroaryl rings include, without limitation, furan, thiophene, phthalazinone, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, triazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine and triazine. In any case where "hetero" is used, it means the group as indicated, for example, an alkyl or aryl group where at least one carbon atom is substituted with a heteroatom selected from nitrogen, oxygen and sulfur. As used herein, "alkyl" refers to a straight or branched chain. chain of a fully saturated (without double or triple bonds) hydrocarbon group. Alkyl group of the compounds described may include from 1 to 20 carbon atoms. The alkyl group here may also have average size from 1 to 10 carbon atoms. The alkyl group here can also be lower alkyl, which has from 1 to 5 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n- propyl, isopropyl, n-butyl, i-butyl, sec-butyl, tert-butyl, amyl, tert-amyl, hexyl, heptyl, octyl, nonyl, decyl undecyl and dodecyl. The alkyl group of the compounds described may be substituted or unsubstituted. When substituted, the group(s) The substituents may be one or more groups independently selected from cycloalkyl, aryl, heteroaryl, heteroalicyclyl, hydroxy, protected hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N- thiocarbamoyl, C-amide, N-amide, sec-sulfonamide, N-sulfonamide, C-carboxy, protected C- carboxy, O-carboxy, isocyanate, thiocyanate, isothiocyanate, nitro, silyl, trihalomethanesulfonyl, - NRxRy and protected amine. As used herein, "alkenyl" refers to an alkyl group containing in straight or branched hydrocarbon chain with one or more double bonds. Alkenyl The group of compounds described may be unsubstituted or substituted. When substituted, the substituent(s) may be selected from the same groups described above with respect to substitution by an alkyl group, or with respect to optional substitution. As used herein, "alkynyl" refers to an alkyl group containing straight or branched hydrocarbon chain with one or more triple bonds. Alkynyl The group of compounds described may be unsubstituted or substituted. When substituted, the substituent(s) may be selected from the same groups described above with respect to the substitution of the alkyl group, or with respect to optional substitution. As used herein, "acyl" refers to the group "RxC(=O)-". As used herein, "cycloalkyl" refers to a fully saturated (without double bonds) of a hydrocarbon ring. The cycloalkyl groups of the compounds described herein, may range from C3 to C8. The cycloalkyl group may be unsubstituted or substituted. If it is substituted the substituent(s) may be selected from those specified above in relation to substitution of an alkyl group. A "cycloalkyl" group may consist of two or more condensed rings (rings that share two adjacent carbon atoms). If the cycloalkyl is a fused ring system, then the ring that is connected to the rest of the molecule is a cycloalkyl, as defined above. Other rings in a fused ring system can be cycloalkyl, cycloalkenyl, aryl, heteroaryl or heteroalicycle. As used herein, "cycloalkenyl" refers to a cycloalkyl group which contains one or more double bonds in the ring, although if there is more than one, they cannot form a fully delocalized pi-electron system in the ring (otherwise the group would be "aryl", as (as defined herein). The cycloalkenyl group of the described compounds may be unsubstituted or substituted. When substituted, the substituent(s) may be selected from the same groups described above with respect to substitution of alkyl groups. A "cycloalkenyl" group may consist of two or more condensed rings (rings that share two adjacent carbon atoms). If the cycloalkenyl is a fused ring system, then the ring that is connected to the rest of the molecule is a cycloalkenyl, as defined above. Other rings in the fused ring system may be cycloalkyl, cycloalkenyl, aryl, heteroaryl or heteroalicycle. The term "alkylene" refers to an alkyl group, as defined herein, which is biradical and is linked to two other fragments. Thus, methylene (-CH2-), ethylene (- CH2CH2-), propylene (-CH2CH2CH2-), isopropylene (IUPAC: (methyl)ethylene) (-CH2-CH(CH3)-) and isobutylene (IUPAC: 2-(methyl)propylene) (-CH2-CH(CH3)-CH2-) are examples, without limitation, of an alkylene group. Similarly, the term "cycloalkylene" refers to a cycloalkyl group as defined herein. document, which similarly binds to the other two fragments. If the alkyl and cycloalkyl groups contain unsaturated carbons, the terms "alkenylene" and "cycloalkenylene". As used herein, "heterocycloalkyl", "heteroalicyclic" or "heteroalicyclyl" refers to a ring having one or more heteroatoms in the ring system, independently selected from nitrogen, oxygen and sulfur. The ring may also contain one or more double bonds provided that they do not form a completely delocalized pi-electron system in rings. A ring as defined herein may be a stable 3-8 membered ring which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. The heteroalicyclic groups of the described compounds can be unsubstituted or substituted. If substituted, the substituent(s) may be one or more groups independently selected from the group consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, alkyl, alkoxy, acyl, acyloxy, carboxy, protected carboxy, amine, protected amine, carboxamide, protected carboxamide, alkylsulfonamido and trifluoromethanesulfonamide. A "heterocycloalkyl" group may consist of two or more fused rings (rings that are (share two adjacent carbon atoms). If the heterocycloalkyl is a fused ring system, then the ring that is connected to the rest of the molecule is a heterocycloalkyl as defined above. The other rings in fused ring system can be cycloalkyl, cycloalkenyl, aryl, heteroaryl or heteroalicycle. As used herein, "aralkyl" refers to an alkylene substituted with an aryl group. group. As used herein, "carbocyclic alkyl" or "(carbocyclic)alkyl" refers to an alkylene substituted with a carbocyclic group. As used herein, "heterocycloalkyl" or "(heterocyclic)alkyl" refers to an alkylene substituted with a heterocyclic group. Similarly, "(heterocycloalkyl)alkyl" refers to an alkylene substituted with a heterocycloalkyl group. As used herein, "heteroarylalkyl" or "(heteroaryl)alkyl" refers to to an alkylene substituted with a heteroaryl group. The "O-carboxy" group refers to the "RxC(=O)O-" group. The group "C-carboxy" refers to the group "-C(=O)R". The "acetyl" group refers to the CH3C(=O)- group. The group "C-amido" refers to the group "-C(=O)NRxRy". The "N-amido" group refers to the "RC(=O)NRx-" group. The term "perhaloalkyl" refers to an alkyl group in which all hydrogen atoms are replaced by atoms halogen. Any unsubstituted or monosubstituted amino group in a compound specified in this document, can be converted to an amide, any hydroxyl group can be converted to an ester, and any the carboxyl group can be converted to an amide or ester using methods well known in the art to those skilled in the art (see, for example, Wuts, supra). It is understood that in any compound described herein, compounds having one or multiple chiral centers, if the absolute stereochemistry is not clearly specified, then each center can independently be R or S or a mixture thereof. Furthermore, it is understood that in any compound described in this document, compounds having one or more double bonds forming geometric isomers that can be defined as E or Z, each double bond can independently be E or Z or their mixture. It is understood that the description of a compound herein inherently includes the description of its tautomer if it is possible. For example, the description: N About Rx also includes a description of: and vice versa, even if only one of the two structures is described. Throughout this description, when a compound is illustrated or named, it is understood that it also isotopically enriched analogues of the compound are considered. For example, the compound may contain deuterium instead of hydrogen or carbon-13 instead of carbon with its natural isotopic distribution. Isotopic enrichment can be located in one place in the compound, i.e. only one hydrogen is replaced by deuterium, or in more than one place. This description also covers compounds where all similar atoms are replaced by their less a common isotope, for example, the compound perdeuterium, where all the hydrogen atoms are replaced by deuterium. Isotope-enriched compounds are useful in obtaining NMR spectra or when using isotope effect in controlling the reaction kinetics of the compound undergoing. The term "pharmaceutical composition" refers to a mixture of one or more compounds described in this document, with other chemical components, such as diluents or carriers. A pharmaceutical composition facilitates the introduction of a compound into the body. There are many ways in this art administration of the compound, including, but not limited to, orally, injectable, aerosolized, parenteral and topical administration. Pharmaceutical compositions can also be prepared by interactions of compounds with inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc. The term "carrier" defines a chemical compound that facilitates the introduction of a compound into cells or tissues. For example, dimethyl sulfoxide (DMSO) is a widely used carrier because it facilitates the absorption of many organic compounds into the cells or tissues of the body. The term "diluent" defines chemical compounds diluted in water that dissolve the compound being of interest, and also stabilize the biologically active form of the compound. Salts dissolved in buffer solutions are used as diluents in this field of technology. One of the widely of the buffer solutions used is sodium phosphate buffer solution, as it mimics salt conditions of human blood. Since buffer salts can control the pH of a solution at low concentrations, the buffer diluent rarely alters the biological activity of the compound. In some embodiments, the same substance may act as a carrier, diluent, or excipient, or have any of the two roles, or have all three roles. Thus, one An additive to a pharmaceutical composition can perform several functions. The term "physiologically acceptable" defines a carrier or diluent that does not abolish the biological activity and properties of the compound. COMPOUNDS In one aspect, the present invention provides compounds of formula I: (I) TL-La-CE-HD or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, wherein: i) TL is a fragment of formulae IIa, IIb, IIIa, IIIb, IIIc or IIId; (IIa) (IIb) (IIIa) (IIIb) (IIIc) (IIId) where: each of Q1, Q2, Q3, Q4, Q5, Q6 and Q8, independently represents nitrogen or -CRb-, where each Rb independently represents hydrogen, halogen, or lower alkyl; R1 represents hydrogen, optionally substituted alkyl, optionally substituted carbocyclic group, optionally substituted aryl group, optionally substituted heterocyclic group, an optionally substituted heteroaryl group, an optionally substituted carbocyclic alkyl group, an optionally substituted aralkyl group, an optionally substituted heterocycloalkyl group, optionally substituted heteroarylalkyl group, optionally substituted amino group, optionally a substituted C-carboxy or O-carboxy group, -CN, an optionally substituted carbamoyl group, or an optionally substituted carbamoylalkyl group, where the nitrogen of the carbamoyl or carbamoylalkyl the group optionally represents a heteroatom in the ring structure; R2 represents hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or -CN; R3 represents hydrogen or lower alkyl; R4 represents an optionally substituted alkyl, an optionally substituted carbocyclic group, optionally substituted aryl group, optionally substituted heterocyclic group, optionally a substituted heteroaryl group, optionally a substituted carbocyclic alkyl group, optionally a substituted aralkyl group, optionally a substituted heterocycloalkyl group, optionally substituted heteroarylalkyl group, optionally substituted amino group, optionally substituted a sulfamoyl group, an optionally substituted carbamoyl group, or an optionally substituted a carbamoylalkyl group, where the nitrogen of the carbamoyl or carbamoylalkyl group is optional represents a heteroatom in a ring structure; and R5 represents hydroxy, NH2, alkylamine, alkanoylamine, or alkylsulfonylamine; or R4 and R5 taken together with the carbon atoms to which they are attached form a five- or six- a membered optionally substituted carbocyclic group, an optionally substituted aryl group, an optionally substituted heterocyclic group, or an optionally substituted heteroaryl group; or R4 and R5 taken together with the carbon atoms to which they are attached form from seven to an eleven-membered, optionally substituted spirocyclic ring or a seven- to eleven- a membered, optionally substituted spiro-heterocyclic ring; and Alk represents hydrogen or optionally substituted alkyl; ii) CE is a fragment of formula IV (IV) where: each of R6 and R7 is independently selected from halogen, -CN, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, or cyclopropyl; R8 is selected from hydrogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, cyano, or halogen; optionally R7 and R8, taken together, together with the carbon atoms to which they are attached, form 4, 5- or 6-membered carbocyclic, heterocyclic, aryl, or heteroaryl ring Q7 represents nitrogen or -CRc-, where Rc represents hydrogen, halogen, or lower alkyl; (TL) denotes the point where the moiety of formula IV is attached to TL-La-; and (HD) denotes the point where the moiety of formula IV is attached to -HD; HD is a fragment of formula V or VI: (V) (VI) where: R9 is selected from hydrogen, -(C(Rd)2)nC(Rd)3, -(C(Rd)2)n-ORd, -(C(Rd)2)nN(Rd)2, -(C(Rd)2)nS(=O)qRd, -(C(Rd)2)n-CN, -(C(Rd)2)nC≡C-Rd, -(C(Rd)2)nC(=O)-ORd, -(C(Rd)2)n-HeAr, or -(C(Rd)2)nC(=O)-N(Rd)2; where each Rd independently represents hydrogen or optionally substituted lower alkyl; each q is independently selected from 0, 1, or 2; each n is independently selected from 0, 1, 2, 3, 4, or 5; and HeAr represents a 5- or 6-membered heteroaryl. R10 represents hydrogen, -C(Re)3, where each Re independently represents hydrogen, halogen, or optionally substituted lower alkyl; and R11 represents an aryl group optionally substituted with lower alkyl, halogen, cycloalkyl; or a bicyclic ring system containing either aromatic or saturated rings; or a bicyclic heterocycle containing either aromatic or saturated ring systems La independently represents a bond; -(C(Ra)2)n-; oxygen; sulfur; -NRa-; where: each Ra independently represents hydrogen or lower alkyl; and n represents 0, 1, 2, 3, 4 or 5. In some embodiments, R1 is optionally substituted alkyl, optionally a substituted carbocyclic group, an optionally substituted aryl group, and an optionally substituted C- carboxy or O-carboxy group. In some of these embodiments, the alkyl is selected from the group consisting of consists of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl and tert-butyl. In some In various embodiments, the carbocyclic group is cyclohexane or cyclopentane. In various embodiments, the carbocyclic group is cyclohexane or cyclopentane. In some embodiments, the aryl group is phenyl. In some embodiments, the C-carboxy group is a fragment of the formula -C(=O)-OR and the O-carboxy group is a fragment of the formula -OC(=O)-R, where R is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl and tert-butyl. In some embodiments, R2 is selected from the group consisting of hydrogen, methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl and tert-butyl. In some embodiments, Q1, Q2, Q3, and Q4 are -CRb-, where each Rb is independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso- butyl and tert-butyl. In some embodiments, R4 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl and tert-butyl. In some embodiments, R5 is hydroxy. In some implementations, the TL is a fragment selected from: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or . In some implementations, the TL is a fragment selected from: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or In some embodiments of the compound of formula I, each of R6 and R7 independently represents chlorine, bromine, and iodine. In other embodiments, each of R6 and R7 independently represents -CN, optionally substituted lower alkyl or optionally substituted lower alkoxy, where lower alkyl and alkyl the lower alkoxy group is each independently selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl and tert-butyl. In some embodiments, R6 and R7 are the same. In some embodiments implementation, each of R6 and R7 independently represents chlorine or methyl. In some embodiments of the compound of formula I, R8 is hydrogen. In some embodiments, Rc represents hydrogen or methyl. In some embodiments, described herein are compounds of formula I, wherein: TL represents a fragment of formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; (IIa) (IIb) (IIIa) (IIIb) (IIIc) (IIId) where: each of Q1, Q2, Q3, Q4, Q5, Q6 and Q8, independently represents nitrogen or -CRb-, where each Rb independently represents hydrogen, halogen, or lower alkyl; R1 represents an optionally substituted alkyl, an optionally substituted carbocyclic group, optionally substituted aryl group, optionally substituted heterocyclic group, optionally a substituted heteroaryl group, optionally a substituted carbocyclic alkyl group, optionally a substituted aralkyl group, optionally a substituted heterocycloalkyl group, optionally a substituted heteroarylalkyl group, an optionally substituted amino group, an optionally substituted C- a carboxy or O-carboxy group, -CN, an optionally substituted carbamoyl group, or optionally a substituted carbamoylalkyl group, where the nitrogen of the carbamoyl or carbamoylalkyl group optionally represents a heteroatom in the ring structure; R2 represents halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or -CN; R3 represents hydrogen R4 represents an optionally substituted alkyl, an optionally substituted carbocyclic group, optionally substituted aryl group, optionally substituted heterocyclic group, optionally a substituted heteroaryl group, optionally a substituted carbocyclic alkyl group, optionally a substituted aralkyl group, optionally a substituted heterocycloalkyl group, optionally substituted heteroarylalkyl group, optionally substituted amino group, optionally substituted a sulfamoyl group, an optionally substituted carbamoyl group, or an optionally substituted a carbamoylalkyl group, where the nitrogen of the carbamoyl or carbamoylalkyl group is optional represents a heteroatom in a ring structure; and R5 represents hydroxy, NH2, alkylamine, alkanoylamine, or alkylsulfonylamine; or R4 and R5 taken together with the carbon atoms to which they are attached form a five- or a six-membered optionally substituted carbocyclic group, an optionally substituted aryl group, an optionally substituted heterocyclic group, or an optionally substituted heteroaryl group; or R4 and R5 taken together with the carbon atoms to which they are attached form from seven to an eleven-membered, optionally substituted spirocyclic ring or a seven- to eleven- a membered, optionally substituted spiro-heterocyclic ring; or when Q6 is nitrogen and R5 is hydroxy, then the tautomer of the fragment of formula III; and Alk represents hydrogen or optionally substituted alkyl; CE represents a fragment of formula IV (IV) where: each of R6 and R7 is independently selected from halogen, -CN, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, or cyclopropyl; R8 is selected from hydrogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, cyano, or halogen; Q7 represents nitrogen or -CRc-, where Rc represents hydrogen, halogen, or lower alkyl; (TL) denotes the point where the moiety of formula IV is attached to TL-La-; and (HD) denotes the point where the moiety of formula IV is attached to -HD; HD is a fragment of formula V or VI: (V) (VI) where R9 represents -NH2 and R10 represents -CH3; and La represents oxygen. In other embodiments, described herein are compounds of formula I, wherein: TL is a fragment of formula II: (II) where: each of Q1, Q2, and Q3 independently represents nitrogen or -CRb-, where each Rb independently represents is hydrogen, halogen, or lower alkyl; R1 represents an optionally substituted alkyl, an optionally substituted carbocyclic group, optionally substituted aryl group, optionally substituted heterocyclic group, optionally a substituted heteroaryl group, optionally a substituted carbocyclic alkyl group, optionally a substituted aralkyl group, optionally a substituted heterocycloalkyl group, optionally a substituted heteroarylalkyl group, an optionally substituted amino group, an optionally substituted C- a carboxy or O-carboxy group, -CN, an optionally substituted carbamoyl group, or optionally a substituted carbamoylalkyl group, where the nitrogen of the carbamoyl or carbamoylalkyl group optionally represents a heteroatom in the ring structure; R2 represents halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or -CN; R3 represents hydrogen; CE represents a fragment of formula IV (IV) where: each of R6 and R7 is independently selected from halogen, -CN, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, or cyclopropyl; R8 is selected from hydrogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, cyano, or halogen; Q7 represents nitrogen or -CRc-, where Rc represents hydrogen, halogen, or lower alkyl; (TL) denotes the point where the moiety of formula IV is attached to TL-La-; and (HD) denotes the point where the moiety of formula IV is attached to -HD; HD is a fragment of formula V: (V) where R9 is hydrogen, -CN or -C≡C-Rd, where Rd is hydrogen or lower alkyl; and La represents oxygen. In some embodiments, La is a combination of two or more bonds; -(C(Ra)2)n-; oxygen; sulfur; or -NRa-. In another aspect, the present invention provides compounds of formula I': (I') TL-La-CE-HD or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, a prodrug form thereof, amide or ester, where: i) TL is a fragment of formula IIa, IIb, IIIa, IIIb, IIIc, or IIId: (IIa) (IIb) (IIIa) (IIIb) (IIIc) (IIId) where: each of Q1, Q2, Q3, Q4, Q5, Q6, and Q8, independently represents nitrogen or -CRb-, where each Rb independently represents hydrogen, halogen, or lower alkyl; R1 represents hydrogen, optionally substituted alkyl, optionally substituted non-aromatic carbocyclic group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group, optionally substituted (carbocyclo)alkyl group, optionally substituted aralkyl group, optionally substituted (heterocycloalkyl)alkyl group, optionally substituted (heteroaryl)alkyl group, optionally a substituted amino group, optionally substituted C-carboxy or O-carboxy group, -CN, optionally a substituted carbamoyl group, or an optionally substituted carbamoylalkyl group, where the nitrogen carbamoyl or carbamoylalkyl group optionally represents a heteroatom in the ring structure; R2 represents hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl or -CN; R3 represents hydrogen or lower alkyl; R4 represents optionally substituted alkyl, optionally substituted alkenyl, optionally a substituted non-aromatic carbocyclic group, optionally a substituted aryl group, optionally substituted heterocyclic group, optionally substituted heteroaryl group, optionally substituted (carbocyclo)alkyl group, optionally substituted aralkyl group, optionally substituted (heterocycloalkyl)alkyl group, optionally substituted (heteroaryl)alkyl group, optionally substituted amino group, optionally substituted sulfamoyl group, optionally substituted a carbamoyl group, or an optionally substituted carbamoylalkyl group, where the nitrogen of the carbamoyl or a carbamoylalkyl group optionally represents a heteroatom in the ring structure; and R5 represents hydroxy, NH2, alkylamine, alkanoylamine or alkylsulfonylamine; or R4 and R5 taken together with the carbon atoms to which they are attached form a five- or six- membered optionally substituted non-aromatic carbocyclic group, optionally substituted aryl a group, an optionally substituted heterocyclic group, or an optionally substituted heteroaryl group; or R4 and R5 taken together with the carbon atoms to which they are attached form from seven to an eleven-membered optionally substituted spirocyclic ring or a seven- to eleven-membered optionally substituted spiro-heterocyclic ring; Alk represents hydrogen or optionally substituted alkyl; and R11 represents an aryl group optionally substituted with one to five substituents independently selected from lower alkyl, alkoxy, haloalkoxy, halogen, and cycloalkyl; or a heteroaryl group optionally substituted with one to five substituents independently selected from lower alkyl, alkoxy, haloalkoxy, halogen, and cycloalkyl; or a bicyclic ring system; or a bicyclic heterocyclic ring system; ii) CE is a fragment of formula IV (IV) where: each of R6 and R7 is independently selected from halogen, -CN, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, or cyclopropyl; R8 is selected from hydrogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, cyano, or halogen; optionally R7 and R8 taken together, together with the carbon atoms to which they are attached, form a 4-, 5- or 6-membered non-aromatic carbocyclic, heterocycloalkyl, aryl, or heteroaryl ring Q7 represents nitrogen or -CRc-, where Rc represents hydrogen, halogen, or lower alkyl; (TL) denotes the point where the moiety of formula IV is attached to TL-La-; and (HD) denotes the point where the moiety of formula IV is attached to -HD; iii) HD is a fragment of formula V or VI: (V) (VI) where: R9 is selected from hydrogen, -(C(Rd)2)nC(Rd)3, -(C(Rd)2)n-ORd, -(C(Rd)2)nN(Rd)2, -(C(Rd)2)nS(=O)qRd, -(C(Rd)2)n-CN, -(C(Rd)2)nC≡C-Rd, -(C(Rd)2)nC(=O)-ORd, -(C(Rd)2)n-HeAr, or -(C(Rd)2)nC(=O)-N(Rd)2; where each Rd independently represents hydrogen or optionally substituted lower alkyl; each q is independently selected from 0, 1, or 2; each n is independently selected from 0, 1, 2, 3, 4, or 5; HeAr represents a 5- or 6-membered heteroaryl; and R10 represents hydrogen or -C(Re)3, where each Re independently represents hydrogen, halogen, or optionally substituted lower alkyl; and La independently represents a bond; -(C(Ra)2)z-; oxygen; sulfur; or -NRa-; where: each Ra independently represents hydrogen or lower alkyl; and z represents 0, 1, 2, 3, 4 or 5; provided that: (1) when TL is a moiety of formula IIIa, where Q4, Q5, and Q6 are -CH-, and R4 is is an optionally substituted C1-C3alkyl group, an optionally substituted sulfamoyl group, or an optionally substituted carbamoyl group; HD represents a fragment of formula V, where R9 represents is H or -CN; and Q7 is -CH-, then R5 cannot be hydroxy; (2) when TL is a fragment of formula IIa, where Q1, Q2, and Q3 are -CH-, R1 is is -CH3, and R2 is hydrogen; HD is a fragment of formula V, where R9 is hydrogen; Q7 represents -CH-; R6 represents halogen or methyl; and R7 and R8 taken together, together with with the carbon atoms to which they are attached, form a 5-membered non-aromatic carbocyclic ring, then R4 and R5 taken together with the carbon atoms to which they are attached cannot form a five- a membered heteroaryl group; (3) when TL is a fragment of formula IIIa, where Q4 is nitrogen, Q5 and Q6 are is -CH-, and R5 is -OH; HD is a fragment of formula V, where R9 is -CN; Q7 represents -CH-; La represents -CH2-, then R4 cannot be cyclohexyl, cycloheptyl, isopropyl, or optionally substituted benzene; (4) when TL is a fragment of formula IIIb, where Q4 is -CH- and Q5 is nitrogen; HD represents a fragment of formula V, where R9 represents hydrogen, -CN, or -CO2H; Q7 represents is -CH-; and R6 and R7 are independently halogen or methyl, or R7 and R8 taken together with the atoms carbons to which they are attached form a 5-membered non-aromatic carbocyclic ring, then R4 is not may be isopropyl or 2-hydroxy-1-methyl-ethyl; (5) when TL is a fragment of formula IIIb, where Q4 is -CRc- and Q5 is nitrogen; HD is a moiety of formula V, where R9 is -CN; Q7 is -CH-; and La represents -O-, then (a) none of R6, R7, and R8 can be deuterium; (b) Q4 cannot be -CD-, where D is deuterium; and (c) R4 cannot be a three- to five-membered cycloalkyl ring optionally substituted one or more halogens; non-aromatic (carbocyclo)alkyl optionally substituted methyl or hydroxy; (1H-pyrazol-4-yl)methyl; (3-methylisoxazol-5-yl)methyl; phenyl; benzyl optionally substituted with methyl, halogen, hydroxy, or methoxy; phenethyl optionally substituted with halogen; C1-C4 alkyl optionally substituted with one to six substituents selected from halogen, hydroxyl, and deuterium; (tetrahydro-2H-pyran-4-yl)methyl; or from three to five-membered heterocycloalkyl optionally substituted with benzyl; (6) when TL is a fragment of formula IIIb, where (i) Q4 and Q5 are nitrogen, (ii) Q4 and Q5 are are -CRb-, or (iii) Q4 is nitrogen and Q5 is -CRc-; HD is a fragment of formula V, where R9 is -CN; and Q7 is -CH-; then R4 cannot be -CH(CH3)2 or -CH(CD3)2; (7) when TL is a fragment of formula IIIa, where Q4 is -CH-, Q5 and Q6 are nitrogen, and R4 is isopropyl; HD is a moiety of formula V, where R9 is -CN; and Q7 represents -CH-; then R5 cannot be -NH2 or -NHCH3; (8) when TL is a fragment of formula IIIb, where Q4 is -CH- and Q5 is nitrogen; La is -O-; Q7 is -CH-; and HD is a moiety of formula V, then R9 is not may be methyl; (9) when TL is a fragment of formula IIIb, where Q4 is -CH-, Q5 is nitrogen, and R4 is isopropyl; La is -O-; Q7 is -CH-; and HD is a fragment of formula V, then R9 cannot be isopropyl; (10) when TL is a moiety of formula IIa, where Q1, Q2, and Q3 are -CH-; La is is -O-; Q7 is -CH-; R6 and R7 independently represent chlorine or trifluoromethyl; and HD is a fragment of formula V, where R9 is -CN or methyl, then R1 cannot be isopropyl, 4-tetrahydropyranyl, or -C(O)NH2; (11) when TL is a fragment of formula IIa, where Q1 and Q2 are -CH-, and Q3 is nitrogen; La is -O-; Q7 is -CH-; R6 and R7 are chlorine; and HD is a fragment of formula V where R9 is -CN, then R1 cannot be isopropyl; (12) when TL is a moiety of formula IIb, where Q1, Q2, and Q3 are -CH-; La is is -O-; Q7 is -CH-; R6 and R7 are chlorine; and HD is a fragment of formula V, where R9 represents -CN, then R1 cannot be isopropyl; (13) when TL is a fragment of formula IIIb, where Q4 is -CH- and Q5 is nitrogen; La is -O-; Q7 is -CH-; R6 and R7 are chlorine; and HD is a fragment of formula VI, where R10 is H, Me, Et, isopropyl, -CH2CF3, or -CH2CHF2, then R4 is not may be C2-C5 alkyl or C1-C3 hydroxyalkyl; (14) when TL is a fragment of formula IIIb, where Q4 is -CH- and Q5 is nitrogen; La is -O-; Q7 is -CH-; R6 and R7 are chlorine; and HD is a fragment of formula VI where R10 is H or Me, then R4 cannot be cyclopropyl; and (15) when TL is a fragment of formula IIIb, where Q4 is -CH- and Q5 is nitrogen; La is -CH2-; Q7 is -CH-; R6 and R7 are both chlorine or both are methyl; and HD is a fragment of formula VI, where R10 is H or Me, then R4 cannot be isopropyl. In some embodiments, when TL is a fragment of formula IIIb, where Q4 is - CH- and Q5 represents nitrogen; HD represents a moiety of formula V, where R9 represents -CH2CN or -C≡CH; Q7 is -CH-; and R6 and R7 are chlorine, then R4 cannot be isopropyl. In another aspect, the present invention provides compounds of formula I': (I') TL-La-CE-HD or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, a prodrug form thereof, amide or ester, where: i) TL is a fragment of formula IIa, IIb, IIIa, IIIb, IIIc, or IIId: (IIa) (IIb) (IIIa) (IIIb) (IIIc) (IIId) where: each of Q1, Q2, Q3, Q4, Q5, Q6, and Q8, independently represents nitrogen or -CRb-, where each Rb independently represents hydrogen, halogen, or lower alkyl; R1 represents hydrogen, optionally substituted alkyl, optionally substituted non-aromatic carbocyclic group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group, optionally substituted (carbocyclo)alkyl group, optionally substituted aralkyl group, optionally substituted (heterocycloalkyl)alkyl group, optionally substituted (heteroaryl)alkyl group, optionally a substituted amino group, optionally substituted C-carboxy or O-carboxy group, -CN, optionally a substituted carbamoyl group, or an optionally substituted carbamoylalkyl group, where the nitrogen carbamoyl or carbamoylalkyl group optionally represents a heteroatom in the ring structure; R2 represents hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or -CN; R3 represents hydrogen or lower alkyl; R4 represents optionally substituted alkyl, optionally substituted alkenyl, optionally a substituted non-aromatic carbocyclic group, optionally a substituted aryl group, optionally substituted heterocyclic group, optionally substituted heteroaryl group, optionally substituted (carbocyclo)alkyl group, optionally substituted aralkyl group, optionally substituted (heterocycloalkyl)alkyl group, optionally substituted (heteroaryl)alkyl group, optionally substituted amino group, optionally substituted sulfamoyl group, optionally substituted a carbamoyl group, or an optionally substituted carbamoylalkyl group, where the nitrogen of the carbamoyl or a carbamoylalkyl group optionally represents a heteroatom in the ring structure; and R5 represents hydroxy, NH2, alkylamine, alkanoylamine, or alkylsulfonylamine; or R4 and R5 taken together with the carbon atoms to which they are attached form a five- or six- membered optionally substituted non-aromatic carbocyclic group, optionally substituted aryl a group, an optionally substituted heterocyclic group, or an optionally substituted heteroaryl group; or R4 and R5 taken together with the carbon atoms to which they are attached form from seven to an eleven-membered optionally substituted spirocyclic ring or a seven- to eleven-membered optionally substituted spiro-heterocyclic ring; Alk represents hydrogen or optionally substituted alkyl; and R11 represents an aryl group optionally substituted with one to five substituents independently selected from lower alkyl, alkoxy, haloalkoxy, halogen, and cycloalkyl; or a heteroaryl group optionally substituted with one to five substituents independently selected from lower alkyl, alkoxy, haloalkoxy, halogen, and cycloalkyl; or a bicyclic ring system; or a bicyclic heterocyclic ring system; ii) CE is a fragment of formula IV (IV) where: each of R6 and R7 is independently selected from halogen, -CN, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, or cyclopropyl; R8 is selected from hydrogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, cyano, or halogen; optionally R7 and R8 taken together, together with the carbon atoms to which they are attached, form a 4-, 5- or 6-membered non-aromatic carbocyclic, heterocycloalkyl, aryl, or heteroaryl ring Q7 represents nitrogen or -CRc-, where Rc represents hydrogen, halogen, or lower alkyl; (TL) denotes the point where the moiety of formula IV is attached to TL-La-; and (HD) denotes the point where the moiety of formula IV is attached to -HD; iii) HD is a fragment of formula V or VI: (V) (VI) where: R9 is selected from hydrogen, -(C(Rd)2)nC(Rd)3, -(C(Rd)2)n-ORd, -(C(Rd)2)nN(Rd)2, -(C(Rd)2)nS(=O)qRd, -(C(Rd)2)n-CN, -(C(Rd)2)nC≡C-Rd, -(C(Rd)2)nC(=O)-ORd, -(C(Rd)2)n-HeAr, or -(C(Rd)2)nC(=O)-N(Rd)2; where each Rd independently represents hydrogen or optionally substituted lower alkyl; each q is independently selected from 0, 1, or 2; each n is independently selected from 0, 1, 2, 3, 4, or 5; HeAr represents a 5- or 6-membered heteroaryl; and R10 represents hydrogen or -C(Re)3, where each Re independently represents hydrogen, halogen, or optionally substituted lower alkyl; and (iv) La independently represents a bond; -(C(Ra)2)z-; oxygen; sulfur; or -NRa-; where: each Ra independently represents hydrogen or lower alkyl; and z represents 0, 1, 2, 3, 4 or 5; provided that: (1) when TL is a moiety of formula IIIa, where Q4, Q5, and Q6 are -CH-, and R4 is is an optionally substituted C1-C3alkyl group, an optionally substituted sulfamoyl group, or an optionally substituted carbamoyl group; HD represents a fragment of formula V, where R9 represents is H or -CN; and Q7 is -CH-, then R5 cannot be hydroxy; (2) when TL is a fragment of formula IIa, where Q1, Q2, and Q3 are -CH-, R1 is is -CH3, and R2 is hydrogen; HD is a fragment of formula V, where R9 is hydrogen; Q7 represents -CH-; R6 represents halogen or methyl; and R7 and R8 taken together, together with with the carbon atoms to which they are attached, form a 5-membered non-aromatic carbocyclic ring, then R4 and R5 taken together with the carbon atoms to which they are attached cannot form a five- a membered heteroaryl group; (3) when TL is a fragment of formula IIIa, where Q4 is nitrogen, Q5 and Q6 are is -CH-, and R5 is -OH; HD is a fragment of formula V, where R9 is -CN; Q7 represents -CH-; La represents -CH2-, then R4 cannot be cyclohexyl, cycloheptyl, isopropyl, or optionally substituted benzene; (4) when TL is a fragment of formula IIIb, where Q4 is -CH- and Q5 is nitrogen; HD represents a fragment of formula V, where R9 represents hydrogen, -CN, or -CO2H; Q7 represents is -CH-; and R6 and R7 are independently halogen or methyl, or R7 and R8 taken together with the atoms carbons to which they are attached form a 5-membered non-aromatic carbocyclic ring, then R4 is not may be isopropyl or 2-hydroxy-1-methyl-ethyl; (5) when TL is a fragment of formula IIIb, where Q4 is -CRc- and Q5 is nitrogen; HD is a moiety of formula V, where R9 is -CN; Q7 is -CH-; and La represents -O-, then (a) none of R6, R7, and R8 can be deuterium; (b) Q4 cannot be -CD-, where D is deuterium; and (c) R4 cannot be a three- to five-membered cycloalkyl ring optionally substituted one or more halogens; non-aromatic (carbocyclo)alkyl optionally substituted methyl or hydroxy; (1H-pyrazol-4-yl)methyl; (3-methylisoxazol-5-yl)methyl; phenyl; benzyl optionally substituted with methyl, halogen, hydroxy, or methoxy; phenethyl optionally substituted with halogen; C1-C4 alkyl optionally substituted with one to six substituents selected from halogen, hydroxyl, and deuterium; (tetrahydro-2H-pyran-4-yl)methyl; or from three to five-membered heterocycloalkyl optionally substituted with benzyl; (6) when TL is a fragment of formula IIIb, where (i) Q4 and Q5 are nitrogen, (ii) Q4 and Q5 are are -CRb-, or (iii) Q4 is nitrogen and Q5 is -CRc-; HD is a fragment of formula V, where R9 is -CN; and Q7 is -CH-; then R4 cannot be -CH(CH3)2 or -CH(CD3)2; (7) when TL is a fragment of formula IIIa, where Q4 is -CH-, Q5 and Q6 are nitrogen, and R4 is isopropyl; HD is a moiety of formula V, where R9 is -CN; and Q7 represents -CH-; then R5 cannot be -NH2 or -NHCH3; (8) when TL is a fragment of formula IIIb, where Q4 is -CH- and Q5 is nitrogen; La is -O-; Q7 is -CH-; and HD is a moiety of formula V, then R9 is not may be methyl; (9) when TL is a fragment of formula IIIb, where Q4 is -CH-, Q5 is nitrogen, and R4 is isopropyl; La is -O-; Q7 is -CH-; and HD is a fragment of formula V, then R9 cannot be isopropyl; (10) when TL is a moiety of formula IIa, where Q1, Q2, and Q3 are -CH-; La is is -O-; Q7 is -CH-; R6 and R7 independently represent chlorine or trifluoromethyl; and HD is a fragment of formula V, where R9 is -CN or methyl, then R1 cannot be isopropyl, 4-tetrahydropyranyl, or -C(O)NH2; (11) when TL is a fragment of formula IIa, where Q1 and Q2 are -CH-, and Q3 is nitrogen; La is -O-; Q7 is -CH-; R6 and R7 are chlorine; and HD is a fragment of formula V where R9 is -CN, then R1 cannot be isopropyl; (12) when TL is a moiety of formula IIb, where Q1, Q2, and Q3 are -CH-; La is is -O-; Q7 is -CH-; R6 and R7 are chlorine; and HD is a fragment of formula V, where R9 represents -CN, then R1 cannot be isopropyl; (13) when TL is a fragment of formula IIIb, where Q4 is -CH- and Q5 is nitrogen; La is -O-; Q7 is -CH-; R6 and R7 are chlorine; and HD is a fragment of formula VI, where R10 is H, Me, Et, isopropyl, -CH2CF3, or -CH2CHF2, then R4 is not may be C2-C5 alkyl or C1-C3 hydroxyalkyl; (14) when TL is a fragment of formula IIIb, where Q4 is -CH- and Q5 is nitrogen; La is -O-; Q7 is -CH-; R6 and R7 are chlorine; and HD is a fragment of formula VI, where R10 represents H or Me, then R4 cannot be cyclopropyl; (15) when TL is a fragment of formula IIIb, where Q4 is -CH- and Q5 is nitrogen; La is -CH2-; Q7 is -CH-; R6 and R7 are both chlorine or both are methyl; and HD is a fragment of formula VI, where R10 is H or Me, then R4 cannot be isopropyl alcohol; and (16) when TL is a fragment of formula IIIb, where Q4 is -CH- and Q5 is nitrogen; HD represents a fragment of formula V, where R9 represents -CH2CN or -C≡CH; Q7 represents is -CH-; and R6 and R7 are chlorine, then R4 cannot be isopropyl. In another aspect, the present invention provides compounds of formula I': (I') TL-La-CE-HD or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, a prodrug form thereof, amide or ester, where: i) TL is a fragment of formula IIa, IIb, IIIa, IIIb, IIIc, or IIId: (IIa) (IIb) (IIIa) (IIIb) (IIIc) (IIId) where: each of Q1, Q2, Q3, Q4, Q5, Q6, and Q8, independently represents nitrogen or -CRb-, where each Rb independently represents hydrogen, halogen, or lower alkyl; R1 represents hydrogen, optionally substituted alkyl, optionally substituted non-aromatic carbocyclic group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group, optionally substituted (carbocyclo)alkyl group, optionally substituted aralkyl group, optionally substituted (heterocycloalkyl)alkyl group, optionally substituted (heteroaryl)alkyl group, optionally a substituted amino group, optionally substituted C-carboxy or O-carboxy group, -CN, optionally a substituted carbamoyl group, or an optionally substituted carbamoylalkyl group, where the nitrogen carbamoyl or carbamoylalkyl group optionally represents a heteroatom in the ring structure; R2 represents hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or -CN; R3 represents hydrogen or lower alkyl; R4 represents optionally substituted alkyl, optionally substituted alkenyl, optionally a substituted non-aromatic carbocyclic group, optionally a substituted aryl group, optionally substituted heterocyclic group, optionally substituted heteroaryl group, optionally substituted (carbocyclo)alkyl group, optionally substituted aralkyl group, optionally substituted (heterocycloalkyl)alkyl group, optionally substituted (heteroaryl)alkyl group, optionally substituted amino group, optionally substituted sulfamoyl group, optionally substituted a carbamoyl group, or an optionally substituted carbamoylalkyl group, where the nitrogen of the carbamoyl or a carbamoylalkyl group optionally represents a heteroatom in the ring structure; and R5 represents hydroxy, NH2, alkylamine, alkanoylamine, or alkylsulfonylamine; or R4 and R5 taken together with the carbon atoms to which they are attached form a five- or six- membered optionally substituted non-aromatic carbocyclic group, optionally substituted aryl a group, an optionally substituted heterocyclic group, or an optionally substituted heteroaryl group; or R4 and R5 taken together with the carbon atoms to which they are attached form from seven to an eleven-membered optionally substituted spirocyclic ring or a seven- to eleven-membered optionally substituted spiro-heterocyclic ring; Alk represents hydrogen or optionally substituted alkyl; and R11 represents an aryl group optionally substituted with one to five substituents independently selected from lower alkyl, halogen, and cycloalkyl; or a bicyclic ring system containing either aromatic or saturated rings; or a bicyclic heterocycle containing either aromatic or saturated rings ring systems; ii) CE is a fragment of formula IV (IV) where: each of R6 and R7 is independently selected from halogen, -CN, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, or cyclopropyl; R8 is selected from hydrogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, cyano, or halogen; optionally R7 and R8 taken together, together with the carbon atoms to which they are attached, form a 4-, 5- or 6-membered non-aromatic carbocyclic, heterocycloalkyl, aryl, or heteroaryl ring Q7 represents nitrogen or -CRc-, where Rc represents hydrogen, halogen, or lower alkyl; (TL) denotes the point where the moiety of formula IV is attached to TL-La-; and (HD) denotes the point where the moiety of formula IV is attached to -HD; iii) HD is a fragment of formula V or VI: (V) (VI) where: R9 is selected from hydrogen, -(C(Rd)2)nC(Rd)3, -(C(Rd)2)n-ORd, -(C(Rd)2)nN(Rd)2, -(C(Rd)2)nS(=O)qRd, -(C(Rd)2)n-CN, -(C(Rd)2)nC≡C-Rd, -(C(Rd)2)nC(=O)-ORd, -(C(Rd)2)n-HeAr, or -(C(Rd)2)nC(=O)-N(Rd)2; where each Rd independently represents hydrogen or optionally substituted lower alkyl; each q is independently selected from 0, 1, or 2; each n is independently selected from 0, 1, 2, 3, 4, or 5; HeAr represents a 5- or 6-membered heteroaryl; and R10 represents hydrogen or -C(Re)3, where each Re independently represents hydrogen, halogen, or optionally substituted lower alkyl; and La independently represents a bond; -(C(Ra)2)z-; oxygen; sulfur; or -NRa-; where: each Ra independently represents hydrogen or lower alkyl; and z represents 0, 1, 2, 3, 4 or 5; provided that: (1) when TL is a moiety of formula IIIa, where Q4, Q5, and Q6 are -CH-, and R4 is is an optionally substituted C1-C3alkyl group, an optionally substituted sulfamoyl group, or an optionally substituted carbamoyl group; HD represents a fragment of formula V, where R9 represents is H or -CN; and Q7 is -CH-, then R5 cannot be hydroxy; (2) when TL is a fragment of formula IIa, where Q1, Q2, and Q3 are -CH-, R1 is is -CH3, and R2 is hydrogen; HD is a fragment of formula V, where R9 is hydrogen; Q7 represents -CH-; R6 represents halogen or methyl; and R7 and R8 taken together, together with with the carbon atoms to which they are attached, form a 5-membered non-aromatic carbocyclic ring, then R4 and R5 taken together with the carbon atoms to which they are attached cannot form a five- a membered heteroaryl group; (3) when TL is a fragment of formula IIIa, where Q4 is nitrogen, Q5 and Q6 are is -CH-, and R5 is -OH; HD is a fragment of formula V, where R9 is -CN; Q7 represents -CH-; La represents -CH2-, then R4 cannot be cyclohexyl, cycloheptyl, isopropyl, or optionally substituted benzene; (4) when TL is a fragment of formula IIIb, where Q4 is -CH- and Q5 is nitrogen; HD represents a fragment of formula V, where R9 represents hydrogen, -CN, or -CO2H; Q7 represents is -CH-; and R6 and R7 are independently halogen or methyl, or R7 and R8 taken together with the atoms carbons to which they are attached form a 5-membered non-aromatic carbocyclic ring, then R4 is not may be isopropyl or 2-hydroxy-1-methyl-ethyl; (5) when TL is a fragment of formula IIIb, where Q4 is -CRc- and Q5 is nitrogen; HD is a moiety of formula V, where R9 is -CN; Q7 is -CH-; and La represents -O-, then (a) none of R6, R7, and R8 can be deuterium; (b) Q4 cannot be -CD-, where D is deuterium; and (c) R4 cannot be a three to five membered cycloalkyl ring optionally substituted one or more halogens; C1-C4 alkyl optionally substituted with one to six substituents selected from halogen, hydroxyl, and deuterium; or three- to five-membered heterocycloalkyl; (6) when TL is a fragment of formula IIIb, where (i) Q4 and Q5 are nitrogen, (ii) Q4 and Q5 are are -CRb-, or (iii) Q4 is nitrogen and Q5 is -CRc-; HD is a fragment of formula V, where R9 is -CN; and Q7 is -CH-; then R4 cannot be -CH(CH3)2 or -CH(CD3)2; and (7) when TL is a fragment of formula IIIa, where Q4 is -CH-, Q5 and Q6 are nitrogen, and R4 is isopropyl; HD is a moiety of formula V, where R9 is -CN; and Q7 represents -CH-; then R5 cannot be -NH2 or -NHCH3. In some embodiments, when TL is a fragment of formula IIIb, where Q4 is - CH- and Q5 represents nitrogen; HD represents a moiety of formula V, where R9 represents -CH2CN or -C≡CH; Q7 is -CH-; and R6 and R7 are chlorine, then R4 cannot be isopropyl. In another aspect, the present invention provides compounds of formula I': (I') TL-La-CE-HD or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, a prodrug form thereof, amide or ester, where: i) TL is a fragment of formula IIa, IIb, IIIa, IIIb, IIIc, or IIId: (IIa) (IIb) (IIIa) (IIIb) (IIIc) (IIId) where: each of Q1, Q2, Q3, Q4, Q5, Q6, and Q8, independently represents nitrogen or -CRb-, where each Rb independently represents hydrogen, halogen, or lower alkyl; R1 represents hydrogen, optionally substituted alkyl, optionally substituted non-aromatic carbocyclic group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group, optionally substituted (carbocyclo)alkyl group, optionally substituted aralkyl group, optionally substituted (heterocycloalkyl)alkyl group, optionally substituted (heteroaryl)alkyl group, optionally a substituted amino group, optionally substituted C-carboxy or O-carboxy group, -CN, optionally a substituted carbamoyl group, or an optionally substituted carbamoylalkyl group, where the nitrogen carbamoyl or carbamoylalkyl group optionally represents a heteroatom in the ring structure; R2 represents hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or -CN; R3 represents hydrogen or lower alkyl; R4 represents optionally substituted alkyl, optionally substituted alkenyl, optionally a substituted non-aromatic carbocyclic group, optionally a substituted aryl group, optionally substituted heterocyclic group, optionally substituted heteroaryl group, optionally substituted (carbocyclo)alkyl group, optionally substituted aralkyl group, optionally substituted (heterocycloalkyl)alkyl group, optionally substituted (heteroaryl)alkyl group, optionally substituted amino group, optionally substituted sulfamoyl group, optionally substituted a carbamoyl group, or an optionally substituted carbamoylalkyl group, where the nitrogen of the carbamoyl or a carbamoylalkyl group optionally represents a heteroatom in the ring structure; and R5 represents hydroxy, NH2, alkylamine, alkanoylamine, or alkylsulfonylamine; or R4 and R5 taken together with the carbon atoms to which they are attached form a five- or six- membered optionally substituted non-aromatic carbocyclic group, optionally substituted aryl a group, an optionally substituted heterocyclic group, or an optionally substituted heteroaryl group; or R4 and R5 taken together with the carbon atoms to which they are attached form from seven to an eleven-membered, optionally substituted spirocyclic ring or a seven- to eleven- a membered, optionally substituted spiro-heterocyclic ring; Alk represents hydrogen or optionally substituted alkyl; and R11 represents an aryl group optionally substituted with one to five substituents independently selected from lower alkyl, halogen, and cycloalkyl; or a bicyclic ring system containing either aromatic or saturated rings; or a bicyclic heterocycle containing either aromatic or saturated rings ring systems; ii) CE is a fragment of formula IV (IV) where: each of R6 and R7 is independently selected from halogen, -CN, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, or cyclopropyl; R8 is selected from hydrogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, cyano, or halogen; optionally R7 and R8 taken together, together with the carbon atoms to which they are attached, form a 4-, 5- or 6-membered non-aromatic carbocyclic, heterocycloalkyl, aryl, or heteroaryl ring Q7 represents nitrogen or -CRc-, where Rc represents hydrogen, halogen, or lower alkyl; (TL) denotes the point where the moiety of formula IV is attached to TL-La-; and (HD) denotes the point where the moiety of formula IV is attached to -HD; iii) HD is a fragment of formula V or VI: (V) (VI) where: R9 is selected from hydrogen, -(C(Rd)2)nC(Rd)3, -(C(Rd)2)n-ORd, -(C(Rd)2)nN(Rd)2, -(C(Rd)2)nS(=O)qRd, -(C(Rd)2)n-CN, -(C(Rd)2)nC≡C-Rd, -(C(Rd)2)nC(=O)-ORd, -(C(Rd)2)n-HeAr, or -(C(Rd)2)nC(=O)-N(Rd)2; where each Rd independently represents hydrogen or optionally substituted lower alkyl; each q is independently selected from 0, 1, or 2; each n is independently selected from 0, 1, 2, 3, 4, or 5; HeAr represents a 5- or 6-membered heteroaryl; and R10 represents hydrogen or -C(Re)3, where each Re independently represents hydrogen, halogen, or optionally substituted lower alkyl; and (iv) La independently represents a bond; -(C(Ra)2)z-; oxygen; sulfur; or -NRa-; where: each Ra independently represents hydrogen or lower alkyl; and z represents 0, 1, 2, 3, 4 or 5; provided that: (1) when TL is a moiety of formula IIIa, where Q4, Q5, and Q6 are -CH-, and R4 is is an optionally substituted C1-C3alkyl group, an optionally substituted sulfamoyl group, or an optionally substituted carbamoyl group; HD represents a fragment of formula V, where R9 represents is H or -CN; and Q7 is -CH-, then R5 cannot be hydroxy; (2) when TL is a fragment of formula IIa, where Q1, Q2, and Q3 are -CH-, R1 is is -CH3, and R2 is hydrogen; HD is a fragment of formula V, where R9 is hydrogen; Q7 represents -CH-; R6 represents halogen or methyl; and R7 and R8 taken together, together with with the carbon atoms to which they are attached, form a 5-membered non-aromatic carbocyclic ring, then R4 and R5 taken together with the carbon atoms to which they are attached cannot form a five- a membered heteroaryl group; (3) when TL is a fragment of formula IIIa, where Q4 is nitrogen, Q5 and Q6 are is -CH-, and R5 is -OH; HD is a fragment of formula V, where R9 is -CN; Q7 represents -CH-; La represents -CH2-, then R4 cannot be cyclohexyl, cycloheptyl, isopropyl, or optionally substituted benzene; (4) when TL is a fragment of formula IIIb, where Q4 is -CH- and Q5 is nitrogen; HD represents a moiety of formula V, where R9 represents hydrogen, -CN, -CH2CN, -C≡CH, or -CO2H; Q7 represents -CH-; and R6 and R7 independently represent halogen or methyl, or R7 and R8 are taken together, together with the carbon atoms to which they are attached, form a 5-membered non-aromatic a carbocyclic ring, then R4 cannot be isopropyl or 2-hydroxy-1-methyl-ethyl; (5) when TL is a fragment of formula IIIb, where Q4 is -CRc- and Q5 is nitrogen; HD is a moiety of formula V, where R9 is -CN; Q7 is -CH-; and La represents -O-, then (a) none of R6, R7, and R8 can be deuterium; (b) Q4 cannot be -CD-, where D is deuterium; and (c) R4 cannot be a three to five membered cycloalkyl ring optionally substituted one or more halogens; C1-C4 alkyl optionally substituted with one to six substituents selected from halogen, hydroxyl, and deuterium; or three- to five-membered heterocycloalkyl; (6) when TL is a fragment of formula IIIb, where (i) Q4 and Q5 are nitrogen, (ii) Q4 and Q5 are are -CRb-, or (iii) Q4 is nitrogen and Q5 is -CRc-; HD is a fragment of formula V, where R9 is -CN; and Q7 is -CH-; then R4 cannot be -CH(CH3)2 or -CH(CD3)2; and (7) when TL is a fragment of formula IIIa, where Q4 is -CH-, Q5 and Q6 are nitrogen, and R4 is isopropyl; HD is a moiety of formula V, where R9 is -CN; and Q7 represents -CH-; then R5 cannot be -NH2 or -NHCH3. In some embodiments of the compound of formula I', TL is a fragment of formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; (IIa) (IIb) (IIIa) (IIIb) (IIIc) (IIId) where: each of Q1, Q2, Q3, Q4, Q5, Q6 and Q8, independently represents nitrogen or -CRb-, where each Rb independently represents hydrogen, halogen, or lower alkyl; R1 represents an optionally substituted alkyl, an optionally substituted non-aromatic carbocyclic group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group, optionally substituted (carbocyclo)alkyl group, optionally substituted aralkyl group, optionally substituted (heterocycloalkyl)alkyl group, optionally substituted (heteroaryl)alkyl group, optionally a substituted amino group, optionally substituted C-carboxy or O-carboxy group, -CN, optionally a substituted carbamoyl group, or an optionally substituted carbamoylalkyl group, where the nitrogen carbamoyl or carbamoylalkyl group optionally represents a heteroatom in the ring structure; R2 represents halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or -CN; R3 represents hydrogen; R4 represents an optionally substituted alkyl, an optionally substituted non-aromatic carbocyclic group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group, optionally substituted (carbocyclo)alkyl group, optionally substituted aralkyl group, optionally substituted (heterocycloalkyl)alkyl group, optionally substituted (heteroaryl)alkyl group, optionally substituted amino group, optionally substituted sulfamoyl group, optionally substituted a carbamoyl group, or an optionally substituted carbamoylalkyl group, where the nitrogen of the carbamoyl or a carbamoylalkyl group optionally represents a heteroatom in the ring structure; and R5 represents hydroxy, NH2, alkylamine, alkanoylamine, or alkylsulfonylamine; or R4 and R5 taken together with the carbon atoms to which they are attached form a five- or six- membered optionally substituted non-aromatic carbocyclic group, optionally substituted aryl group, an optionally substituted heterocycloalkyl group, or an optionally substituted heteroaryl group; or R4 and R5 taken together with the carbon atoms to which they are attached form from seven to an eleven-membered, optionally substituted spirocyclic ring or a seven- to eleven- a membered, optionally substituted spiro-heterocyclic ring; and Alk represents hydrogen or optionally substituted alkyl; CE represents a fragment of formula IV (IV) where: each of R6 and R7 is independently selected from halogen, -CN, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, or cyclopropyl; R8 is selected from hydrogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, cyano, or halogen; Q7 represents nitrogen or -CRc-, where Rc represents hydrogen, halogen, or lower alkyl; (TL) denotes the point where the moiety of formula IV is attached to TL-La-; and (HD) denotes the point where the moiety of formula IV is attached to -HD; HD is a fragment of formula V or VI: (V) (VI) where: R9 is selected from -NH2, -CN, -CH2-S-CH3, or -CH2-S(=O)2-CH3; R10 represents -CH3; and La represents oxygen or -CH2-. In some embodiments, the compound of formula I', TL is a fragment of formula IIa: (IIa); and HD is a fragment of formula V: (V). In some embodiments, the compound of formula I': TL is a fragment of formula IIa: (IIa); and HD is a fragment of formula VI: (VI). In some embodiments, the compound of formula I': TL is a fragment of formula IIb: (IIb); and HD is a fragment of formula V: (V). In some embodiments, the compound of formula I': TL is a fragment of formula IIb: (IIb); and HD is a fragment of formula VI: (VI). In some embodiments, the compound of formula I', TL represents a fragment of formula IIIa: (IIIa); and HD is a fragment of formula V: (V). In some embodiments, the compound of formula I', TL represents a fragment of formula IIIa: (IIIa); and HD is a fragment of formula VI: (VI). In some embodiments, the compound of formula I', TL is a fragment of formula IIIb: (IIIb); and HD is a fragment of formula V: (V); where: R9 is selected from hydrogen, -(C(Rd)2)n-ORd, -(C(Rd)2)nN(Rd)2, -(C(Rd)2)nS(=O)qRd, -(C(Rd)2)nC≡C-Rd, - (C(Rd)2)nC(=O)-ORd, -(C(Rd)2)n-HeAr, or -(C(Rd)2)nC(=O)-N(Rd)2; where each Rd independently represents hydrogen or optionally substituted C1-C5 alkyl; each q independently represents 0 or 2; and each n independently represents 0 or 1. In some embodiments, the compound of formula I', TL is a fragment of formula IIIb: (IIIb); and HD is a fragment of formula VI: (VI). In some embodiments, the compound of formula I', TL is a fragment of formula IIIc: (IIIc); and HD is a fragment of formula V: (V). In some embodiments, the compound of formula I', TL is a fragment of formula IIIc: (IIIc); and HD is a fragment of formula VI: (VI). In some embodiments, the compound of formula I', TL is a fragment of formula IIId: (IIId); and HD is a fragment of formula V: (V). In some embodiments, the compound of formula I', TL is a fragment of formula IIId: (IIId); and HD is a fragment of formula VI: (VI). In some embodiments, the compound of formula I', TL is a fragment of formula II: (II) where: each of Q1, Q2, and Q3 independently represents nitrogen or -CRb-, where each Rb independently represents is hydrogen, halogen, or lower alkyl; R1 represents an optionally substituted alkyl, an optionally substituted non-aromatic carbocyclic group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group, optionally substituted (carbocyclo)alkyl group, optionally substituted aralkyl group, optionally substituted (heterocycloalkyl)alkyl group, optionally substituted (heteroaryl)alkyl group, optionally a substituted amino group, optionally substituted C-carboxy or O-carboxy group, -CN, optionally a substituted carbamoyl group, or an optionally substituted carbamoylalkyl group, where the nitrogen carbamoyl or carbamoylalkyl group optionally represents a heteroatom in the ring structure; R2 represents halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or -CN; R3 represents hydrogen; CE represents a fragment of formula IV (IV) where: each of R6 and R7 is independently selected from halogen, -CN, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, or cyclopropyl; R8 is selected from hydrogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, cyano, or halogen; Q7 represents nitrogen or -CRc-, where Rc represents hydrogen, halogen, or lower alkyl; (TL) denotes the point where the moiety of formula IV is attached to TL-La-; and (HD) denotes the point where the moiety of formula IV is attached to -HD; HD is a fragment of formula V: (V) where R9 is hydrogen, -CN, -NH2, -C(Rd)2-S-Rd, -C(Rd)2-S(=O)2Rd, or -C≡C-Rd, where each Rd independently represents hydrogen or lower alkyl; and La represents oxygen or -CH2-. In some embodiments of compounds of formula I', Q1, Q2, Q3, and Q4 are -CRb-, where each Rb is independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl and tert-butyl. In some embodiments of the compounds of formula I', Q1, Q2, and Q3 are itself -CH-. In some embodiments of the compound of formula I', Q1 is -CH-, and Q2 and Q3 are nitrogen. In some embodiments of the compound of formula I', Q2 is -CH-, and Q1 and Q3 are is nitrogen. In some embodiments of the compound of formula I', Q3 is -CH-, and Q1 and Q2 are nitrogen. In some embodiments of the compound of formula I', Q1 is nitrogen, and Q2 and Q3 are -CH-. In some embodiments of the compound of formula I', Q2 is nitrogen, and Q1 and Q3 are is -CH-. In some embodiments of the compound of formula I', Q3 is nitrogen, and Q1 and Q2 are -CH-. In some embodiments of compounds of formula I', Q4, Q5, and Q6 are -CRb-, where each Rb independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl and tert-butyl. In some embodiments of the compounds of formula I', Q4, Q5, and Q6 are itself -CH-. In some embodiments of the compound of formula I', Q4 is -CH-, and Q5 and Q6 are nitrogen. In some embodiments of the compound of formula I', Q5 is -CH-, and Q4 and Q6 are is nitrogen. In some embodiments of the compound of formula I', Q6 is -CH-, and Q4 and Q5 are nitrogen. In some embodiments of the compound of formula I', Q4 is nitrogen, and Q5 and Q6 are -CH-. In some embodiments of the compound of formula I', Q5 is nitrogen, and Q4 and Q6 are is -CH-. In some embodiments of the compound of formula I', Q6 is nitrogen, and Q4 and Q5 are -CH-. In some embodiments of the compound of formula I', Q4 is -CH- and Q5 is nitrogen. In some embodiments of compounds of formula I', Q5 and Q6 are nitrogen. In some embodiments of the compound of formula I', Q5 represents nitrogen and Q8 represents -CH-. In some embodiments of compounds of formula I', Q5, Q6, and Q8 are -CRb-, where each Rb independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl and tert-butyl. In some embodiments of the compounds of formula I', Q5, Q6, and Q8 are itself -CH-. In some embodiments of the compound of formula I', Q5 is -CH-, and Q6 and Q8 are nitrogen. In some embodiments of the compound of formula I', Q6 is -CH-, and Q5 and Q8 are is nitrogen. In some embodiments of the compound of formula I', Q8 is -CH-, and Q5 and Q6 are nitrogen. In some embodiments of the compound of formula I', R1 represents hydrogen, optionally substituted alkyl, optionally substituted non-aromatic carbocyclic group, optionally substituted an aryl group, and an optionally substituted C-carboxy group. In some embodiments, the compound of formula I', alkyl is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl and tert-butyl. In some embodiments of the compound of formula I', at least one atom carbon of the listed alkyl fragments is perfluorinated. In some embodiments compounds of formula I', alkyl is replaced by cycloalkyl or aryl. In some embodiments compounds of formula I', cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentyl, and cyclohexyl. In some embodiments of the compound of formula I', aryl is optionally substituted phenyl. In some embodiments of the compound of formula I', the carbocyclic group is cyclohexane or cyclopentane. In some embodiments of the compound of formula I', the aryl group is is phenyl. In some embodiments of the compound of formula I', the C-carboxy group is a fragment of the formula -C(=O)-OR, where R is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl and tert-butyl. In some embodiments of the compound of formula I', R1 is hydrogen, C1-C6 alkyl, non-aromatic C3-C12 carbocyclic group, C6-C10 aryl group, 3- to 6-membered a heterocycloalkyl group containing from one to four ring heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group, which contains from one to four ring heteroatoms independently selected from oxygen, sulfur or nitrogen, (carbocyclo)alkyl group, aralkyl group, (heterocycloalkyl)alkyl group, (heteroaryl)alkyl group, amino group, C-carboxy or O-carboxy group, -CN, or carbamoyl group; and R1 is optionally substituted with one to five Rk independently selected from the group consisting of consists of hydroxy, halogen, -CN, amine, oxy, O-carboxy, C-carboxy, C-amide, C1-C6 alkoxy, C6- C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl group containing from one up to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to a ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R1 is hydrogen. In some embodiments In embodiments of the compound of formula I', R1 represents -CN. In some embodiments of the compound of formula I', R1 is an optionally substituted C1-C6 alkyl. In some embodiments of the compound of formula I', R1 is C1-C6 alkyl optionally substituted with one to five Rk independently selected from the group consisting of hydroxy, halogen, - CN, Amine, O-Carboxy, C-Carboxy, C-Amide, N-Amide, C1-C6 Alkoxy, C6-C10 Aralkoxy, C3-C9 cycloalkyl, a 3- to 6-membered heterocycloalkyl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to ten-membered a heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R1 is is C1-C6 alkyl. In some embodiments of the compound of formula I', R1 represents an optionally substituted a non-aromatic carbocyclic group. In some embodiments of the compound of formula I', R1 is a non-aromatic C3-C12 carbocyclic group optionally substituted with one to five Rk independently selected from the group consisting of hydroxy, oxo, halogen, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6- a membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R1 represents an optionally substituted aryl group. In some embodiments of the compound of formula I', R1 represents a C6-C10 aryl group optionally substituted with one to five Rk independently selected from the group consisting of hydroxy, halogen, -CN, O-carboxy, C-carboxy, C-amide, N-amide, amine, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl a group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R1 represents an optionally substituted a heterocycloalkyl group. In some embodiments of the compound of formula I', R1 is from 3- to A 6-membered heterocycloalkyl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, where the heterocycloalkyl ring is optionally substituted from one to five Rk independently selected from the group consisting of hydroxy, oxo, halogen, amine, O-Carboxy, C-Carboxy, C-Amide, N-Amide, C1-C6 Alkyl, C1-C6 Haloalkyl, C1-C6 Alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, a 3- to 6-membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to ten a membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R1 represents an optionally substituted a heteroaryl group. In some embodiments of the compound of formula I', R1 is from five to a ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, where the heteroaryl group is optionally substituted by one to five Rk independently selected from the group consisting of hydroxy, halogen, -CN, amine, O- carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, a 3- to 6-membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to ten a membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R1 represents an optionally substituted (carbocyclo)alkyl group. In some embodiments of the compound of formula I', R1 is (cyclopentyl)C1-C6 alkyl, (cyclobutyl)C1-C6 alkyl, (cyclopentyl)C1-C6 alkyl, (cyclohexyl)C1-C6 alkyl, (cycloheptyl)C1-C6 alkyl, (cyclooctyl)C1-C6 alkyl, or (cyclononyl)C1-C6 alkyl, and R1 is optional substituted with one to five Rk independently selected from the group consisting of hydroxy, halogen, - CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from a five- to ten-membered heteroaryl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R1 represents an optionally substituted an aralkyl group. In some embodiments of the compound of formula I', R1 represents a benzyl group optionally substituted with one to five Rk independently selected from the group consisting of hydroxy, halogen, -CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl a group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R1 represents an optionally substituted (heterocycloalkyl)alkyl group. In some embodiments of the compound of formula I', R1 is (heterocycloalkyl)alkyl group optionally substituted with one to five Rk independently selected from the group consisting of hydroxy, oxo, halogen, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1- C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl In some embodiments of the compound of formula I', R1 represents an optionally substituted (heteroaryl)alkyl group. In some embodiments of the compound of formula I', R1 is a (heteroaryl)alkyl group optionally substituted with one to five Rk independently selected from groups consisting of hydroxy, halogen, -CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl In some embodiments of the compound of formula I', R1 represents an optionally substituted amino group. In some embodiments of the compound of formula I', R1 represents an amino group optionally substituted with one or two substituents independently selected from the group consisting of from C1-C6 alkyl, C1-C6 haloalkyl, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, C6-C10 aryl, C-carboxy, C-amide, -(SO2)(C1- C6 alkyl), -C(O)O(C1-C6 alkyl), -C(O)O(C1-C6 haloalkyl), -C(O)O(C3-C9 cycloalkyl), -C(O)O(3- to 6- membered heterocycloalkyl), -C(O)O(five- to ten-membered heteroaryl), and -C(O)O(C6-C10 aryl). In In some embodiments of the compound of formula I', R1 is -NRmRn, where Rm and Rn are independently selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, C6-C10 aryl, C-carboxy, C-amide, -(SO2)(C1-C6 alkyl), -C(O)O(C1-C6 alkyl), -C(O)O(C3-C9 cycloalkyl), - C(O)O(3- to 6-membered heterocycloalkyl), -C(O)O(five- to ten-membered heteroaryl), and - C(O)O(C6-C10 aryl); or Rm and Rn together with the nitrogen to which they are attached form from 3- to 18- a membered heterocycloalkyl ring; and R1 is optionally substituted with one to five Rk independently selected from the group consisting of hydroxy, halogen, -CN, amine, C1-C6 alkyl, O-carboxy, C- carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl In some embodiments of the compound of formula I', R1 represents an optionally substituted C- carboxy group. In some embodiments of the compound of formula I', R1 is -C(O)(C1-C6 alkyl), - C(O)(C3-C9 cycloalkyl), -C(O)(3- to 6-membered heterocycloalkyl), -C(O)(five- to ten- membered heteroaryl), and -C(O)(C6-C10 aryl); and R1 is optionally substituted with one to five Rk independently selected from the group consisting of hydroxy, halogen, -CN, amine, C1-C6 alkyl, O- carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6- a membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R1 is an optionally substituted O- carboxy group. In some embodiments of the compound of formula I', R1 is -OC(O)(C1-C6 alkyl), -OC(O)(C3-C9 cycloalkyl), -OC(O)(3- to 6-membered heterocycloalkyl), -OC(O)(five- to ten- membered heteroaryl), and -OC(O)(C6-C10 aryl); and R1 is optionally substituted with one to five Rk independently selected from the group consisting of hydroxy, halogen, -CN, amine, C1-C6 alkyl, O- carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6- a membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R1 represents an optionally substituted carbamoyl group. In some embodiments of the compound of formula I', R1 is -C(O)NRmRn, where Rm and Rn are independently selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C9 cycloalkyl, from 3- to a 6-membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl; or Rm and Rn together with the nitrogen to which they are attached form a 3- to 18-membered heterocycloalkyl ring; and R1 is optionally substituted with one to five Rk independently selected from the group consisting of hydroxy, halogen, -CN, amine, C1-C6 alkyl, O-carboxy, C- carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl In some embodiments of the compound of formula I', R1 represents hydrogen, optionally substituted C1-C6 alkyl, optionally substituted non-aromatic C3-C12 carbocyclic group, an optionally substituted C6-C10 aryl group, and an optionally substituted C-carboxy group. In some embodiments of the compound of formula I', R1 represents hydrogen, optionally substituted C1-C6 alkyl, optionally substituted non-aromatic C3-C12 carbocyclic group, an optionally substituted C6-C10 aryl group, an optionally substituted C-carboxy group, and an optionally substituted carbamoyl group. In some embodiments of the compound of formula I', R1 is hydrogen; -CN; C1-C6 alkyl; non-aromatic C3-C12 carbocyclic ring; C6-C10 aryl group; 3- to 6-membered a heterocycloalkyl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; a five- to ten-membered heteroaryl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; (carbocyclic)alkyl group; aralkyl group; (heterocycloalkyl)alkyl group; or -C(O)-Rj; where Rj is -NRmRn or -ORm; Rm is hydrogen or C1-C6 alkyl; Rn is C1-C6 alkyl; or Rm and Rn, together with the nitrogen to which they are attached, form a ring structure; and R1 optionally substituted with one to five Rk independently selected from hydroxy, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C6-C10 aralkoxy. In some embodiments of the compound of formula I', R1 is hydrogen, -CN, C1-C6 alkyl; non-aromatic C3-C12 carbocyclic ring; C6-C10 aryl group; 3- to 6-membered a heterocycloalkyl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; a five- to ten-membered heteroaryl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; (carbocyclic)alkyl group; aralkyl group; (heterocycloalkyl)alkyl group; or -C(O)-Rj; where Rj is -NRmRn or -ORm; Rm is hydrogen or C1-C6 alkyl; Rn is C1-C6 alkyl; or Rm and Rn, together with the nitrogen to which they are attached, form a ring structure; and R1 represents is optionally substituted with one to three Rk independently selected from phenyl and haloalkyl. In some embodiments of the compound of formula I', R1 is hydrogen, -CN, C1-C6 alkyl, cyclopentyl, phenyl, (cyclopropyl)alkyl, benzyl, or -C(O)-Rj; where Rj is -NRmRn or -ORm; Rm is hydrogen or C1-C6 alkyl; Rn is C1-C6 alkyl; or Rm and Rn, together with nitrogen, to to which they are attached, form 1,2,3,4-tetrahydroisoquinoline; and R1 is optionally substituted by one up to three Rk independently selected from phenyl and haloalkyl. In some embodiments of the compound of formula I', R1 is hydrogen, -CN, C1-C6 alkyl, cyclopentyl, phenyl, (cyclopropyl)alkyl, benzyl, isopropylamine, or -C(O)-Rj; where Rj is -NRmRn or -ORm; Rm represents hydrogen or C1-C6 alkyl; Rn represents C1-C6 alkyl; or Rm and Rn, together with with the nitrogen to which they are attached, form 1,2,3,4-tetrahydroisoquinoline; and R1 is optionally substituted with one to three Rk independently selected from phenyl and haloalkyl. In some embodiments of the compound of formula I', R2 is hydrogen, halogen, C1-C6 alkyl, C3-C9 cycloalkyl, or -CN; and R2 is optionally substituted with one to five substituents independently selected from the group consisting of hydroxy, halogen, -CN, amine, C1-C6 alkyl, O-carboxy, C- carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl In some embodiments of the compound of formula I', R2 is hydrogen. In some embodiments In some embodiments of the compound of formula I', R2 is halogen. In some embodiments of the compound of formula I', R2 represents -CN. In some embodiments of the compound of formula I', R2 is an optionally substituted C1-C6 alkyl. In some embodiments of the compound of formula I', R2 is C1-C6 alkyl optionally substituted with one to five substituents independently selected from the group consisting of hydroxy, halogen, -CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkyl, C3-C8 cycloalkyl, a 3- to 6-membered heterocycloalkyl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to ten-membered a heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R2 is an optionally substituted C3-C9 cycloalkyl. In some embodiments of the compound of formula I', R2 is C3-C8 cycloalkyl optionally substituted with one to five substituents independently selected from the group consisting of consists of hydroxy, halogen, -CN, amine, C1-C6 alkyl, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments compounds of formula I', R2 represents C3-C9 cycloalkyl optionally substituted with one to ten substituents independently selected from the group consisting of hydroxy, halogen and C1-C6 alkoxy. In some embodiments of the compound of formula I', R2 represents hydrogen or optionally substituted C1-C6 alkyl. In some embodiments of the compounds of formula I', R2 is selected from the group consisting of consists of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl and tert-butyl. In some embodiments of the compound of formula I', R2 is hydrogen; halogen; C1-C6 alkyl optionally substituted with one to five substituents independently selected from the group consisting of consists of hydroxy, halogen and C1-C6 alkoxy; C3-C9 cycloalkyl optionally substituted by one up to ten substituents independently selected from the group consisting of hydroxy, halogen and C1-C6 alkoxy; or -CN. In some embodiments of the compound of formula I', R3 is hydrogen. In some embodiments In embodiments of the compound of formula I', R3 represents lower alkyl. In some embodiments of the compound of formula I', R4 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted non-aromatic carbocyclic group, an optionally substituted aryl group, an optionally substituted heterocycloalkyl group, an optionally substituted heteroaryl group, an optionally substituted (carbocyclo)alkyl group, optionally substituted aralkyl group, or optionally substituted (heterocycloalkyl)alkyl group. In some embodiments of the compound of formula I', R4 is C1-C6 alkyl; C2-C10 alkenyl; non-aromatic C3-C12 carbocyclic ring; C6-C10 aryl group; 3- to 6-membered alkyl a heterocycloalkyl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; a five- to ten-membered heteroaryl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; (carbocyclic)alkyl group; aralkyl group; or (heterocycloalkyl)alkyl group; and R4 optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, CN, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy, C1-C6 haloalkoxy and C6-C10 aralkoxy, or two Rg together with the atoms to which they are attached form an aromatic or non-aromatic 3- to a 6-membered ring optionally containing one or two heteroatoms independently selected from oxygen, sulfur or nitrogen. In some embodiments of the compound of formula I', R4 is C1-C6 alkyl; C2-C10 alkenyl; non-aromatic C3-C12 carbocyclic ring; C6-C10 aryl group; 3- to 6-membered a heterocycloalkyl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; a five- to ten-membered heteroaryl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; (carbocyclic)alkyl group; aralkyl group; or (heterocycloalkyl)alkyl group; and R4 optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy and C6-C10 aralkoxy, or two Rg together with with the atoms to which they are attached, form a ring. In some embodiments of the compound of formula I', R4 is C1-C6 alkyl; C2-C10 alkenyl; non-aromatic C3-C12 carbocyclic ring; 3- to 6-membered heterocycloalkyl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; (carbocyclic)alkyl group; aralkyl group; or (heterocycloalkyl)alkyl group; and R4 optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, CN, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy, C1-C6 haloalkoxy and C6-C10 aralkoxy, or two Rg together with the atoms to which they are attached form an aromatic or non-aromatic 3- to a 6-membered ring optionally containing one or two heteroatoms independently selected from oxygen, sulfur or nitrogen. In some embodiments of the compound of formula I', R4 is C1-C6 alkyl, C2-C10 alkenyl, non-aromatic C3-C12 carbocyclic ring, 3- to 6-membered heterocycloalkyl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a (carbocyclic)alkyl group, an aralkyl group, or a (heterocycloalkyl)alkyl group; and R4 optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy and C6-C10 aralkoxy. In some embodiments of the compound of formula I', R4 is C1-C6 alkyl, C2-C10 alkenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyridazin-3(2H)-one, phenyl, naphthyl, pyridinyl, cinnolinyl, isoquinolinyl, quinolinyl, pyrazolo[1,5-a]pyridinyl, imidazo[1,5-a]pyridinyl, benzo[b]thiophenyl, (cyclobutyl)alkyl group, (cyclopentyl)alkyl group, benzyl group, (tetrahydrofuranyl)alkyl group, or (tetrahydropyranyl)alkyl group; and R4 is optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, CN, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy, C1-C6 haloalkoxy and C6-C10 aralkoxy, or two Rg together with the atoms to which they are attached, form aromatic or non-aromatic 3- to 6-membered ring, optionally containing one or two the heteroatoms are independently selected from oxygen, sulfur or nitrogen. In some embodiments of the compound of formula I', R4 is C1-C6 alkyl, C2-C10 alkenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, (cyclobutyl)alkyl group, (cyclopentyl)alkyl group, benzyl group, (tetrahydrofuranyl)alkyl group, or (tetrahydropyranyl)alkyl group; and R4 is optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy and C6-C10 armethoxy. In some embodiments of the compound of formula I', R4 is optionally substituted alkyl. In some embodiments of the compound of formula I', R4 is an optionally substituted C1-C6 alkyl. In some embodiments of the compound of formula I', R4 is C1-C6 alkyl optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, - CN, Amine, O-Carboxy, C-Carboxy, C-Amide, N-Amide, C6-C10 Aryl, C1-C6 Alkoxy, C6-C10 Aralkoxy, C3- C9 cycloalkyl, a 3- to 6-membered heterocycloalkyl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to ten-membered a heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R4 is is C1-C6 alkyl optionally substituted with one to five Rg independently selected from the group consisting of consists of hydroxy, halogen, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy and C6-C10 aralkoxy. In some In embodiments of the compound of formula I', R4 is selected from the group consisting of methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl and tert-butyl. In some embodiments, the compound of formula I', R4 is C1-C6 alkyl. In some embodiments of the compound of formula I', R4 is C1-C3 alkyl. In some embodiments of the compound of formula I', R4 is C5-C6 alkyl. In some embodiments of the compound of formula I', R4 is an optionally substituted alkenyl. In some embodiments of the compound of formula I', R4 is an optionally substituted C2-C10 alkenyl. In some embodiments of the compound of formula I', R4 is C2-C10 alkenyl optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, -CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, C6-C10 aryl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to a ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments, the compound of formula I', R4 represents C2-C10 alkenyl optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy and C6- C10 aralkoxy. In some embodiments of the compound of formula I', R4 represents an optionally substituted a non-aromatic carbocyclic group. In some embodiments of the compound of formula I', R4 is optionally substituted non-aromatic C3-C12 carbocyclic group. In some embodiments compounds of formula I', R4 represents a non-aromatic C3-C12 carbocyclic group optionally substituted from one to five Rg independently selected from the group consisting of hydroxy, oxo, halogen, CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, C1-C6 alkoxy, C1-C6 haloalkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl, or two Rg together with the atoms to which they are attached form an aromatic or non-aromatic a 3- to 6-membered ring optionally containing one or two heteroatoms independently selected from oxygen, sulfur or nitrogen. In some embodiments of the compound of formula I', R4 is a non-aromatic C3-C12 carbocyclic group optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, oxo, halogen, amine, O-carboxy, C-carboxy, C-amide, N-Amide, C1-C6 Alkyl, C1-C6 Haloalkyl, C6-C10 Aryl, C1-C6 Alkoxy, C6-C10 Arlkoxy, C3-C9 cycloalkyl, a 3- to 6-membered heterocycloalkyl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to ten-membered a heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R4 is is a non-aromatic C3-C12 carbocyclic group optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, CN, C1-C6 alkyl, C6-C10 aryl, C1- C6 alkoxy, C1-C6 haloalkoxy and C6-C10 aralkoxy, or two Rg together with the atoms to which they are attached, form an aromatic or non-aromatic 3- to 6-membered ring, optionally containing one or two heteroatoms are independently selected from oxygen, sulfur, or nitrogen. In some embodiments In embodiments of the compound of formula I', R4 represents a non-aromatic C3-C12 carbocyclic group optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy and C6-C10 armethoxy. In some embodiments of the compound of formula I', R4 represents an optionally substituted a heterocycloalkyl group. In some embodiments of the compound of formula I', R4 is an optionally substituted 3- to 6-membered heterocycloalkyl ring containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; where the heterocycloalkyl ring is optionally substituted with one to five Rg independently selected from groups consisting of hydroxy, oxo, halogen, CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 Alkyl, C1-C6 Haloalkyl, C6-C10 Aryl, C1-C6 Alkoxy, C1-C6 Haloalkoxy, C6-C10 Aralkoxy, C3-C9 cycloalkyl, a 3- to 6-membered heterocycloalkyl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to ten-membered a heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl, or two Rg together with the atoms to which they are attached form aromatic or non-aromatic 3- to 6-membered ring, optionally containing one or two the heteroatoms are independently selected from oxygen, sulfur, or nitrogen. In some embodiments compounds of formula I', R4 represents an optionally substituted 3- to 6-membered heterocycloalkyl a ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; where the heterocycloalkyl ring is optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, oxo, halogen, amine, O-carboxy, C-carboxy, C-amide, N-Amide, C1-C6 Alkyl, C1-C6 Haloalkyl, C6-C10 Aryl, C1-C6 Alkoxy, C6-C10 Arlkoxy, C3-C9 cycloalkyl, a 3- to 6-membered heterocycloalkyl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to ten-membered a heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R4 is is an optionally substituted 3- to 6-membered heterocycloalkyl ring containing from one up to four heteroatoms independently selected from oxygen, sulfur or nitrogen; where the heterocycloalkyl ring is optionally substituted with one to five Rg independently selected from groups consisting of hydroxy, halogen, CN, oxo, C1-C6 alkyl, C6-C10 aryl C1-C6 alkoxy, C1-C6 haloalkoxy and C6-C10 aralkoxy. In some embodiments of the compound of formula I', R4 is an optionally substituted 3- to 6-membered heterocycloalkyl ring containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; where the heterocycloalkyl ring is optionally substituted with one to five Rg independently selected from groups consisting of hydroxy, halogen, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy and C6-C10 aralcox. In some embodiments of the compound of formula I', R4 represents an optionally substituted (carbocyclo)alkyl group. In some embodiments of the compound of formula I', R4 is (cyclopropyl)C1-C6 alkyl, (cyclobutyl)C1-C6 alkyl, (cyclopentyl)C1-C6 alkyl, (cyclohexyl)C1-C6 alkyl, (cycloheptyl)C1-C6 alkyl, (cyclooctyl)C1-C6 alkyl, or (cyclononyl)C1-C6 alkyl, and R4 is optional substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, - CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, C1-C6 alkoxy, C1-C6 haloalkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl, or two Rg together with the atoms to which they are attached form an aromatic or non-aromatic a 3- to 6-membered ring optionally containing one or two heteroatoms independently selected from oxygen, sulfur or nitrogen. In some embodiments of the compound of formula I', R4 is (cyclopropyl)C1-C6 alkyl, (cyclobutyl)C1-C6 alkyl, (cyclopentyl)C1-C6 alkyl, (cyclohexyl)C1-C6 alkyl, (cycloheptyl)C1-C6 alkyl, (cyclooctyl)C1-C6 alkyl, or (cyclononyl)C1-C6 alkyl, and R4 is optional substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, - CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl a group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some In embodiments of the compound of formula I', R4 is (cyclopropyl)C1-C6 alkyl, (cyclobutyl)C1-C6 alkyl, (cyclopentyl)C1-C6 alkyl, (cyclohexyl)C1-C6 alkyl, (cycloheptyl)C1-C6 alkyl, (cyclooctyl)C1-C6 alkyl, or (cyclononyl)C1-C6 alkyl, and R4 is optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy and C6- C10 aralkoxy. In some embodiments of the compound of formula I', R4 represents an optionally substituted an aralkyl group. In some embodiments of the compound of formula I', R4 represents a benzyl group optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, -CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, C1-C6 alkoxy, C1-C6 haloalkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, from 3- to a 6-membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl, or two Rg together with the atoms to which they are attached form an aromatic or a non-aromatic 3- to 6-membered ring, optionally containing one or two heteroatoms independently selected from oxygen, sulfur, or nitrogen. In some embodiments, the compounds of formula I', R4 represents a benzyl group optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, -CN, amine, O-carboxy, C-carboxy, C-amide, N-Amide, C1-C6 Alkyl, C1-C6 Haloalkyl, C6-C10 Aryl, C1-C6 Alkoxy, C6-C10 Arlkoxy, C3-C9 cycloalkyl, a 3- to 6-membered heterocycloalkyl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to ten-membered a heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R4 is is a benzyl group optionally substituted with one to five Rg independently selected from the group, consisting of hydroxy, halogen, CN, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy, C1-C6 haloalkoxy and C6-C10 aralkoxy. In some embodiments of the compound of formula I', R4 represents a benzyl group optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy and C6-C10 aralkoxy. In some embodiments of the compound of formula I', R4 represents an optionally substituted (heterocycloalkyl)alkyl group. In some embodiments of the compound of formula I', R4 is (heterocycloalkyl)alkyl group optionally substituted with one to five Rg independently selected from groups consisting of hydroxy, oxo, halogen, amine, CN, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 Alkyl, C1-C6 Haloalkyl, C6-C10 Aryl, C1-C6 Alkoxy, C1-C6 Haloalkoxy, C6-C10 Aralkoxy, C3-C9 cycloalkyl, a 3- to 6-membered heterocycloalkyl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to ten-membered a heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl, or two Rg together with the atoms to which they are attached form aromatic or non-aromatic 3- to 6-membered ring, optionally containing one or two the heteroatoms are independently selected from oxygen, sulfur, or nitrogen. In some embodiments compounds of formula I', R4 represents a (heterocycloalkyl)alkyl group optionally substituted by one to five Rg independently selected from the group consisting of hydroxy, oxo, halogen, amine, O- carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, C1-C6 alkoxy, C6- C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl group containing from one up to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to a ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments, the compound of formula I', R4 represents a (heterocycloalkyl)alkyl group optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy and C6-C10 aralkoxy. In some embodiments of the compound of formula I', R4 represents an optionally substituted (heteroaryl)alkyl group. In some embodiments of the compound of formula I', R4 is a (heteroaryl)alkyl group optionally substituted with one to five Rg independently selected from groups consisting of hydroxy, halogen, -CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1- C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to a 6-membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl, or two Rg together with the atoms to which they are attached form an aromatic or a non-aromatic 3- to 6-membered ring, optionally containing one or two heteroatoms independently selected from oxygen, sulfur, or nitrogen. In some embodiments, the compounds of formula I', R4 represents a (heteroaryl)alkyl group optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, -CN, amine, O-carboxy, C- carboxy, C-amide, N-amide, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, a 3- to 6-membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to ten a membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compounds of formula I', R4 represents a (heteroaryl)alkyl group optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, CN, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy, C1-C6 haloalkoxy and C6-C10 aralkoxy. In some embodiments of the compound of formula I', R4 is is a (heteroaryl)alkyl group optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy and C6- C10 aralkoxy. In some embodiments of the compound of formula I', R4 represents a C6-C10 aryl group or a five- to ten-membered heteroaryl ring containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; and R4 is optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, CN, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy, C1-C6 haloalkoxy and C6-C10 aralkoxy, or two Rg together with the atoms to which they are attached attached, form an aromatic or non-aromatic 3- to 6-membered ring, which is optional contains one or two heteroatoms independently selected from oxygen, sulfur or nitrogen. In some In embodiments of the compound of formula I', R4 represents a C6-C10 aryl group or a five- to ten- a membered heteroaryl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; and R4 is optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy and C6- C10 aralkoxy. In some embodiments of the compound of formula I', R4 is an optionally substituted C6-C10 an aryl group. In some embodiments of the compound of formula I', R4 represents a C6-C10 aryl group optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, -CN, O-carboxy, C-carboxy, C-amide, N-amide, amine, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, C1-C6 alkoxy, C1-C6 haloalkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl, or two Rg together with the atoms to which they are attached form an aromatic or non-aromatic a 3- to 6-membered ring optionally containing one or two heteroatoms independently selected from oxygen, sulfur or nitrogen. In some embodiments of the compound of formula I', R4 is a C6-C10 aryl group optionally substituted with one to five Rg independently selected from the group consisting of consists of hydroxy, halogen, -CN, O-carboxy, C-carboxy, C-amide, N-amide, amine, C1-C6 alkyl, C1- C6 haloalkyl, C6-C10 aryl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R4 represents a C6-C10 aryl group optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, CN, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy, C1-C6 haloalkoxy and C6-C10 aralkoxy, or two Rg together with the atoms to which they are attached form an aromatic or non-aromatic 3- to a 6-membered ring optionally containing one or two heteroatoms independently selected from oxygen, sulfur or nitrogen. In some embodiments of the compound of formula I', R4 is a C6-C10 aryl group optionally substituted with one to five Rg independently selected from the group consisting of consists of hydroxy, halogen, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy and C6-C10 aralkoxy. In some embodiments of the compound of formula I', R4 is optionally substituted benzene one to five Rg independently selected from the group consisting of hydroxy, halogen, CN, C1-C6 alkyl, C1-C6 alkoxy and C1-C6 haloalkoxy, or two Rg together with the atoms to which they are attached, form an aromatic or non-aromatic 3- to 6-membered ring, optionally containing one or two heteroatoms are independently selected from oxygen, sulfur, or nitrogen. In some embodiments In embodiments of the compound of formula I', R4 represents benzene optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, C1-C6 alkyl and C1-C6 alkoxy, or two Rg together with the atoms to which they are attached form a ring. In some embodiments of the compound of formula I', R4 is optionally naphthalene substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, C1-C6 alkyl and C1-C6 alkoxy. In some embodiments of the compound of formula I', R4 represents an optionally substituted a heteroaryl group. In some embodiments of the compound of formula I', R4 is from five to a ten-membered heteroaryl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, where the heteroaryl ring is optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, -CN, amine, O- carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, C1-C6 alkoxy, C1- C6 haloalkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl, or two Rg together with atoms, to to which they are attached, form an aromatic or non-aromatic 3- to 6-membered ring, which optionally contains one or two heteroatoms independently selected from oxygen, sulfur or nitrogen. In some embodiments of the compound of formula I', R4 is from five to ten a membered heteroaryl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, where the heteroaryl ring is optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, -CN, amine, O-carboxy, C- carboxy, C-amide, N-amide, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, a 3- to 6-membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from five to ten a membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compounds of formula I', R4 is a five- to ten-membered heteroaryl ring containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, where the heteroaryl ring optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, CN, C1-C6 alkyl, C6-C10 aryl, C1-C6 alkoxy, C1-C6 haloalkoxy and C6-C10 aralkoxy. In some embodiments of the compound of formula I', R4 is a five- to ten-membered a heteroaryl ring containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, where the heteroaryl ring is optionally substituted with one to the five Rg are independently selected from the group consisting of hydroxy, halogen, C1-C6 alkyl, C6-C10 aryl, C1-C6 Alkoxy and C6-C10 Aralkoxy. In some embodiments of the compound of formula I', R4 represents an optionally substituted amino group. In some embodiments of the compound of formula I', R4 represents an amino group optionally substituted with one or two substituents independently selected from the group consisting of from C1-C6 alkyl, C1-C6 haloalkyl, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, C6-C10 aryl, C-carboxy, C-amide, -(SO2)(C1- C6 alkyl), -C(O)O(C1-C6 alkyl), -C(O)O(C1-C6 haloalkyl), -C(O)O(C3-C9 cycloalkyl), -C(O)O(3- to 6- membered heterocycloalkyl), -C(O)O(five- to ten-membered heteroaryl), and -C(O)O(C6-C10 aryl). In In some embodiments of the compound of formula I', R4 is -NRmRn, where Rm and Rn are independently selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, C6-C10 aryl, C-carboxy, C-amide, -(SO2)(C1-C6 alkyl), -C(O)O(C1-C6 alkyl), -C(O)O(C3-C9 cycloalkyl), - C(O)O(3- to 6-membered heterocycloalkyl), -C(O)O(five- to ten-membered heteroaryl), and - C(O)O(C6-C10 aryl); or Rm and Rn together with the nitrogen to which they are attached form from 3- to 18- a membered heterocycloalkyl ring; and R1 is optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, -CN, amine, C1-C6 alkyl, O-carboxy, C- carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl In some embodiments of the compound of formula I', R4 represents an optionally substituted a sulfamoyl group. In some embodiments of the compound of formula I', R4 is -SO2NRmRn, where Rm and Rn are independently selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C9 cycloalkyl, from a 3- to 6-membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl; or Rm and Rn together with the nitrogen to which they are attached form a 3- to 18-membered heterocycloalkyl ring; and R1 is optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, -CN, amine, C1-C6 alkyl, O-carboxy, C- carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl In some embodiments of the compound of formula I', R4 represents an optionally substituted carbamoyl group. In some embodiments of the compound of formula I', R4 is -C(O)NRmRn, where Rm and Rn are independently selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C9 cycloalkyl, from 3- to a 6-membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl; or Rm and Rn together with the nitrogen to which they are attached form a 3- to 18-membered heterocycloalkyl ring; and R1 is optionally substituted with one to five Rg independently selected from the group consisting of hydroxy, halogen, -CN, amine, C1-C6 alkyl, O-carboxy, C- carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl In some embodiments of the compound of formula I', R5 is hydroxy. In some embodiments In embodiments of the compound of formula I', R5 represents NH2. In some embodiments of the compound of formula I', R5 is alkylamine. In some embodiments In embodiments of the compound of formula I', R5 is -NRuRv, where Ru is hydrogen or C1-C6 alkyl and Rv is C1-C12 alkyl optionally substituted with one to five substituents independently selected from the group consisting of hydroxy, halogen, -CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl a group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R5 is an alkanoylamine. In some In embodiments of the compound of formula I', R5 is -NRuC(O)Rv, where Ru is hydrogen or C1-C6 alkyl and Rv is C1-C12 alkyl optionally substituted with one to five substituents independently selected from the group consisting of hydroxy, halogen, -CN, amine, O-carboxy, C- carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl In some embodiments of the compound of formula I', R5 is alkylsulfonylamine. In some In embodiments of the compound of formula I', R5 is -NRuSO2Rv, where Ru is hydrogen or C1-C6 alkyl and Rv is C1-C12 alkyl optionally substituted with one to five substituents independently selected from the group consisting of hydroxy, halogen, -CN, amine, O-carboxy, C- carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl In some embodiments of the compound of formula I', R5 is hydroxy or NH2. In some In embodiments of the compound of formula I', R5 is hydroxy, NH2, C1-C6 alkylamine, C1-C6 alkanoylamine, or C1-C6 alkylsulfonylamine. In some embodiments of the compounds of formula I', R4 and R5 are taken together with the carbon atoms to which they are attached, forming a five- or six-membered optionally substituted non-aromatic C3-C12 carbocyclic group, optionally substituted C6-C10 aryl group, optionally substituted a heterocyclic group, or an optionally substituted heteroaryl group. In some embodiments compounds of formula I', R4 and R5 taken together with the carbon atoms to which they are attached form a five- or a six-membered non-aromatic C3-C12 carbocyclic group, a C6-C10 aryl group, a 4- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, where carbocyclic group, aryl group, heterocycloalkyl group, and heteroaryl group optionally substituted with one to five substituents independently selected from the group consisting of hydroxy, halogen, -CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from a five- to ten-membered heteroaryl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compounds of formula I', R4 and R5 are taken together with the carbon atoms to which they are attached, forming a seven- to eleven-membered, optionally substituted spirocyclic ring or a seven- to eleven-membered, optionally substituted spiro-heterocyclic ring. In In some embodiments of the compounds of formula I', R4 and R5 are taken together with the carbon atoms to which they are attached. attached, form a seven- to eleven-membered, spirocyclic ring or a seven- to eleven-membered spiro-heterocyclic ring; and spirocyclic ring and spiro-heterocyclic ring optionally substituted with one to five substituents independently selected from the group consisting of consists of hydroxy, halogen, -CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl In some embodiments of the compounds of formula I', R4 and R5 are taken together with the carbon atoms to which they are attached, forming a five- or six-membered optionally substituted non-aromatic carbocyclic group, optionally substituted aryl group, optionally substituted a heterocycloalkyl group, or an optionally substituted heteroaryl group. In some embodiments of the compounds of formula I', R4 and R5 are taken together with the carbon atoms to which they are attached, forming a five- or six-membered non-aromatic carbocyclic group; C6-C10 an aryl group; a 3- to 6-membered heterocycloalkyl ring containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; or a five- to ten-membered a heteroaryl ring containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; and where the carbocyclic group, aryl group, heterocycloalkyl ring and heteroaryl ring are optionally substituted with one to five Rg independently selected from a group consisting of hydroxy, halogen, C1-C6 alkyl, C1-C6 alkoxy, and oxo, and / or optionally two Rg together with the atom(s) to which they are attached form a 3- to 6-membered carbocyclic group. In some embodiments of the compounds of formula I', R4 and R5 are taken together with the carbon atoms to which they are attached, forming a 3- to 6-membered heterocycloalkyl ring containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; and where the heterocycloalkyl ring is optionally substituted with one to five Rg independently selected from a group consisting of C1-C6 alkyl and oxo, and / or optionally two Rg together with the atom(s) to which they are attached they are attached to form a 3- to 6-membered non-aromatic carbocyclic group. In some embodiments of the compounds of formula I', R4 and R5 are taken together with the carbon atoms to which they are attached, forming a pyrrolidine optionally substituted with one to five Rg independently selected from the group consisting of C1-C6 alkyl and oxo, and / or optionally two Rg together with with the atom(s) to which they are attached form a 3- to 6-membered non-aromatic carbocyclic group. In some embodiments of the compound of formula I', TL is a fragment of formula IIIaa: (IIIaa); wherein each Rg independently represents C1-C6 alkyl; or two Rg together with the atom to which they are attached attached to form an alkene optionally substituted with C1-C6 alkyl; or two Rg together with an atom to to which they are attached to form a 3- to 6-membered non-aromatic carbocyclic group. In some In embodiments of the compound of formula I', the two Rg together with the atom to which they are attached form a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group. In some embodiments of the compound of formula I', TL is a fragment of formula IIIaa: (IIIaa); where each Rg independently represents C1-C6 alkyl or two Rg together with the atom(s) to which they are attached attached form a 3- to 6-membered non-aromatic carbocyclic group. In some embodiments realization of the compound of formula I', the two Rg together with the atom to which they are attached form a cyclopentyl group or a cyclohexyl group. In some embodiments of the compound of formula I', TL is a fragment of formula IIIab: (IIIab); where Rg is C1-C6 alkyl. In some embodiments of the compound of formula I', Rg is isopropyl In some embodiments of the compound of formula I', TL is a fragment of formula IIIac: (IIIac); where Rg is C1-C6 alkyl. In some embodiments of the compound of formula I', Rg is methyl. In some embodiments of the compound of formula I', TL is a fragment of formula IIIad: (IIIad); where each Rg independently represents hydrogen or C1-C6 alkyl. In some embodiments of the compound of formula I', R4 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted non-aromatic carbocyclic group, an optionally substituted aryl group, an optionally substituted heterocycloalkyl group, an optionally substituted heteroaryl group, an optionally substituted (carbocyclo)alkyl group, an optionally substituted aralkyl group, an optionally substituted (heterocycloalkyl)alkyl group, an optionally substituted (heteroaryl)alkyl group, or an optionally substituted carbamoyl group; and R5 represents hydroxy, NH2, alkylamine, alkanoylamine, or alkylsulfonylamine. In some embodiments of the compound of formula I', R4 is C1-C6 alkyl; C2-C10 alkenyl; non-aromatic C3-C12 carbocyclic ring, C6-C10 aryl group; 3- to 6-membered a heterocycloalkyl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; a five- to ten-membered heteroaryl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; (carbocyclic)alkyl group; aralkyl group; (heterocycloalkyl)alkyl group; a (heteroaryl)alkyl group; or -C(O)NRmRn; Rm and Rn are independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C2- C6 alkoxy, C6-C10 aryl group; 3- to 6-membered heterocycloalkyl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; from five to up to ten-membered heteroaryl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; a (carbocyclic)alkyl group; an aralkyl group; (heterocycloalkyl)alkyl group; or (heteroaryl)alkyl group; or Rm and Rn together with nitrogen to which they are attached to form a 3- to 18-membered heterocycloalkyl ring; and R4 is optionally substituted with one to five Rg independently selected from the group, consisting of hydroxy, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, C1-C6 alkoxy and C6- C10 aralkoxy; and R5 represents hydroxy, NH2, alkylamine, alkanoylamine, or alkylsulfonylamine. In some embodiments of the compound of formula I', R4 is C1-C6 alkyl; C2-C10 alkenyl; non-aromatic C3-C12 carbocyclic ring, C6-C10 aryl group; 3- to 6-membered a heterocycloalkyl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; a five- to ten-membered heteroaryl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; (carbocyclic)alkyl group; aralkyl group; (heterocycloalkyl)alkyl group; a (heteroaryl)alkyl group; or -C(O)NRmRn; Rm and Rn are independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C2- C6 alkoxy, C6-C10 aryl group; 3- to 6-membered heterocycloalkyl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; from five to up to ten-membered heteroaryl ring containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen; a (carbocyclic)alkyl group; an aralkyl group; (heterocycloalkyl)alkyl group; or (heteroaryl)alkyl group; or Rm and Rn together with nitrogen to which they are attached to form a 3- to 18-membered heterocycloalkyl ring; and R4 is optionally substituted with one to five Rg independently selected from the group consisting of from hydroxy, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, C1-C6 alkoxy and C6-C10 aralkoxy; and R5 represents hydroxy. In some embodiments of the compound of formula I', Alk represents hydrogen or optionally substituted C1-C6 alkyl. In some embodiments of the compound of formula I', Alk is hydrogen or C1-C6 alkyl optionally substituted with one to five substituents independently selected from the group, consisting of hydroxy, halogen, -CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from a five- to ten-membered heteroaryl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments compounds of formula I', Alk represents hydrogen. In some embodiments of compounds of formula I', Alk is C1-C6 alkyl optionally substituted with one to five substituents independently selected from the group consisting of hydroxy, halogen, -CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl a group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some In embodiments of the compound of formula I', Alk is C1-C6 alkyl optionally substituted by one to five substituents independently selected from the group consisting of hydroxy, halogen and C1-C6 alkoxy. In some embodiments of the compound of formula I', R11 represents an aryl group optionally substituted with one to five substituents independently selected from lower alkyl, alkoxy, haloalkoxy, halogen and C3-C9 cycloalkyl; or a heteroaryl group optionally substituted by one up to five substituents independently selected from lower alkyl, alkoxy, haloalkoxy, halogen, and cycloalkyl; or a bicyclic ring system containing either aromatic or saturated rings; or a bicyclic heterocyclic ring system containing either aromatic or saturated ring systems. In some embodiments of the compound of formula I', R11 represents an aryl group optionally substituted with one to five substituents independently selected from lower alkyl, halogen and C3-C9 cycloalkyl; or a bicyclic ring system containing either aromatic or saturated rings; or a bicyclic heterocyclic ring system containing either aromatic or saturated ring systems. In some embodiments of the compound of formula I', R11 represents a C6-C10 aryl group optionally substituted with one to five substituents independently selected from lower alkyl, alkoxy, haloalkoxy, halogen and C3-C9 cycloalkyl; or a five- to ten-membered heteroaryl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, wherein the heteroaryl group is optionally substituted with one to five substituents independently selected from lower alkyl, alkoxy, haloalkoxy, halogen and C3-C9 cycloalkyl; or from 7 to 12 a bicyclic ring system containing either aromatic or saturated rings; or a 7- to 12-membered a membered bicyclic heterocyclic ring system containing either aromatic or saturated ring members system. In some embodiments of the compound of formula I', R11 represents a C6-C10 aryl group optionally substituted with one to five substituents independently selected from lower alkyl, halogen and C3-C9 cycloalkyl; or a 7- to 12-membered bicyclic ring system containing either aromatic or saturated rings; or a 7- to 12-membered bicyclic heterocyclic ring system, containing either aromatic or saturated ring systems. In some embodiments, the compound of formula I', R11 represents a C6-C10 aryl group optionally substituted with one to five substituents independently selected from lower alkyl, alkoxy, haloalkoxy, halogen and C3-C9 cycloalkyl. In some embodiments of the compound of formula I', R11 represents a C6-C10 aryl group optionally substituted with one to five substituents independently selected from lower alkyl, halogen and C3-C9 cycloalkyl. In some embodiments of the compounds of formula I', R11 is from five to a ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, where the heteroaryl group is optionally substituted by one to five substituents independently selected from lower alkyl, alkoxy, haloalkoxy, halogen and C3-C9 cycloalkyl. In some embodiments of the compound of formula I', R11 is from 7- to 12- a membered bicyclic ring system containing either aromatic or saturated rings. In some In embodiments of the compound of formula I', R11 is a 7- to 12-membered bicyclic a heterocyclic ring system containing either aromatic or saturated ring systems. In some In embodiments of the compound of formula I', R11 represents benzene optionally substituted with one up to five substituents independently selected from C1-C5 alkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, halogen and C3-C9 cycloalkyl; pyridine optionally substituted with C1-C5 alkyl; cinnoline; isoquinoline; quinoline; pyrazolo[1,5-a]pyridine; imidazo[1,5-a]pyridine; benz[b]thiophene; chroman; 1,2,3,4-tetrahydronaphthalene; or naphthalene. In some embodiments of the compound of formula I', R11 is benzene optionally substituted with one to five substituents independently selected from C1-C5 alkyl, halogen and C3-C9 cycloalkyl; 1,2,3,4-tetrahydronaphthalene; or naphthalene. In some embodiments of the compound of formula I', each of R6 and R7 independently represents halogen. or C1-C5 alkyl optionally substituted with one to five substituents independently selected from hydroxy, halogen, and C1-C6 alkoxy; and R8 is hydrogen; or R6 is halogen or C1-C5 alkyl optionally substituted with one to five substituents independently selected from hydroxy, halogen and C1-C6 alkoxy; and R7 and R8 taken together, together with the carbon atoms to which they are attached, form a 4-, 5- or 6-membered carbocyclic ring. In some embodiments of the compound of formula I', each of R6 and R7 independently represents chlorine, bromine and iodine. In some embodiments of the compound of formula I', each of R6 and R7 independently represents - CN, optionally substituted lower alkyl or optionally substituted lower alkoxy, where lower alkyl and each alkyl group of lower alkoxy is independently selected from methyl, ethyl, n-propyl, iso- propyl, n-butyl, sec-butyl and tert-butyl. In some embodiments of the compound of formula I', R6 and R7 In some embodiments of the compound of formula I', each of R6 and R7 independently represents chlorine or methyl. In some embodiments of the compound of formula I', R6 is Cl, R7 is Cl, and R8 is hydrogen. In some embodiments of the compound of formula I', R6 is Cl, R7 is is Cl, and R8 is methyl. In some embodiments of the compound of formula I', R6 is is halogen and R7 and R8 taken together, together with the carbon atoms to which they are attached, form a 4- membered carbocyclic ring. In some embodiments of the compound of formula I', R8 is hydrogen. In some embodiments In some embodiments of the compound of formula I', R8 is optionally substituted lower alkyl. In some embodiments of the compound of formula I', R8 is optionally substituted lower alkyl. In embodiments of the compound of formula I', R8 represents lower alkyl optionally substituted by one to five substituents selected from the group consisting of hydroxy, halogen, amine, -CN, O- carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkoxy, C3-C5 cycloalkyl, 3- to 5-membered a heterocycloalkyl group containing one heteroatom independently selected from oxygen, sulfur, or nitrogen. In some embodiments of the compound of formula I', R8 is optionally substituted lower alkoxy. In some embodiments of the compound of formula I', R8 is lower alkoxy optionally substituted with one to five substituents selected from the group consisting of hydroxy, halogen, amine, -CN, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkoxy, C3-C5 cycloalkyl, a 3- to 5-membered heterocycloalkyl group containing one heteroatom independently selected from oxygen, sulfur or nitrogen. In some embodiments of the compounds of formula I', R8 is cyano. In some embodiments of the compound of formula I', R8 is halogen. In some embodiments of the compounds of formula I', R7 and R8 are taken together, together with the carbon atoms, to to which they are attached, form a 4-, 5- or 6-membered non-aromatic carbocycle, a 3- to 5-membered heterocycloalkyl, C6-C10 aryl, or a five- to ten-membered heteroaryl ring. In some embodiments of the compound of formula I', Q7 is nitrogen. In some embodiments In some embodiments of the compound of formula I', Q7 is -CRc-. In some embodiments of the compound of formula I', Rc is hydrogen. In some embodiments of the compound of formula I', Rc is halogen. In some embodiments of the compound of formula I', Rc is lower alkyl. In some embodiments In some embodiments of the compound of formula I', Rc is hydrogen or methyl. In some embodiments compounds of formula I', Q7 represents -CH-. In some embodiments of the compound of formula I', R9 is hydrogen, -(C(Rd)2)nN(Rd)2, -(C(Rd)2)n-CN or -(C(Rd)2)nC≡C-Rd. In some embodiments of the compound of formula I', R9 is hydrogen, -(CH2)nN(Rd)2, -(CH2)n-CN or -(CH2)nC≡C-Rd. In some embodiments, the compound of formula I', R9 are selected from hydrogen, -N(Rd)2, -CN or -C≡C-Rd. In some embodiments, the compound of formula I', R9 are selected from hydrogen, -NH2, -CN or -C≡CH. In some embodiments of the compound of formula I', R9 is hydrogen. In some embodiments In some embodiments of the compound of formula I', R9 is -(C(Rd)2)nC(Rd)3. In some embodiments of the compound of formula I', R9 is -(C(Rd)2)n-ORd. In some embodiments of the compound of formula I', R9 is is -(C(Rd)2)nN(Rd)2. In some embodiments of the compound of formula I', R9 is -NH2. In In some embodiments of the compound of formula I', R9 is -(C(Rd)2)nS(=O)qRd. In some In some embodiments of the compound of formula I', R9 is -(C(Rd)2)n-CN. In some embodiments compounds of formula I', R9 is -CN. In some embodiments of compounds of formula I', R9 is is -(C(Rd)2)nC≡C-Rd. In some embodiments of the compound of formula I', R9 is -C≡CH. In In some embodiments of the compound of formula I', R9 is -(C(Rd)2)nC(=O)-ORd. In some embodiments of the compound of formula I', R9 is -(C(Rd)2)nC(=O)-ORd. In some embodiments of the compound of formula I', R9 is -(C(Rd)2)n-HeAr. In some embodiments compounds of formula I', R9 represents -(C(Rd)2)nC(=O)-N(Rd)2. In some embodiments of the compound of formula I', each Rd independently represents hydrogen or lower alkyl optionally substituted with one to five substituents independently selected from the group, consisting of hydroxy, halogen, -CN, amine, O-carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, from a five- to ten-membered heteroaryl group containing one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments compounds of formula I', each Rd represents hydrogen. In some embodiments of compounds of formula I', each Rd independently represents lower alkyl optionally substituted with one to five substituents independently selected from the group consisting of hydroxy, halogen, -CN, amine, O- carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6- a membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', q represents 0. In some embodiments compounds of formula I', q represents 1. In some embodiments of compounds of formula I', q represents 2. In some embodiments of the compound of formula I', n represents 0. In some embodiments compounds of formula I', n represents 1. In some embodiments of compounds of formula I', n represents 2. In some embodiments of the compound of formula I', n is 3. In some embodiments compounds of formula I', n represents 4. In some embodiments of compounds of formula I', n represents 5. In some embodiments of the compound of formula I', HeAr is a 5- or 6-membered a heteroaryl group containing from one to three ring heteroatoms independently selected from oxygen, sulfur or nitrogen. In some embodiments of the compound of formula I', R10 is hydrogen or -C(Re)3, where each Re independently represents hydrogen, halogen, or lower alkyl optionally substituted with one to five substituents independently selected from the group consisting of hydroxy, halogen, -CN, amine, O- carboxy, C-carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6- a membered heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group, which contains from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R10 is hydrogen. In some In embodiments of the compound of formula I', R10 is -C(Re)3, where each Re independently is hydrogen, halogen, or lower alkyl optionally substituted with one to five substituents independently selected from the group consisting of hydroxy, halogen, -CN, amine, O-carboxy, C- carboxy, C-amide, N-amide, C1-C6 alkoxy, C6-C10 aralkoxy, C3-C9 cycloalkyl, 3- to 6-membered a heterocycloalkyl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, a five- to ten-membered heteroaryl group containing from one to four heteroatoms independently selected from oxygen, sulfur or nitrogen, and C6-C10 aryl. In some embodiments of the compound of formula I', R10 is -C(Re)3, where each Re independently represents hydrogen, halogen, or lower alkyl. In some embodiments, the compound of formula I', R10 represents hydrogen, -CHF2, -CH3, or ethyl. In some embodiments of the compound of formula I', La represents a bond; -(C(Ra)2)z-; oxygen; sulfur; or -NRa-. In some embodiments of the compound of formula I', La represents a bond. In In some embodiments of the compound of formula I', La is -(C(Ra)2)z-. In some embodiments In some embodiments of the compound of formula I', La is -CH2-. In some embodiments of the compound of formula I', La is oxygen. In some embodiments of the compound of formula I', La is sulfur. In In some embodiments of the compound of formula I', La is -NRa-. In some embodiments compounds of formula I', each Ra represents hydrogen. In some embodiments of compounds of formula I', each Ra independently represents lower alkyl. In some embodiments of the compounds of formula I', each Ra independently represents hydrogen or lower alkyl. In some embodiments of the compound of formula I', z represents 0. In some embodiments compounds of formula I', z represents 1. In some embodiments of compounds of formula I', z represents 2. In some embodiments of the compound of formula I', z is 3. In some embodiments compounds of formula I', z represents 4. In some embodiments of compounds of formula I', z represents 5. In another aspect, described herein is a compound selected from the group consisting of: , , , , , , , , , , , N H N Cl About About Cl N N NH About About CN12, , , , , , , , , , , , , , , , , , , , , , , , , , , , , N H N Cl About About Cl N N NH O O NH 2 39-A або 39-В , N N Cl O O Cl N N NH O O NH 239-A або 39-В H , , , , , , , , , , , , , , , , , , , , , , , N Cl O O Cl N NH O O NH 2 F F N N 61-A або 61-В H , N Cl O O Cl N NH O O NH 2 F F N N 61-A або 61-В H , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , N Cl Oh Oh Cl N NH Oh Oh NH 2 N N CN H trans 105 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , N Cl O O Cl N NH O O NH 2 N N H 163 або 164 , N Cl O O Cl N NH O O NH 2 N N H 163 або 164 , N Cl O O Cl N NH O O NH 2 N N H 165 або 166 , N Cl O O Cl N NH O O NH 2 N N H 165 або 166 , N Cl O O Cl N N NH N O N About H 167 or 168 H , N Cl About About Cl N N N About N About NH 2 H 167 or 168 H , N Cl About About Cl N N N About N About NH 2 H 169 or 170 H , N Cl About About Cl N N N About N About NH 2 H 169 or 170 H , , , , , and . SYNTHESIS OF COMPOUNDS The compounds described herein were synthesized using general synthetic techniques, outlined in diagrams 1-10 below. The execution of each separately illustrated stage belongs to the skills of an ordinary person of ordinary skill in the art, who also knows how to modify the techniques synthesis from the schemes below to synthesize the full range of compounds described in this document. The synthesis procedure for individual compounds is given below in the Examples section. As described in Scheme 1, the aromatic amino compound of formula S-II is transformed into the aza- of uracil of formula S-III, first by forming the corresponding diazonium salt, and then by reaction with N-(2- cyanoacetyl)-carbamate and, finally, cyclization to obtain the compound of formula S-III. Then the nitrile of formula S-III is hydrolyzed to a carboxylic acid compound of formula S-IV. The compound of formula S-IV then reacts with diphenylphosphoryl azide (DPPA) to give the compound of formula SV. Finally, the protection of the compound of formula SV is removed. Scheme 1 As described in Scheme 2, the aromatic amino compound of formula S-II can be converted to the compound of boronic acid of formula S-VII first by forming a diazonium salt, and then reacting with tetrahydroxydiborane. The appropriate boronic acid is then coupled to the appropriate protected (with the protecting group "PG") bromo-azauracil compound of formula Int-I. The resulting bromide the compound of formula S-VIII is further converted, either by a substitution reaction or by reactions, transition metal catalyzed reactions as shown in the Examples section below. Removal of the protecting group "PG" results in a compound of formula SX. Scheme 2 The synthesis of the aromatic amino compound of formula S-XIV is described in Scheme 3. Compound of formula S-XI reacts with a compound of formula S-XII ("X" represents a halogen such as F or Cl) with the following protection with a protecting group "PG" to obtain a compound of formula S-XIII. Reduction nitrofunctional compounds of formula S-XIII leads to the production of an aromatic amino compound formulas S-XIV. Scheme 3 Scheme 4 describes the synthesis of the compound of formula S-XIX. By the transmetalation reaction of the compound of formula S-XVI ("X" in the structure represents a halogen, for example, Br or I) is the addition of a general aldehyde of formula S-XV to obtain an alcohol compound of formula S-XVII, which is then reduced to the compound of formula S-XVIII. Deprotection of PG2 of the compound of formula S-XVIII results in the preparation of the compound formulas S-XIX. Scheme 4 As described in Scheme 5, the compound of formula S-XX is prepared by condensing the compound of formula S- VII with a bromide compound of formula Int-II. Scheme 5 Scheme 6a depicts an alternative synthesis of compounds of general formula S-XIX. The compound of formula S- XXI (where the structure represents a halogen, e.g. Cl, Br or I) condenses with a compound of formula S- XXII in a Suzuki-type coupling to give a compound of formula S-XXIII. A protecting group PG3, for example the benzyl moiety can then be removed to give the compound of formula S-XXIV. The resulting the phenol functionality can then be replaced with a triflate group to give the compound of general formula S-XXV. The -OTf group can then be replaced by a -NH2 moiety via the reaction, transition metal catalyzed reaction, such as the Buchwald condensation, for example, with tertiary butylcarbamate or benzophenoneimine, followed by deprotection to give the compound of general formula S-XIX. The method described in scheme 6a can also be used when as starting material, indazole halide is used instead of S-XXI. Alternatively, halide indazole can undergo lithium-halogen exchange. The resulting aryllithium compounds can react with with an aldehyde of type S-XXVIII to form compounds of formula S-XXIX. Further developments of the structures of formula S-XXIX are described in Scheme 7. Scheme 6a Scheme 6b depicts the synthesis of a compound of formula S-XXII from a compound of formula S-XXVI in a Suzuki reaction with 4,4,5,5-tetramethyl-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl]-1,3,2-dioxaborolane. Scheme 6b Scheme 7 describes the synthesis of the compound of formula S-XXXI. By the transmetalation reaction of the compound of formula S-XXVII ("X" in the structure represents a halogen, e.g. Br or I) is added to an aldehyde of general formula S-XXVIII to obtain an alcohol compound of formula S-XXIX, which is then reduced to the compound of formula S-XXX. Deprotection of PG2 of the compound of formula S-XXX results in the preparation of compounds of formula S-XXXI. Scheme 7 Scheme 8 describes the general synthesis of compounds of formula S-XXI and their products. When R1, for example, represents is hydrogen and Y is hydrogen, then R1 can be converted to the corresponding acyl group using hydrochloric acid and a Lewis acid (e.g., InBr3) in a nonpolar aprotic solvent (e.g., dichloroethane). The newly formed ketone group can be partially reduced to alcohol or completely reduced to the corresponding alkane. Further transformations of the ketone group obvious to those skilled in the art. In the second example, where R1 is hydrogen and Y is is a suitable protecting group (e.g. tosyl), then R1 can be converted to the iodide by using an iodizing agent (e.g., NIS) using available literature methods. Scheme 8 Q 3 Q 2 Q 1 N X R1 R2 Y Q 3 Q 2 Q 1 N X R1 R2 Y S-XXI S-XXIa R1=acyl, substituted alkyl, halogen Scheme 9 describes the general synthesis of compounds of formula S-XXXIII. 4-Bromo-6-chloropyridazin-3-amine can be converted to the corresponding 4-aryl-6-chloropyridazin-3-amine (S-XXXII) using, for example, ArB(OH)2 (e.g., phenylboronic acid) and a palladium catalyst (e.g., PdCl2(PPh3)2) under typical Suzuki-Miyaura conditions. Further conversion of the amino group to Cl under typical Sandmeyer reaction conditions (e.g. CuCl2, tert-Bu-ONO, acetonitrile, heating) gives compounds of the type S- XXXIII. Scheme 9 Scheme 10 describes the general synthesis of compounds of formula S-XXXVI. Compounds of formula S-XXXIV can be condensed with phenol HO-CE-HD during a Cu(I)-mediated condensation reaction in DMSO with base (e.g., K2CO3) at elevated temperature to give intermediate products of the S-type XXXV. Further hydrolysis of chloropyridazine using acetic acid and acetate salt (e.g. NaOAc) gives products of formula S-XXXVI, where the desired regioisomer can be isolated. In In the context of Scheme 10, the HD group may contain a common protecting group that can be cleaved at the step intermediates S-XXXV or at the end of the synthesis to obtain compounds of formula S-XXXVI. Scheme 10 The synthesis of compounds of formula S-XXXVII can be carried out using literature methods. For example, an alkynyl ester can be coupled to a protected aniline using a Ru catalyst as follows: conditions described in Org. Lett. 2014, 16, 3568−3571 to obtain 6-bromoquinolones. Alternatively, compounds of formula S-XXXVII can be formed by other methods described in the literature, including, without limitation, the following examples: (a) Kadnikov, DV; et al. J. Org. Chem. 2004, 69, 6772. (b) Manley, PJ; et al. Org. Lett. 2004, 6, 2433. (c) Jia, C.; Piao, D.; et al. J. Org. Chem. 2000, 65, 7516. (d) Inamoto, K.; et al. J. Org. Chem. 2010, 75, 3900. (e) Ferguson, J.; et al. Org. Lett. 2013, 15, 1998. (f) Fan, H; Org. Lett. 2018, 20, 7929−7932. Alternatively, Scheme 11 depicts the synthesis of compounds of formula S-XXXVII, which can be obtained by starting with a dihalogenated aminaryl (S-XXXVII-a). The amine is then protected (e.g., trimethylacetamide) to give the amide intermediate (S-XXXVII-b). Under strongly basic conditions (e.g., n-buLi, THF) S-XXXVII-b reacts with an aldehyde containing the desired Rg substitution, with obtaining the alcohol product S-XXXVI-c, which is oxidized (using a conventional oxidant; e.g. Dess-Martin reagent) in the next step, to give ketone S-XXXVII-d. Ketone reacts in an aldol-type reaction with a protected ester (e.g., tert-butyl) to give intermediate S-XXXVII-e. At the final stage, intramolecular cyclization with obtaining a compound of formula S-XXXVII. Scheme 11 The incorporation of compounds of formula S-XXXVII to form the final products can occur by using similar methods described in Schemes 6a and 6b. There are several ways to access compounds of formula XXXVIII, including, without limitation, methods that are given in the following references or referred to in this document: (a) Hajra, S; et al. Org. Lett. 2018, 20, 4540−4544. (b) Zaytsev, S. et al. Journal of Organic Chemistry (2018), 83(15), 8695-8709. (c) Wu, C; et al. Organic Letters (2014), 16(7), 1960-1963. (d) Ye, N; et al. ACS Infect Dis. 2016, 2(6), 382-392. The incorporation of compounds of formula S-XXXVIII into the formation of final products can occur by using similar methods described in Schemes 6a and 6b. As described in Scheme 12, the compound of formula S-XXXIX is prepared by condensation of the compound of formula S-VII with an azauracil compound of formula Int-A. The protection can then be deprotected from of benzyloxymethyl acetal using various methods described in the literature. Scheme 12 PHARMACEUTICAL COMPOSITIONS In another aspect, the present document describes pharmaceutical compositions comprising, essentially, or consisting of a compound as described herein and at least one pharmaceutically acceptable excipient. In another aspect, the present document describes pharmaceutical compositions comprising a compound of formula I as described herein, and a pharmaceutically acceptable diluent, an auxiliary substance or carrier. In some embodiments, pharmaceutical compositions described herein compositions comprising, essentially, or consisting of a compound of formula I as described herein, and at least one pharmaceutically acceptable diluent, excipient or carrier. In another aspect, the present document describes pharmaceutical compositions comprising, essentially, or consisting of a compound of formula I' as described herein, and at least one pharmaceutically acceptable acceptable excipient. The pharmaceutical composition described herein may contain a pharmaceutically acceptable an acceptable carrier such as diluents, disintegrants, sweeteners, glidants or flavorings, and can be formulated into an oral dosage form such as tablets, capsules, powders, granules, suspensions, emulsions, or syrups; or a parenteral dosage form such as liquids for external use, suspensions for external use, emulsions for external use applications, gels (ointments or similar), inhalations, sprays, injections, etc. The indicated dosages forms can be manufactured in different forms, for example, a dosage form for single use or multiple injection. The pharmaceutical composition described herein may include excipients such as: such as lactose, corn starch or the like, glidants such as magnesium stearate, etc., emulsifiers, suspending agents, stabilizers and isotonic agents, etc. Optionally, there may be sweetener and / or flavoring added. Exemplary excipients include, but are not limited to, polyethylene glycol (PEG), hydrogenated castor oil (HCO), cremophores, carbohydrates, starches (e.g. corn starch), inorganic salts, antimicrobial agents, antioxidants, binders / fillers, surfactants, lubricants (e.g. stearate calcium or magnesium), glidants such as talc, disintegrants, diluents, buffers, acids, bases, film coatings, their combinations, etc. Specific carbohydrate excipients include, for example: monosaccharides such as fructose, maltose, galactose, glucose, D-mannose, sorbose, etc.; disaccharides such as lactose, sucrose, trehalose, cellobiose, etc.; polysaccharides such as raffinose, melezitose, maltodextrins, dextrans, starches, etc.; and alditols such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranosylsorbitol, myoinositol, etc. Inorganic salts or buffers include, without limitation, citric acid, sodium chloride, chloride potassium, sodium sulfate, potassium nitrate, monobasic sodium phosphate, dibasic sodium phosphate and their combinations. Suitable antioxidants for use herein include, for example, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphoric acid, monothioglycerol, propyl gallate, sodium bisulfite, sodium formaldehyde sulfoxylate, metabisulfite sodium and their combinations. Additional examples of excipients include surfactants such as polysorbates, such as "Tween 20" and "Tween 80", and pluronics such as F68 and F88 (both of which available from BASF, Mount Olive, NJ), sorbitan esters, lipids (e.g., phospholipids such as lecithin and other phosphatidylcholines, and phosphatidylethanolamines), fatty acids and fatty esters, steroids, such like cholesterol, and chelating agents such as EDTA, zinc, and other similar cations. In addition, the composition described herein may optionally include one or more acids or bases. Non-limiting examples of acids that can be used include acids, selected from the group consisting of hydrochloric acid, acetic acid, phosphoric acid, citric acid, malic acid, lactic acid, formic acid, trichloroacetic acid, nitric acid, perchloric acid, phosphoric acid, sulfuric acid, fumaric acid, and their combinations. Non-limiting examples of suitable bases include bases selected from the group consisting of consists of sodium hydroxide, sodium acetate, ammonium hydroxide, potassium hydroxide, ammonium acetate, potassium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium formate, sodium sulfate, potassium sulfate, potassium fumarate, and combinations thereof. The amount of any individual excipient in a formulation will vary depending on its role. excipient, dosage requirements for active ingredient components and special needs composition. However, typically the excipient will be present in the composition in an amount of from about 1% to about 99% by weight, preferably from about 5% to about 98% by weight, more preferably from about 15% to about 95% by weight of the excipient. In general, the amount of excipient of the substance present in the composition of the disclosure is selected from the following: at least about 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or even 95% by weight. The pharmaceutical compositions described herein can be administered to a human patient themselves. by themselves or in pharmaceutical compositions where they are mixed with other active ingredients, as in combination therapy, or with suitable carriers or excipients. Methods The formulation and introduction of the compounds of this application can be found in "Remington's Pharmaceutical Sciences", Mack Publishing Co., Easton, Pa., 18 edition, 1990. Suitable routes of administration may, for example, include oral, transdermal, rectal, transmucosal or enteral administration; parenteral administration, including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as inhalation, intrathecal, direct intraventricular, intraperitoneal, intranasal or intraocular injections. The pharmaceutical compositions described herein can be prepared by known methods, for example, by conventional mixing, dissolving, granulating, dragee making, levigation, emulsification, encapsulation, entrapment or tableting. These pharmaceutical compositions can be formulated in the usual way using one or more known physiologically acceptable carriers containing excipients and / or adjuvants that facilitate processing of active compounds into preparations that can be used pharmaceutically. Any of well-known techniques, carriers and excipients may be used as appropriate and understood in the art; for example, in Remington's Pharmaceutical Sciences, supra. Pharmaceutical compositions suitable for use in the presently described formulations, include compositions where the active ingredients are contained in an amount effective to achieve the purpose. More specifically, a therapeutically effective amount means an amount of a compound effective for preventing, relieving, or improving symptoms of a disease or prolonging survival subject being treated. In some embodiments, a therapeutically effective amount means an amount of the compound effective to alleviate or ameliorate the symptoms of the disease or prolonging the survival of the subject being treated. Although the exact dose can vary depending on the medicine, in most cases it is possible to make some generalizations regarding dosage. Daily dosage regimen for an adult patient human may comprise, for example, an oral dose of from 0.001 mg to 1000 mg of each ingredient, preferably from 0.01 mg to 500 mg, for example from 1 to 200 mg, or each active ingredient a pharmaceutical composition described herein, or a pharmaceutically acceptable salt thereof, calculated as the free base or free acid, the composition is administered 1-4 times a day or week. Alternatively, the compositions described herein may be administered continuously, for example, with prolonged, delayed or slow release, preferably in a dose of each ingredient up to 500 mg per day. Thus, the total daily dose when administered orally of each ingredient will typically range from 0.1 mg to 2000 mg. Treatment methods In another aspect, the present document describes methods of treating a disorder associated with thyroid hormone receptor, in a patient, a method comprising, consisting essentially of or consists of the stages of identifying a patient who needs treatment for a disorder related to thyroid hormone receptor, and administering to the patient or contacting the patient with compounds, as described in this document. In another aspect, the present document describes methods of treating a disorder associated with thyroid hormone receptor, in a patient, a method comprising, consisting essentially of or consists of the stages of identifying a patient who needs treatment for a disorder related to thyroid hormone receptor, and administering to the patient or contacting the patient with the compound of formula I as described herein. In some embodiments, the method of treating a disorder, thyroid hormone receptor-bound, in a patient, consisting essentially of or consists of the stages of identifying a patient who needs treatment for a disorder related to thyroid hormone receptor, and administering to the patient or contacting the patient with the compound of formula I as described herein. In another aspect, the present document describes methods of treating a disorder associated with thyroid hormone receptor, in a patient, a method comprising, consisting essentially of or consists of the stages of identifying a patient who needs treatment for a disorder related to thyroid hormone receptor, and administering to the patient or contacting the patient with the compound of formula I' as described herein. In some implementations, a healthcare professional, such as a physician, physician assistant, paramedic, or similar, identifies an individual who needs treatment for a hormone receptor-related disorder thyroid gland, and / or a candidate for treatment with a compound described herein. Identification may be based on medical test results, insensitivity to other methods treatment, first-line therapy, specific nature of the particular liver disorder, etc. In some embodiments, the thyroid hormone receptor disorder is selected from nonalcoholic steatohepatitis (NASH), obesity, hyperlipidemia, hypercholesterolemia, diabetes, fatty liver, atherosclerosis, cardiovascular disease, hypothyroidism and thyroid cancer glands. In another aspect, methods of treating a disorder or disease in humans are described herein. subject in need thereof, a method comprising, consisting essentially of, or consisting of introducing to a subject a therapeutically effective amount of a compound or composition described herein, wherein a disorder or disease selected from nonalcoholic steatohepatitis (NASH), obesity, hyperlipidemia, hypercholesterolemia, diabetes, fatty liver, atherosclerosis, cardiovascular diseases, hypothyroidism and thyroid cancer. In another aspect, the present document describes methods of treating NASH in a subject suffering from it. requires, a method that includes, consists essentially of, or consists of introducing a subject a therapeutically effective amount of a compound or composition described herein. In another aspect, the present document describes methods of treating obesity in a subject who is requires, a method that includes, consists essentially of, or consists of introducing a subject a therapeutically effective amount of a compound or composition described herein. In another aspect, the present disclosure provides methods for treating hyperlipidemia in a subject, which requires, a method that includes, consists essentially of, or consists of introducing the subject a therapeutically effective amount of a compound or composition described herein. In another aspect, the present disclosure provides methods for treating hypercholesterolemia in a subject, which requires it, a method that includes, consists essentially of, or consists of introducing the subject a therapeutically effective amount of a compound or composition described herein. In another aspect, the present document describes methods of treating diabetes in a subject suffering from it. requires, a method that includes, consists essentially of, or consists of introducing a subject a therapeutically effective amount of a compound or composition described herein. In another aspect, described herein are methods of treating hepatic steatosis in a subject who requires, a method that includes, consists essentially of, or consists of introducing the subject a therapeutically effective amount of a compound or composition described herein. In another aspect, methods for selectively modulating beta-1 activity are described herein. thyroid hormone receptor (THR-β), comprising, consisting essentially of, or consisting of contacting a compound described herein with a thyroid hormone receptor B In some embodiments, the contacting occurs in vitro or ex vivo, while in other embodiments, implementation, contacting occurs in vivo. In another aspect, methods for selectively modulating beta-1 activity are described herein. thyroid hormone receptor (THR-β) comprising contacting a compound of formula I as described herein, with a thyroid hormone receptor. In some embodiments, contacting occurs in vitro or ex vivo, while in other embodiments, contacting occurs in vivo. In some embodiments, the method of selectively modulating beta- thyroid hormone receptor (THR-β) consists essentially of, or consists of, contacting compounds of formula I, as described herein, with the thyroid hormone receptor. In another aspect, methods for selectively modulating beta-1 activity are described herein. thyroid hormone receptor (THR-β), comprising, consisting essentially of, or consisting of by contacting a compound of formula I', as described herein, with a hormone receptor thyroid gland. In some embodiments, the contacting occurs in vitro or ex vivo, then as in other embodiments, the contacting occurs in vivo. In another aspect, methods for selectively modulating beta-1 activity are described herein. thyroid hormone receptor (THR-β), comprising, consisting essentially of, or consisting of by contacting the composition described herein with a thyroid hormone receptor. In In some embodiments, the contacting occurs in vitro or ex vivo, while in other embodiments, implementation, contacting occurs in vivo. EXAMPLES The following are examples of aspects of the present invention and are not intended to limit its scope. conditions for the preparation of several compounds described in this document. Methods for the synthesis of common intermediates are listed only once. Chemical names were generated using Marvin 17.28.0 or Chemdraw 18.1. Abbreviation table: The following abbreviations are used in this description: Ac Acetate ACN Acetonitrile anhydrous Anhydrous aq. Water Bu butyl CAN Cerium Ammonium Nitrate conc. Concentrated DCM Dichloromethane DIPEA N,N-Diisopropylethylamine DMA N,N-dimethylacetamide DMF N,N-Dimethylformamide DMSO Dimethyl sulfoxide DPPA Diphenylphosphoryl azide dppf 1,1'-Bis(diphenylphosphine)ferrocene EA=EtOAc ethyl acetate ECF ethyl chloroformate Et Ethyl EtOH Ethanol FA Formic acid g gram(s) h. Hour(s) Me methyl MeOH Methanol min Minute(s) NIS N-Iodosuccinimide PE Petroleum ether k.t. Room temperature saturated. Saturated SelectfluorTM 1-Chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) TBAF Tetra-n-butylammonium fluoride TBSCL tert-butyldimethylsilyl chloride TFA Trifluoroacetic acid THF tetrahydrofuran Synthesis of components 1. Synthesis of 3-isopropyl-1H-indol-5-ol To a stirred mixture of (4-methoxyphenyl)hydrazine (10.00 g, 72.375 mmol, 1.0 equiv.) in 100 mL Isovaleraldehyde (6.23 g, 0.072 mmol, 1 equiv.) was added dropwise to AcOH at 80 °C. The resulting mixture was stirred for 2 h at 120 °C. The resulting mixture was concentrated in vacuo. The resulting mixture extracted with EA (3 × 100 mL). The combined organic layers were washed with brine (1 × 100 mL), dried anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to give 3-isopropyl-5-methoxy-1H-indole (2.6 g, 19%) as a brown solid. To a solution of 3-isopropyl-5-methoxy-1H-indole (9.03 g, 47.713 mmol, 1.0 equiv.) in DCM (100.00 mL) Boron tribromide (35.88 g, 143.217 mmol, 3 equiv.) was added dropwise over 1 h at -78 °C. The resulting mixture was further stirred for 3 h at room temperature. The reaction mixture was quenched by adding H2O at 0 °C. The resulting mixture was extracted with EA. The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to give 3-isopropyl-1H-indol-5-ol. (5.86 g, 56%) as a black oil. 2a. Synthesis of 5-bromo-3-isopropyl-1H-indole To a stirred solution of 4-bromophenylhydrazine (50.00 g, 267.32 mmol, 1.00 equiv.) in AcOH (500 ml) was added isovaleraldehyde (23.03 g, 267.37 mmol, 1.00 equiv.) dropwise at 80 °C. The resulting The mixture was stirred for 3 h at 120 °C. The resulting mixture was concentrated in vacuo. The resulting The mixture was extracted with EA (3 × 500 mL). The combined organic layers were washed with brine (1 × 300 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to give 5-bromo-3-isopropyl-1H- indole (28 g, 44%) as a brown solid. 2b. Synthesis of 5-bromo-3-isopropyl-1-(p-tolylsulfonyl)pyrrolo[3,2-b]pyridine: To a stirred solution of 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine (2.0 g, 8.36 mmol, 1 equiv.), DMAP (20.44 mg, 167.29 μmol, 0.02 equiv.) and DIPEA (2.38 g, 18.40 mmol, 2.2 equiv.) in DCM (60 mL) TosCl (1.91 g, 10.04 mmol, 1.2 equiv.) was added at 20 °C. The resulting mixture was then stirred at 20 °C for 12 h. TLC (petroleum ether / ethyl acetate=5 / 1, UV) showed that the starting material The mixture was diluted with H2O (100 mL) and extracted with DCM (100 mL x 3). The combined The organic layers were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered, and concentrated to give a residue. The residue was purified by flash chromatography on silica gel (ethyl acetate in petroleum ether = 0~10 %) to obtain 5-bromo-3-isopropyl-1-(p- tolylsulfonyl)pyrrolo[3,2-b]pyridine (2.6 g, 5.61 mmol, yield 67.0%) as an off-white solid substances. 2c. Synthesis of 5-bromo-3-pentyl-1H-indazole To a solution of 5-bromo-2-fluoro-benzaldehyde (25 g, 123.15 mmol, 1 equiv.) in THF (100 mL) was added bromo(pentyl)magnesium (1 M, 184.73 mL, 1.5 equiv.) at 0 °C. The mixture was stirred at 20 °C for 1 h. The reaction mixture was quenched by addition of sat. aq. NH4Cl (50 mL) at 0 °C, and then diluted with H2O (50 mL) and extracted with EA (100 mL * 2). The combined organic layers were washed with brine (50 mL), dried anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash chromatography on silica gel (eluent 0~30% ethyl acetate / petroleum ether) with obtaining 1-(5-bromo-2-fluoro-phenyl)hexan-1-ol (9.5 g, 34.53 mmol, yield 28%) as colorless oil. To a solution of 1-(5-bromo-2-fluoro-phenyl)hexan-1-ol (9.5 g, 34.53 mmol, 1 equiv.) in DCM (100 mL) 4A MS (10 g) and PDC (25.98 g, 69.05 mmol, 2 equiv.) were added at 20 °C. The mixture was stirred at 20 °C. for 12 h. The mixture was filtered and concentrated under reduced pressure to give a residue which was purified by flash chromatography on silica gel (eluent 0~30% ethyl acetate / petroleum ether) with obtaining 1-(5-bromo-2-fluoro-phenyl)hexan-1-one (8.2 g, 30.02 mmol, yield 87%) as a pale- yellow solid. To a solution of 1-(5-bromo-2-fluoro-phenyl)hexan-1-one (5 g, 18.31 mmol, 1 equiv.) in NMP (2 mL) was added hydrazine hydrate (2.16 g, 36.61 mmol, 2.09 mL, 85% purity, 2 equiv.) at 20 °C. The mixture was stirred at 100 °C for 12 h. The reaction mixture was added to ice water (50 mL) and extracted with EA (50 ml * 2). The combined organic layers were washed with brine (10 ml), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash chromatography on silica gel (eluent 0~20% ethyl acetate / petroleum ether) to give 5-bromo-3- pentyl-1H-indazole (2 g, 7.49 mmol, 41% yield) as a white solid. 3. Synthesis of 3-isopropyl-1-(4-methylbenzenesulfonyl)indole-5-carbaldehyde To a stirred solution of 5-bromo-3-isopropyl-1H-indole (3.0 g, 12.6 mmol, 1.00 equiv.) in toluene (50 mL) was added Bu4NHSO4 (0.43 g, 1.27 mmol, 0.10 equiv.) portionwise at 0 °C. TsCl (2.90 g, 15.26 mmol, 1.2 equiv.) dropwise at 0 °C. The resulting mixture was stirred overnight at r.t. The resulting mixture was concentrated in vacuo. The resulting mixture was extracted with EA (3 × 100 mL). The combined The organic layers were washed with brine (1 × 200 mL), dried over anhydrous Na2SO4. After filtration, The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to give 5-bromo-3-isopropyl-1-(4-methylbenzenesulfonyl)indole (4.0 g, 67%) as light yellow solid. To a stirred solution of 5-bromo-3-isopropyl-1-(4-methylbenzenesulfonyl)indole (4 g, 10.2 mmol, 1.00 equiv.) in THF was added n-BuLi (31.2 mL, 51.0 mmol, 5.0 equiv., 1.6 M in hexane) dropwise at -78 °C under nitrogen. The resulting mixture was stirred for 40 min at -78 °C under nitrogen. DMF (3.70 g, 0.051 mmol, 5.0 equiv.) was added at -78 °C under nitrogen. The resulting The mixture was stirred for 1.5 h at -78 °C under nitrogen. The reaction mixture was quenched water (50 mL). The resulting mixture was extracted with EA (3 × 100 mL). The combined organic layers were washed with brine (1 × 200 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated at under reduced pressure. The residue was purified by column chromatography on silica gel to give 3- isopropyl-1-(4-methylbenzenesulfonyl)indole-5-carbaldehyde (1.1 g, 31%) as a light yellow oil. 4. Synthesis of 4-[(benzyloxy)methyl]-6-bromo-2H-1,2,4-triazine-3,5-dione 6-Bromo-2,4-dihydro-1,2,4-triazine-3,5-dione (10.00 g, 52.091 mmol, 1.00 equiv.) was placed in acetic acid. anhydride (50 ml) under reflux (140 °C) for 5 h. After concentration to dryness reaction medium, the precipitate is isolated and then recrystallized from ether to obtain the desired The desired product was isolated as a light yellow solid (11.6 g, purity 95%, yield 90%). NaH (2.19 g, 54.755 mmol, 1.10 equiv, 60%) was placed in DMF (50 mL) under nitrogen. A solution of 2-acetyl-6- bromo-4H-1,2,4-triazine-3,5-dione (11.60 g, 49.571 mmol, 1.0 equiv.) in DMF (150 mL) was added dropwise. The reaction medium was stirred for 1 h at room temperature and then added [(chloromethoxy)methyl]benzene (8.54 g, 54.53 mmol, 1.1 equiv.) and then continue stirring for 18 h at rt. After concentration to dryness, the resulting residue was dissolved in H2O (200 ml) and was extracted with ethyl acetate (EA) (3 × 500 mL). After drying over Na2SO4, the organic phase was evaporated and The resulting clear oil was purified and 15 g of crystals were isolated. The crystals were placed in EtOH (400 ml) in in the presence of TsOH (100.0 mg, 0.581 mmol, 0.01 equiv.). This mixture was heated under reflux refrigerator for 4 h and then concentrated to dryness. The residue was dissolved in H2O and then extracted with EA. After drying and evaporation of the organic phases, the desired product was obtained. product as a yellow oil (9.5 g, yellow oil, purity 90%, yield 61%). 5a. Synthesis of 6-bromo-2-methyl-4H-1,2,4-triazine-3,5-dione N N H NH About Br ON N NH About Br About 82 oC, 20 g BSA, CH3l, ACN To a stirred solution of 6-bromo-2,4-dihydro-1,2,4-triazine-3,5-dione (200.0 mg, 1.04 mmol, 1.0 equiv.) in ACN (5 mL) was added BSA (529.8 mg, 2.61 mmol, 2.5 equiv.) dropwise at 0 °C under atmosphere argon. The resulting mixture was stirred for 3 h at 82 °C under argon, and then CH3I (251.4 mg, 1.77 mmol, 1.7 equiv.) was added dropwise at 82 °C, stirring was continued for 20 h at 82 °C. The mixtures were allowed to cool to rt, concentrated under reduced pressure, and then dissolved in DCM, washed with water and brine, dried over anhydrous Na2SO4. After filtration, the filtrate concentrated under reduced pressure. The residue was purified by column chromatography on silica gel with obtaining 6-bromo-2-methyl-4H-1,2,4-triazine-3,5-dione (870 mg, 69%) as a yellow solid substances. 5b. Synthesis of 6-bromo-2-ethyl-4H-1,2,4-triazine-3,5-dione 6-Bromo-2-ethyl-4H-1,2,4-triazine-3,5-dione was prepared in the same manner as described for 6-bromo-2-methyl-4H- of 1,2,4-triazine-3,5-dione using 2.5 equiv. iodoethane instead of 1.7 equiv. CH3I. 6. Synthesis of 5-(2,6-dichloro-4-nitrophenoxy)-3-isopropyl-1H-indole To a stirred solution of 3-isopropyl-1H-indol-5-ol (1.00 g, 5.71 mmol, 1.00 equiv.) in THF tert-Butoxy potassium (0.64 g, 5.70 mmol, 1.0 equiv.) was added dropwise at 0 °C. The resulting mixture was stirred for 30 min at rt. After completion of the reaction, the resulting mixture was concentrated in vacuum and redissolved in DMF. Second reaction flask: To the stirred solution of 1,2,3-trichloro- 5-Nitrobenzene (1.29 g, 5.70 mmol, 1.0 equiv) in DMF was added to the contents of the first reaction flask at 0 °C. The resulting mixture was stirred for 5 min at 0 °C, and then heated to 100 °C and stirred for 1 h. The resulting mixture was extracted with EA. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. The residue was purified by column chromatography on silica gel with obtaining 5-(2,6-dichloro-4-nitrophenoxy)-3-isopropyl-1H-indole (1.3 g, 55%) as a yellow solid substances. 7. Synthesis of 5-(2,6-dimethyl-4-nitrophenoxy)-3-isopropyl-1H-indole To a stirred mixture of 3-isopropyl-1H-indol-5-ol (5.10 g, 29.10 mmol, 1.0 equiv.) in 50 mL DMSO K2CO3 (4.42 g, 32.0 mmol, 1.1 equiv.) and 2-fluoro-1,3-dimethyl-5-nitrobenzene (4.92 g, 29.1 mmol, 1.0 equiv.) in portions at room temperature. The resulting mixture was stirred for 2 h at 100 °C. The resulting mixture was extracted with EA (3 × 100 mL). The combined organic layers were washed with brine (3 × 50 ml), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to give 5-(2,6-dimethyl-4- nitrophenoxy)-3-isopropyl-1H-indole (6 g, 64%) as a light yellow solid. 8. Synthesis of 5-(2,6-dichloro-4-nitrophenoxy)-1H-indole To a solution of 5-hydroxyindole (16.0 g, 120.2 mmol, 1.0 equiv.) in acetonitrile (320 mL) was added tert- potassium butoxide (13.48 g, 120.2 mmol, 1.0 equiv.) at 0 °C. After 20 minutes, the mixture was concentrated with by removing acetonitrile and dissolved in N,N-dimethylformamide (320 ml). Then 1,2,3- trichloro-5-nitrobenzene (27.21 g, 120.2 mmol, 1.00 equiv.) at 0 °C. The resulting solution was stirred at 100 °C overnight and then quenched with water (300 mL). The resulting solution was extracted with ethyl acetate (3 × 500 mL) and the organic layers were combined, washed with brine (2 × 300 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by obtaining 28 g (yield 68%) of 5-(2,6-dichloro-4-nitrophenoxy)-1H-indole as a yellow solid substances. 9. Synthesis of 5-dichloro-4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indol-5-yl]oxy]aniline To a stirred solution of 5-(2,6-dichloro-4-nitrophenoxy)-3-isopropyl-1H-indole (1.29 g, 3.532 mmol, 1.0 equiv.) in toluene (50.00 mL) was added TsCl (0.81 g, 4.239 mmol, 1.2 equiv.) in toluene (10 mL), KOH (50%) (21.4 mL), Bu4NHSO4 (0.12 g, 0.353 mmol, 0.1 equiv.) dropwise at 0 °C. The resulting mixture was stirred for 6 h at rt. After completion of the reaction, the resulting mixture was extracted with EA (3 × 50 ml). The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography. chromatography on silica gel to give 5-(2,6-dichloro-4-nitrophenoxy)-3-isopropyl-1-(4- methylbenzenesulfonyl)indole (1.40 g, 75%) as a yellow solid. To a stirred solution of 5-(2,6-dichloro-4-nitrophenoxy)-3-isopropyl-1-(4- methylbenzenesulfonyl)indole (1.40 g, 2.73 mmol, 1.0 equiv.) and NH4Cl (1.16 g, 21.62 mmol, 8.0 equiv.) in EtOH (50 mL) and H2O (25 mL) were added to Fe powder (0.75 g, 13.514 mmol, 5.00 equiv.) in portions at rt in under nitrogen atmosphere. The resulting mixture was stirred for 2 h at 50 °C under nitrogen atmosphere. The resulting mixture was filtered, the filter residue was washed with EA. The filtrate was concentrated at under reduced pressure. The aqueous layer was extracted with EA, dried with anhydrous Na2SO4. After filtration, The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gels to obtain 3,5-dichloro-4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)-indol-5-yl]oxy]aniline (1.11 g, 78%) as a white solid. 10. Synthesis of 4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indol-5-yl]oxy]-3,5-dimethylaniline To a stirred mixture of 5-(2,6-dimethyl-4-nitrophenoxy)-3-isopropyl-1H-indole (5.00 g, 15.414 mmol, 1.00 equiv.) in 50 ml of toluene was added TsCl (3.53 g, 0.018 mmol, 1.2 equiv.), Bu4NHSO4 (0.52 g, 0.002 mmol, 0.1 equiv.), KOH (50 mL) was added dropwise at 0 °C. The mixture was stirred overnight at rt and was quenched with water (50 mL). The resulting mixture was extracted with EA (3 × 200 mL). The combined organic layers washed with brine (1 × 100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate concentrated under reduced pressure. The residue was purified by column chromatography on silica gel in hexane to give 5-(2,6-dimethyl-4-nitrophenoxy)-3-isopropyl-1-(4-methylbenzenesulfonyl)indole (5.8 g, 79%) as a light yellow solid. To the stirred mixture of 5-(2,6-dimethyl-4-nitrophenoxy)-3-isopropyl-1-(4- methylbenzenesulfonyl)indole (5.80 g, 12.120 mmol, 1.0 equiv.) in MeOH (70 mL) was added Pd / C (1.74 g) portions. The resulting mixture was stirred overnight at room temperature under a hydrogen atmosphere. The resulting The mixture was filtered, the filter residue was washed with MeOH (1 × 500 mL). The filtrate was concentrated at under reduced pressure to obtain a residue, which was purified by column chromatography on silica gel with obtaining 4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indol-5-yl]oxy]-3,5-dimethylaniline (3.2 g, 59%) as a light yellow solid. 11. Synthesis of 4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indol-5-yl]methyl]-3,5-dimethylaniline To a stirred solution of N-(4-bromo-3,5-dimethylphenyl)-2,2,2-trifluoroacetamide (260.16 mg, 0.879 mmol, 1.0 equiv.) in THF (5 mL) under nitrogen was added MeLi-LiBr (1.7 mL, 1.76 mmol, 2.0 equiv., 1 M in ether) at -78 °C. Then t-BuLi (1.6 mL, 2.64 mmol, 3.00 equiv., 1.6M in hexane) was added in dropwise at -78 °C. The mixture was stirred for 20 min at -78 °C. 3-Isopropyl-1-(4- methylbenzenesulfonyl)indole-5-carbaldehyde (300 mg, 0.879 mmol, 1.0 equiv.) at -78 °C. The resulting the mixture was stirred for 1 h at rt. The reaction mixture was quenched with water (10 ml) at rt. The resulting The mixture was extracted with EA (3 × 50 mL). The combined organic layers were washed with brine (2 × 100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified to give 2,2,2-trifluoro-N-(4-[hydroxy[3-isopropyl-1-(4- methylbenzenesulfonyl)indol-5-yl]methyl]-3,5-dimethylphenyl)acetamide (300 mg, 61%) as a white solid substance. A solution of 2,2,2-trifluoro-N-(4-[hydroxy[3-isopropyl-1-(4-methylbenzenesulfonyl)indole- 5-yl]methyl]-3,5-dimethylphenyl)acetamide (300.0 mg, 0.537 mmol, 1.00 equiv.) in DCM (5 mL) under atmosphere nitrogen at 0 °C. Then a solution of Et3SiH (374.7 mg, 3.22 mmol, 6.0 equiv.) in DCM (15 mL) was added and TMSOTf (7.16 mg, 0.032 mmol, 0.06 equiv.) in DCM (5mL) was added dropwise to the reaction mixture. The reaction mixture The mixture was stirred for 30 min at 0 °C and 1.5 h at room temperature. The reaction mixture was quenched with saturated NaHCO3 solution (20 ml). The resulting solution was extracted with dichloromethane (3 × 50 ml) and the organic The layers were combined, washed with brine (2 × 30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. Crude product containing 2,2,2-trifluoro-N-(4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indol-5-yl]methyl]- 3,5-Dimethylphenyl)acetamide was isolated as a yellow solid (260 mg, purity 85%, yield 76%). To the solution of 2,2,2-trifluoro-N-(4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indol-5-yl]methyl]-3,5- dimethylphenyl)acetamide (260.0 mg, 0.479 mmol, 1.0 equiv.) in MeOH (10 mL) and H2O (2 mL) stirred under nitrogen atmosphere at rt. NaOH (76.66 mg, 1.917 mmol, 4.0 equiv.) was added. The reaction mixture was stirred at 60 °C overnight. The reaction mixture was quenched with water (20 mL). The resulting solution extracted with dichloromethane (3 × 50 mL) and the organic layers were combined, washed with brine (2 × 30 ml), dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure with obtaining the crude product. The crude product was isolated as a yellow solid, containing 4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indol-5-yl]methyl]-3,5-dimethylaniline (230 mg, purity 90%, yield 97%). 12. Synthesis of 3,5-dichloro-4-[[1-(4-methylbenzenesulfonyl)indol-5-yl]oxy]aniline To a solution of 5-(2,6-dichloro-4-nitrophenoxy)-1H-indole (28.0 g, 86.65 mmol, 1.0 equiv.) in toluene (720 ml) tetrabutylammonium hydrogen sulfate (2.94 g, 8.665 mmol, 0.10 equiv.) and potassium hydroxide were added (120.00 g, 2138.8 mmol, 25.0 equiv.) in water (120 mL) at 0 °C. 4-Toluenesulfonyl chloride (19.82 g, 103.98 mmol, 1.20 equiv.) in toluene (720 mL) dropwise at 0 °C. Then the reaction mixture stirred at r. t. for 3 h. and quenched with water (200 ml). The mixture was extracted with ethyl acetate (3 × 500 ml) and the organic layers were combined, concentrated under reduced pressure. The residue was purified with obtaining 5-(2,6-dichloro-4-nitrophenoxy)-1-(4-methylbenzenesulfonyl)indole (34 g, yield 78%) in as a yellow solid. To a solution of 5-(2,6-dichloro-4-nitrophenoxy)-1-(4-methylbenzenesulfonyl)-indole (26.00 g, 54.47 mmol, 1.0 equiv.) in ethanol (500 ml) and water (250 ml) was added iron dust (15.21 g, 272.36 mmol, 5.0 equiv.) and ammonium chloride (23.31 g, 435.78 mmol, 8.0 equiv.). The resulting solution was stirred for 2 h. at 50 °C. The resulting mixture was filtered, the filter residue was washed with dichloromethane (6 × 100 The filtrate was extracted with dichloromethane (3 × 500 mL). The combined organic layers were combined, washed with brine (300 ml), dried over anhydrous sodium sulfate and concentrated under reduced pressure pressure to give 3,5-dichloro-4-[[1-(4-methylbenzenesulfonyl)indol-5-yl]oxy]aniline (23 g, yield 88%) as a light yellow solid. 13a. Synthesis of 6-(4-amino-2,6-dichlorophenoxy)-4-isopropyl-2H-pyridazin-3-one To a solution of 3,6-dichloropyridazine (50.00 g, 335.64 mmol, 1.0 equiv.) in H2O (1.20 L) was added AgNO3 (57.02 g, 335.64 mmol, 1.0 equiv.), isobutyric acid (29.57 g, 335.64 mmol, 1.0 equiv.) in portions at r.t. in air and then stirred at 50 °C under nitrogen. H2SO4 (98.76 g, 1006.9 mmol, 3.0 equiv.) was added in portions at 50 °C and stirred at 60 °C. Then (NH4)2S2O8 was added (229.78 g, 1006.914 mmol, 3.0 equiv.) and stirred for 30 min at 70 °C under nitrogen atmosphere. The mixture was neutralized to pH 9 with NaOH solution. The resulting mixture was extracted with EA (3 × 1 L). The combined The organic layers were washed with brine (2 × 1 L), dried over anhydrous Na2SO4. After filtration, The filtrate was concentrated. The residue was purified by column chromatography on silica gel to give 3,6-dichloro-4-isopropylpyridazine (30 g, 47%) as a light yellow oil. To a solution of 3,6-dichloro-4-isopropylpyridazine (20.00 g, 104.679 mmol, 1.0 equiv.) in DMSO (200 mL) phenol, 4-amino-2,6-dichloro (18.63 g, 104.68 mmol, 1.0 equiv.), K2CO3 (58.16 g, 420.81 mmol, 4.02 equiv.) and CuI (11.96 g, 62.81 mmol, 0.60 equiv.) in portions. The resulting mixture was stirred overnight at 90 °C under nitrogen. The mixture was acidified to pH 8 with conc. HCl. The resulting mixture extracted with EA (3 × 500 mL). The combined organic layers were washed with brine (3 × 300 mL), dried anhydrous Na2SO4. After filtration, the filtrate was concentrated. The residue was purified by column chromatography. chromatography on silica gel to obtain 3,5-dichloro-4-[(6-chloro-5-isopropyl-pyridazin-3-yl)oxy]- aniline (17 g, 49%) as a green solid. To a solution of 3,5-dichloro-4-[(6-chloro-5-isopropylpyridazin-3-yl)oxy]aniline (17.00 g, 51.111 mmol, 1.0 equiv.) in HOAc (200 mL) was added NaOAc (24.33 g, 178.89 mmol, 3.50 equiv.) portionwise. The mixture was stirred overnight at 100 °C under nitrogen. NaOH (12.27 g, 306.77 mmol, 6.0 equiv.), and MeOH (200 mL) in portions. The resulting mixture was stirred overnight at 120 °C in under nitrogen atmosphere. The resulting mixture was extracted with EA (3 × 500 mL). The combined organic layers washed with brine (2 × 200 mL), dried over anhydrous Na2SO4. After filtration, the filtrate The residue was purified by column chromatography on silica gel to give 6-(4-amino- 2,6-dichlorophenoxy)-4-isopropyl-2H-pyridazin-3-one (11 g, 69%) as an off-white solid substances. 13b. Synthesis of 3,5-dichloro-4-[(5-isopropyl-6-methoxypyridazin-3-yl)oxy]aniline A mixture of 3,6-dichloro-4-isopropylpyridazine (80.0 g, 419 mmol, 1.00 equiv.), 4-amino-2,6-dichlorophenol (74.5 g, 419 mmol, 1.0 equiv.), K2CO3 (232 g, 1675 mmol, 4.0 equiv.) and CuI (47.9 g, 251 mmol, 0.6 equiv.) in DMSO (800 ml) was stirred overnight at 60 °C. After cooling to 25 °C, the solution was poured into ice water (3 L) and the pH of the mixture was adjusted to 8 with hydrochloric acid (3 N). The resulting mixture extracted with EA (3 × 1 L). The combined organic layers were washed with brine (3 × 1 L), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified column chromatography on silica gel (eluting with a ratio of petroleum ether to ethyl acetate (PE:EA) 5:1) to give 3,5-dichloro-4-[(6-chloro-5-isopropylpyridazin-3-yl)oxy]aniline (35.0 g, 24% yield) as an off-white solid. HPLC (ECI, m / z): 332 [M+H]+. A mixture of 3,5-dichloro-4-[(6-chloro-5-isopropylpyridazin-3-yl)oxy]-aniline (10.0 g, 30.1 mmol, 1.00 equiv.) and potassium methoxide (21.1 g, 301 mmol, 10.0 equiv.) in MeOH (50 mL) was stirred for 48 h at 65 °C. After cooling to 25 °C, the pH of the mixture was adjusted to 6-7 with hydrochloric acid (1 The resulting mixture was extracted with EA (3 × 500 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography. chromatography on silica gel (eluting with PE:EA 5:1) to give 3,5-dichloro-4-[(5-isopropyl-6- methoxypyridazin-3-yl)oxy]aniline (6.80 g, yield 65%) as a white solid. LCMS (ESI, m / z): 328 [M+H]+. 14a. Synthesis of 3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenylboronic acid A 1000 ml round-bottom flask was charged with 6-(4-amino-2,6-dichlorophenoxy)-4-isopropyl-2H- pyridazin-3-one (14.13 g, 44.98 mmol, 1.0 equiv.) in MeOH (200 mL). HCl (4.10 mL, 112.439 mmol, 3 equiv.) dropwise at 0 °C. H2O (100 mL) was added at 0 °C. The mixture was stirred for 10 min, then NaNO2 (3.72 g, 53.971 mmol, 1.20 equiv.) was added, and stirred for an additional 30 min at 0 °C. Tetrahydroxyborane (40.32 g, 449.749 mmol, 10.0 equiv.) was added. The reaction mixture stirred for 1 h at 60 °C. The resulting solution was quenched with water (50 ml). The resulting solution extracted with dichloromethane (3 × 400 mL) and the organic layers were combined, dried over anhydrous sulfate sodium, filtered and concentrated under reduced pressure. Purification led to the preparation of 3.5- dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenylboronic acid (6.3 g, 37%) as white solid. 14b. Synthesis of 3,5-dichloro-4-[(5-isopropyl-6-methoxypyridazin-3-yl)oxy]phenylboronic acid To a stirred mixture of 3,5-dichloro-4-[(5-isopropyl-6-methoxy-pyridazin-3-yl)oxy]aniline (5.80 g, 17.7 mmol, 1.00 equiv.) and CuBr2 (7.89 g, 35.3 mmol, 2.00 equiv.) in ACN (40 mL) was added tert-butyl nitrite (4.24 mL, 35.4 mmol, 2.0 equiv.) was added dropwise at 0 °C. The resulting mixture was then warmed to room temperature. temperature and stirred for an additional 3 h. The resulting mixture was concentrated under reduced The residue was purified by column chromatography on silica gel (eluting with PE:EA 10:1) with obtaining 6-(4-bromo-2,6-dichlorophenoxy)-4-isopropyl-3-methoxypyridazine (3.50 g, yield 48%) in as a yellow solid. LCMS (ESI, m / z): 391[M+H]+. A mixture of 6-(4-bromo-2,6-dichlorophenoxy)-4-isopropyl-3-methoxypyridazine (1.00 g, 2.55 mmol, 1.00 equiv.), bis(pinacolato)diboron (972 mg, 3.83 mmol, 1.50 equiv.), Pd(dppf)Cl2 (187 mg, 0.256 mmol, 0.10 equiv.) and KOAc (750 mg, 7.64 mmol, 3.00 equiv.) in 1,4-dioxane (10 mL) was stirred for 2 h at 90 °C. After cooling to 25 °C, the solids were filtered off and the filter residue was washed with EA (3 × 20 ml). The filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography (Column: silica gel C18; Mobile phase, A: water (containing 0.5% TFA) and B: ACN (from 20% to 95% over 20 min) to give 3,5-dichloro-4-[(5-isopropyl-6-methoxypyridazine-3- yl)oxy]phenylboronic acid (610 mg, 64% yield) as a brown solid. LCMS (ESI, m / z): 359 [M+H]+. 15. Synthesis of 2-(3,5-dichloro-4-[[3-iodo-1-(4-methylbenzenesulfonyl)-indol-5-yl]oxy]phenyl)-3,5-dioxo- 4H-1,2,4-triazine-6-carbonitrile To a solution of 3,5-dichloro-4-[[1-(4-methylbenzenesulfonyl)indol-5-yl]oxy]aniline (15.00 g, 33.532 mmol, 1.0 equiv.) in water (700 ml) concentrated hydrochloric acid (336 ml) and acetic acid (942 ml) was added sodium nitrite (4.86 g, 70.418 mmol, 2.1 equiv.) in water (50 ml) dropwise at 0 °C. After addition, the reaction mixture was stirred at 0 °C for 45 min. Then the reaction mixture was rapidly was poured into a solution of ethyl N-(2-cyanoacetyl)carbamate (7.85 g, 50.30 mmol, 1.5 equiv.) in water (600 mL) and of pyridine (336 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 30 min and filtered. The filter residue was washed with water (100 ml) and petroleum ether (200 ml), dried under reduced pressure. pressure to give ethyl (Z)-(2-cyano-2-(2-(3,5-dichloro-4-((1-tosyl-1H-indol-5-yl)oxy)phenyl)- hydrazinylidene)-acetyl) carbamate (18.4 g, 80% yield) as a red solid. To the solution of ethyl (Z)-(2-cyano-2-(2-(3,5-dichloro-4-((1-tosyl-1H-indol-5- yl)oxy)phenyl)hydrazinylidene)acetyl)carbamate (18.40 g, 29.95 mmol, 1.0 equiv.) in N,N- Potassium acetate (11.76 g, 119.782 mmol, 4.0 equiv.) was added to dimethylacetamide (300 mL). The reaction mixture was stirred at 120 °C for 2 h and quenched with water (100 mL). The mixture was extracted with ethyl acetate (3 × 100 mL) and the organic layers were combined, washed with brine (100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified to give 2-(3,5- dichloro-4-[[1-(4-methylbenzenesulfonyl)indol-5-yl]oxy]phenyl)-3,5-dioxo-4H-1,2,4-triazine-6- carbonitrile (14 g, 80% yield) as a brown solid. To a stirred solution of 2-(3,5-dichloro-4-[[1-(4-methylbenzenesulfonyl)indol-5-yl]oxy]phenyl)- 3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (7.0 g, 12.32 mmol, 1.0 equiv.) and p-toluenesulfonic acid acid (0.210 g, 1.232 mmol, 0.1 equiv.) in dichloromethane (300 mL) was added N-iodosuccinimide (4.16 g, 18.47 mmol, 1.5 equiv.) at 0 °C under nitrogen. The reaction mixture was stirred for 6 h. at 0 °C and quenched with water (200 mL). The resulting mixture was extracted with dichloromethane (3 × 200 mL) and The combined organic layers were combined, washed with saturated sodium thiosulfate solution (2 × 500 ml), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified from obtaining 2-(3,5-dichloro-4-[[3-iodo-1-(4-methylbenzenesulfonyl)indol-5-yl]oxy]phenyl)-3,5-dioxo-4H- 1,2,4-triazine-6-carbonitrile (5.30 g, 43% yield) as a brown solid. 16. Synthesis of 2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-4H-1,2,4- Triazine-6-carbonitrile To a solution of 6-(4-amino-2,6-dichlorophenoxy)-4-isopropyl-2H-pyridazin-3-one (500 mg, 1.591 mmol, 1.0 equiv.) in HOAc (43.8 mL, 764.03 mmol) and HCl (15.3 mL, 503.55 mmol) was added NaNO2 (230.59 mg, 3.34 mmol, 2.1 equiv.) in H2O (33.4 mL) dropwise at 0 °C. The resulting mixture was stirred for 30 min at 0 °C under nitrogen. The above solution was quickly poured into a second reaction flask which contained ethyl N-(2-cyanoacetyl)carbamate (372.75 mg, 2.387 mmol, 1.5 equiv.) and H2O (40.9 ml) in pyridine (20 mL) at 0 °C. The resulting mixture was kept for 30 min at 0 °C. A solid precipitate was collected by filtration and washed with PE and H2O (3 × 300 mL) to give ethyl N-[(Z)-cyano(2-[3,5- dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]hydrazin-1-ylidene)carbonyl]carbamate, which can also be called ethyl (Z)-(2-cyano-2-(2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6- dihydropyridazin-3-yl)oxy)phenyl)-hydrazinylidene)acetyl)-carbamate (name created by Chemdraw) (640 mg, 84%) as an orange solid. To the solution of ethyl N-[(Z)-cyano(2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3- yl)oxy]phenyl]hydrazin-1-ylidene)carbonyl]carbamate, which can also be called ethyl (Z)-(2-cyano-2-(2- (3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazine-3- yl)oxy)phenyl)hydrazinylidene)acetyl)carbamate (640.00 mg, 1.330 mmol, 1.00 equiv.) in DMA (13.36 mL) KOAc (261.01 mg, 2.660 mmol, 2.00 equiv.) was added portionwise at rt. The mixture was stirred for 3 h. at 120 °C under nitrogen. The reaction mixture was quenched with water. The resulting mixture was extracted EA (3 × 100 mL). The combined organic layers were washed with brine (4 × 100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated. This resulted in the preparation of 2-[3,5-dichloro-4-[(5- isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (590 mg, 102%) as a dark orange solid. 17. Synthesis of 4-[(benzyloxy)methyl]-6-bromo-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazine-3- yl)oxy]-phenyl]-1,2,4-triazine-3,5-dione To a stirred solution of 3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazine-3- 4- (( [(benzyloxy)methyl]-6-bromo-2H-1,2,4-triazine-3,5-dione (4.37 g, 13.995 mmol, 1.2 equiv), Cu(OAc)2 (4.24 g, 23.326 mmol, 2 equiv.) and pyridine (1.85 g, 23.326 mmol, 2 equiv.). The reaction mixture was stirred for 2 days at rt in an oxygen atmosphere, and then concentrated under reduced pressure to give of the crude product. Purification gave 4-[(benzyloxy)methyl]-6-bromo-2-[3,5-dichloro- 4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]-phenyl]-1,2,4-triazine-3,5-dione (2.2 g, yield 28%) in in the form of an almost white solid. 18. Synthesis of (E)-N'-[3,5-dichloro-4-([3-iodo-1H-pyrrolo[3,2-b]pyridin-5-yl]oxy)phenyl]-N, N- dimethylmethanimidamide 6-chloro-2-methyl-3-nitropyridine (20.00 g, 115.895 mmol, 1.0 equiv.), phenol, 4-amino-2,6-dichloro- (24.76 g, 139.07 mmol, 1.2 equiv.), K2CO3 (48.05 g, 347.69 mmol, 3.0 equiv.) and DMF (200 mL). The resulting mixture was stirred overnight at 60 °C. The reaction mixture was quenched water (400 mL). The resulting mixture was extracted with EA (3 × 500 mL) and the organic layers were combined, washed with brine (2 × 400 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was purified by column chromatography chromatography on silica gel and eluted with EA:PE (0% ~ 40% over 30 min) to give the desired product 3,5-dichloro-4-[(6-methyl-5-nitropyridin-2-yl)oxy]aniline (36.4 g, 91%) as a yellow solid substances. LCMS (ESI, m / z): 314 [M+H]+. To a solution of 3,5-dichloro-4-[(6-methyl-5-nitropyridin-2-yl)oxy]-aniline (36.40 g, 115.88 mmol, 1.0 equiv.) and (dimethoxymethyl)dimethylamine (33.14 g, 278.1 mmol, 2.4 equiv.) in dimethylformamide (400 mL) TEA (11.73 g, 115.9 mmol, 1.0 equiv.) was added. The resulting mixture was stirred for 4 h at 100 °C. The mixture was cooled to 60 °C and concentrated under reduced pressure to remove half of the DMF. The resulting solution was transferred to the next stage without further treatment. To the solution of (E)-N'-(3,5-dichloro-4-((6-((E)-2-(dimethylamino)vinyl)-5-nitropyridin-2-yl)oxy)phenyl)-N, N- dimethylformimidamide (49.17 g, 115.89 mmol, 1.0 equiv.) in DMF (200 mL) and MeOH (400 mL) was added Pd / C (10.0 g, 93.967 mmol, 0.81 equiv.) and NaOAc (9.51 g, 115.89 mmol, 1.0 equiv.) under hydrogen atmosphere. The resulting mixture was stirred overnight at room temperature. The mixture was filtered through Celite pad and washed with MeOH (50 mL). The filtrate was concentrated under reduced pressure with obtaining the crude product. The crude product was purified by column chromatography on silica gel and eluted with EA:PE (0% ~ 70% over 30 min) to give the desired product (E)-N'-(3,5- dichloro-4-[1H-pyrrolo[3,2-b]pyridin-5-yloxy]phenyl)-N, N-dimethylmethanimidamide (21.5 g, 45%) as brown solid. LCMS (ESI, m / z): 349 [M+H]+. To the solution of (E)-N'-(3,5-dichloro-4-[1H-pyrrolo[3,2-b]pyridin-5-yloxy]phenyl)-N,N- dimethylmethanimidamide (5.00 g, 14.32 mmol, 1.0 equiv.) and I2 (4.00 g, 15.75 mmol, 1.1 equiv.) in KOH (3.21 g, 57.27 mmol, 4.0 equiv.) was added to dimethylformamide (50 mL). The resulting mixture was stirred overnight at room temperature and quenched with water (80 mL). The resulting mixture extracted with EA (3 × 100 mL) and the organic layers were combined, washed with brine (2 × 80 mL), dried anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give crude product. The crude product was triturated with PE:EA 5:1 to give the desired product (E)-N'-[3,5-dichloro-4-([3-iodo-1H-pyrrolo[3,2-b]pyridin-5-yl]oxy)phenyl]-N,N-dimethylmethanimidamide (5.9 g, 78%) as a yellow solid. LCMS (ESI, m / z): 475 [M+H]+. 19. Synthesis of 3,5-dichloro-4-([3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl]oxy)aniline To the solution of (E)-N'-[3,5-dichloro-4-([3-iodo-1H-pyrrolo[3,2-b]pyridin-5-yl]oxy)phenyl]-N, N- dimethylmethanimidamide (3.0 g, 6.31 mmol, 1.0 equiv.), K3PO4 (2.01 g, 9.471 mmol, 1.5 equiv.) and 1,1'-bis(di- tert-butylphosphine)ferrocene dichloridepalladium (0.410 g, 0.631 mmol, 0.10 equiv.) in dioxane (75 mL) and H2O (15 ml) was added 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (4.24 g, 25.26 mmol, 4.0 equiv.) under nitrogen. The resulting mixture was stirred overnight at 60 °C and quenched with water (100 mL). The resulting mixture was extracted with EA (3 × 150 mL) and the organic layers were combined, washed brine (2 × 100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated at under reduced pressure to obtain the crude product. The crude product was purified on a column and eluted with EA:PE (0% ~ 50% over 30 min) to give the desired product (E)-N'-(3,5-dichloro-4-[[3- (prop-1-en-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]oxy]phenyl)-N, N-dimethylmethanimidamide (430 mg, 14 %) in as a yellow solid. LCMS (ESI, m / z): 389 [M+H]+. To the solution of (E)-N'-(3,5-dichloro-4-[[3-(prop-1-en-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]oxy]phenyl)-N, N- To dimethylmethanimidamide (400.0 mg, 1.028 mmol, 1.0 equiv.) in MeOH (25 mL) was added Pd / C (250.0 mg, 2.349 mmol, 2.3 equiv.). The resulting mixture was stirred for 1 h at room temperature in under hydrogen atmosphere. The mixture was filtered through a pad of celite and washed with MeOH (20 mL). The combined organic layers were concentrated under reduced pressure to give the crude product. (E)-N'-[3,5-dichloro-4-([3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl]-oxy)phenyl]-N, N-dimethylmethanimidamide (380 mg, crude) as a yellow solid. LCMS (ESI, m / z): 391 [M+H]+. To the solution of (E)-N'-[3,5-dichloro-4-([3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl]oxy)phenyl]-N, N- dimethylmethanimidamide (380.0 mg, 0.97 mmol, 1.0 equiv.) in ethyl alcohol (25 ml) was added ethylenediamine (262.6 mg, 4.37 mmol, 4.5 equiv.). The resulting mixture was stirred with reflux The reaction mixture was concentrated under reduced pressure to give of the crude product 3,5-dichloro-4-([3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl]oxy)aniline (350 mg, crude) as a yellow semi-solid. LCMS (ESI, m / z): 336 [M+H]+. 20. Synthesis of 4-[(benzyloxy)methyl]-6-[3,5-dichloro-4-[(5-isopropyl-6-methoxypyridazine-3- yl)oxy]phenyl]-2H-1,2,4-triazine-3,5-dione A mixture of 3,5-dichloro-4-[(5-isopropyl-6-methoxypyridazin-3-yl)oxy]-phenylboronic acid (400 mg, 1.12 mmol, 1.0 equiv.), 4-[(benzyloxy)methyl]-6-bromo-2H-1,2,4-triazine-3,5-dione (398 mg, 1.28 mmol, 1.15 equiv.), PdAmphos(Cl)2 (79.3 mg, 0.112 mmol, 0.1 equiv.) and K3PO4 (713 mg, 3.36 mmol, 3.0 equiv.) in 1.4- dioxane (8 ml) / water (0.8 ml) was stirred for 2 h at 90 °C. After cooling to 25 °C, The solids were filtered off and the filter residue was washed with EA (3 × 15 mL). The filtrate concentrated under reduced pressure. The residue was purified by silica gel column chromatography. (eluting with PE:EA 1:1) to give 4-[(benzyloxy)methyl]-6-[3,5-dichloro-4-[(5-isopropyl-6- methoxypyridazin-3-yl)oxy]-phenyl]-2H-1,2,4-triazine-3,5-dione (190 mg, yield 30%) as a light- yellow solid. LCMS (ESI, m / z): 544 [M+H]+. 21. Synthesis method of 2-(4-(benzyloxy)-2,6-dimethylbenzyl)-4,4,5,5-tetramethyl-1,3,2- Dioxaborolane: To a solution of 5-benzyloxy-2-bromo-1,3-dimethyl-benzene (1 g, 3.43 mmol) and 4,4,5,5-tetramethyl-2- [(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl]-1,3,2-dioxaborolane (1.84 g, 6.87 mmol) in dioxane (10 mL) was added 8 N aq. KOH (858.57 μL, 6.86 mmol), followed by the addition of Pd[P(t- Bu)3]2 (87.75 mg, 171.71 μmol) at rt (~15 °C) under N2. The mixture was then stirred at 30 °C. for 18 h. TLC (PE:EA 10:1, stained with I2) showed that the bromide was completely consumed and Two new spots formed. The mixture was diluted with water (40 mL), extracted with ethyl acetate (50 × 2 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo to obtaining a crude product, which was purified by flash chromatography on silica gel (eluent 0~2% ethyl acetate / petroleum ether) to give the desired 2-(4-(benzyloxy)-2,6-dimethylbenzyl)-4,4,5,5- tetramethyl-1,3,2-dioxaborolane (870 mg, 72% yield) as a white solid. 22. Synthesis of [4-[[3-isopropyl-1-(p-tolylsulfonyl)pyrrolo[3,2-b]pyridin-5-yl]methyl]-3,5-dimethyl-phenyl] trifluoromethanesulfonate To a solution of 5-bromo-3-isopropyl-1-(p-tolylsulfonyl)pyrrolo[3,2-b]pyridine (1.0 g, 2.54 mmol, 1 equiv.) and 2-[(4-benzyloxy-2,6-dimethyl-phenyl)methyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.79 g, 5.09 mmol, 2 equiv.) in dioxane (30 mL) and H2O (6 mL) was added tris-o-tolylphosphanedichloropalladium (299.79 mg, 381.39 μmol, 0.15 equiv.) and K3PO4 (1.62 g, 7.63 mmol, 3 equiv.) at 20 °C under N2 atmosphere. Then the resulting the mixture was stirred at 100 °C for 15 h under N2 atmosphere. The combined mixture (combined with loading 300 mg) was diluted with H2O (100 mL) and extracted with EA (100 mL x 3). The combined organics The layers were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated at under reduced pressure to give a residue which was purified by flash chromatography on silica gel (ethyl acetate in petroleum ether = 0~10 %) to obtain 5-[(4-benzyloxy-2,6-dimethyl- phenyl)methyl]-3-isopropyl-1-(p-tolylsulfonyl)pyrrolo[3,2-b]pyridine (1.36 g, 2.44 mmol, yield 74%, purity 96.5%) as a yellow solid. To a solution of 5-[(4-benzyloxy-2,6-dimethyl-phenyl)methyl]-3-isopropyl-1-(p-tolylsulfonyl)pyrrole[3,2- b]pyridine (1.36 g, 2.52 mmol, 1 equiv.) in MeOH (20 mL) and THF (10 mL) was added Pd-C (10%, 1.07 g) in under N2 atmosphere. The suspension was degassed in vacuum and purged with H2 several times. The mixture was stirred in under H2 atmosphere (50 psi) at 35 °C for 18 hours. The mixture was filtered and the filtrate concentrated, purified by flash chromatography on silica gel (0~100% ethyl acetate in petroleum ether) to give 4-[[3-isopropyl-1-(p-tolylsulfonyl)pyrrolo[3,2-b]pyridin-5-yl]methyl]-3,5-dimethyl- phenol (1 g, 2.23 mmol, 88% yield) as a white solid. To a solution of 4-[[3-isopropyl-1-(p-tolylsulfonyl)pyrrolo[3,2-b]pyridin-5-yl]methyl]-3,5-dimethyl-phenol (1 g, 2.23 mmol, 1 equiv.) and pyridine (440.84 mg, 5.57 mmol, 2.5 equiv.) in DCM (25 mL) at 0 °C slowly Tf2O (754.76 mg, 2.68 mmol, 441.38 μL, 1.2 equiv.) was added dropwise. After addition, the mixture was stirred at 0 °C for 1 h. The reaction mixture was partitioned between H2O (30 mL) and DCM (30 mL). The organic phase was separated, washed with brine (10 ml * 3), dried with anhydrous MgSO4, filtered and concentrated to give the crude product, which was purified by flash chromatography on silica gel (0~10% ethyl acetate in petroleum ether) to obtain [4-[[3-isopropyl-1-(p- tolylsulfonyl)pyrrolo[3,2-b]pyridin-5-yl]methyl]-3,5-dimethyl-phenyl]trifluoromethanesulfonate (1.25 g, 2.15 mmol, yield 97%) as a colorless gum. 23. Synthesis of 4-[[3-isopropyl-1-(p-tolylsulfonyl)pyrrolo[3,2-b]pyridin-5-yl]methyl]-3,5-dimethylaniline: To the solution of [4-[[3-isopropyl-1-(p-tolylsulfonyl)pyrrolo[3,2-b]pyridin-5-yl]methyl]-3,5-dimethyl- phenyl]trifluoromethanesulfonate (300 mg, 516.67 μmol, 1 equiv.) and tert-butyl carbamate (121.05 mg, 1.03 mmol, 2 equiv.) in dioxane (8 ml) was added Pd2(dba)3 (47.31 mg, 51.67 μmol, 0.1 equiv.), (5- diphenylphosphanyl-9,9-dimethyl-xanthen-4-yl)-diphenylphosphane (59.79 mg, 103.33 μmol, 0.2 equiv.) and Cs2CO3 (505.03 mg, 1.55 mmol, 3 equiv.) at 20 °C under N2. The resulting mixture was then stirred at 100 °C for 15 h under N2. HPLC showed that the reaction was complete. The mixture diluted with H2O (50 mL) and extracted with EA (50 × 3 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give The residue was purified by flash chromatography on silica gel (ethyl acetate in petroleum ether = 0~10 %) to obtain tert-butyl N-[4-[[3-isopropyl-1-(p-tolylsulfonyl)pyrrolo[3,2-b]pyridine-5- yl]methyl]-3,5-dimethyl-phenyl]carbamate (200 mg, 350.19 μmol, yield 68%, purity 95.9%) as light yellow solid. To the solution of tert-butyl N-[4-[[3-isopropyl-1-(p-tolylsulfonyl)-pyrrolo[3,2-b]pyridin-5-yl]methyl]-3,5- dimethyl-phenyl]carbamate (170 mg, 310.39 μmol, 1 equiv.) in MeOH (3 mL) was added 4 M gaseous HCl in MeOH (8 mL) at 20 °C. The resulting mixture was then stirred at 20 °C for 12 h. It was removed MeOH under reduced pressure and the residue was partitioned between EA (50 mL) and H2O (50 mL). The EA phase was washed with H2O (50 ml) again. The combined aqueous layers were adjusted to pH 7~8 with sat. aq. NaHCO3, then extracted EA (50 mL x2). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated to give 4-[[3-isopropyl-1-(p-tolylsulfonyl)-pyrrolo[3,2-b]pyridine-5- yl]methyl]-3,5-dimethylaniline (120 mg, 261.40 μmol, yield 84%, purity 97.5%) as a light- yellow solid. 24. Synthesis of 2,2,2-trifluoro-N-(4-formyl-3,5-dimethylphenyl)acetamide Trifluoroacetic anhydride (2 equiv., 5.63 mL) was added to a solution of 4-iodo-3,5-dimethylaniline (1 equiv., 5 g, 20.24 mmol) in anhydrous DCM (150 mL) under N2 at 0 °C. Then, the reaction mixture was stirred at 25 °C for 2.5 hours. Water (200 mL) was added to the reaction mixture, the layers was separated and the aqueous layer was extracted with DCM (2 × 150 mL). The combined organic layers were dried over MgSO4, filtered and evaporated to dryness. The crude mixture was purified by flash chromatography on silica gel (DCM) to give 2,2,2-trifluoro-N-(4-iodo-3,5-dimethylphenyl)acetamide (6.35 g, 91%) as white solid. Anhydrous THF (35 mL) was added to the mixture of 2,2,2-trifluoro-N-(4-iodo-3,5-dimethylphenyl)acetamide (1 equiv., 2.40 g, 7 mmol) and NaH 60% (1.5 equiv., 420 mg) under N2 at 0 °C. The reaction mixture stirred at 25 °C for 1.5 g, then cooled to -78 °C and tert-BuLi (2.4 equiv., 9.88 mL) was added dropwise. The reaction mixture was stirred at -78 °C for 40 min. Then, was added anhydrous DMF (5 equiv., 2.71 mL) and the reaction mixture was further stirred at −78 °C for 1 h. The reaction mixture was hydrolyzed with sat. aq. NH4Cl (5 mL), poured into DCM (250 mL) and washed 4 times. brine. The combined organic layers were dried over MgSO4, filtered and evaporated to dryness. The crude The mixture was recrystallized from hot EtOH to give 2,2,2-trifluoro-N-(4-formyl-3,5- dimethylphenyl)acetamide (317 mg, 19%) as a yellow solid. Supernatant recrystallized from hot toluene to give a larger amount of 2,2,2-trifluoro-N-(4-formyl- 3,5-dimethylphenyl)acetamide (909 mg, 53%) as a light yellow solid. 25. Synthesis of 3,5-dimethyl-4-((3-pentyl-1H-indazol-5-yl)methyl)aniline Anhydrous THF (8.3 mL) was added to a mixture of 5-bromo-3-pentyl-1H-indazole (1 eq., 668 mg, 2.5 mmol) and NaH 60% (1.5 equiv., 150 mg) at 0 °C, under N2 atmosphere. The resulting reaction mixture was stirred at 25 °C for 1 h. The mixture was then cooled to -78 °C and n-BuLi (1.5 equiv., 2.34 ml) was added dropwise and the reaction mixture was stirred at -78 °C for 2 h. Then the solution of 2,2,2- trifluoro-N-(4-formyl-3,5-dimethylphenyl)acetamide (1 equiv., 613 mg) in anhydrous THF (8.3 mL) was added dropwise to the reaction mixture at -78 °C. The reaction mixture was further stirred at at this temperature for 1.75 g and finally hydrolyzed with sat. aq. NH4Cl (5 ml), poured into DCM (100 ml) and washed 3 times with water. The organic phase was dried over MgSO4, filtered and evaporated to dryness. The crude mixture was purified by flash chromatography on silica gel (20% to 40% EA in cyclohexane) with obtaining 2,2,2-trifluoro-N-(4-(hydroxy(3-pentyl-1H-indazol-5-yl)methyl)-3,5- dimethylphenyl)acetamide (317 mg, 29%) as a white solid. A solution of Et3SiH (6 equiv., 0.71 mL) in anhydrous DCM (20 mL) was added, followed by a solution of TMSOTf (0.075 equiv., 0.01 mL) in anhydrous DCM (7 mL) was added dropwise to a solution of 2,2,2-trifluoro-N-(4-(hydroxy(3- pentyl-1H-indazol-5-yl)methyl)-3,5-dimethylphenyl)acetamide (1 equiv., 317 mg, 0.73 mmol) in anhydrous DCM (7 mL) at 0 °C under N2. The reaction mixture was stirred at 0 °C for 1 h, after which whereupon the ice bath was removed and the reaction mixture was stirred at 25 °C. After 19 h, an additional Et3SiH (6 equiv., 0.71 mL) and TMSOTf (0.075 equiv., 0.01 mL) were added and the reaction mixture was further was stirred at 25 °C for 5 h. The reaction mixture was then quenched with sat. aq. NaHCO3 (20 mL) and The aqueous phase was extracted 3 times with DCM (3 × 50 mL). The combined organic layers were washed with brine (150 ml), dried with MgSO4, filtered and evaporated to dryness. The crude mixture was purified by flash chromatography on silica gel (0% to 30% EA in cyclohexane) to give N-(3,5-dimethyl-4-((3- pentyl-1H-indazol-5-yl)methyl)phenyl)-2,2,2-trifluoroacetamide (144 mg, 47%) as a white solid substances. NaOH (4 equiv., 54 mg) was added to a solution of N-(3,5-dimethyl-4-((3-pentyl-1H-indazol-5- yl)methyl)phenyl)-2,2,2-trifluoroacetamide (1 equiv., 141 mg, 0.34 mmol) in MeOH (7 mL) and water (1.4 mL) in under N2 atmosphere. The reaction mixture was stirred at 60 °C for 90 h. The reaction mixture was then quenched water (30 mL). The resulting solution was extracted with DCM (3 × 20 mL) and the combined organic layers were washed with brine (2 × 20 mL), dried with MgSO4, filtered and evaporated to dryness to give 3,5-dimethyl-4- ((3-pentyl-1H-indazol-5-yl)methyl)aniline (105 mg, 97%) as a white solid, which used without further purification. Example 1: Synthesis of compound 1 N Cl About Cl NH 2 Ts N Cl About Cl N H Ts N About NH About About CN About N H About About 1) NaNO2, HCl 2) Py, H2O KOAc DMA NC N Cl About Cl N Ts N H N About About CN N H Cl About Cl CN N N N H About About THF TBAF (1M in THE) 1 To a stirred solution of 3,5-dichloro-4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indole-5- yl]methyl]aniline (1.11 g, 2.277 mmol, 1.00 equiv.) in HCl (21.90 mL), HOAc (62.50 mL), and H2O (47.68 mL) NaNO2 (0.32 g, 4.566 mmol, 2 equiv.) in H2O (4.2 mL) was added dropwise over 1 h at 0 °C. The second The reaction flask was charged with ethyl N-(2-cyanoacetyl)carbamate (0.53 g, 3.424 mmol, 1.5 equiv.) in H2O (58.41 mL) and pyridine (22.35 mL) for 10 min at 0 °C. The above solution quickly was poured into a second reaction flask for 30 min at 0 °C. The solid precipitate was collected by filtration and washed with water and PE. The resulting mixture was concentrated in vacuo. This resulted in the preparation of ethyl N- [(Z)-cyano[2-(3,5-dichloro-4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indol-5-yl]methyl]phenyl]hydrazine-1- ylidene]carbonyl]carbamate, which can also be called ethyl (Z)-(2-cyano-2-(2-(3,5-dichloro-4-((3- isopropyl-1-tosyl-1H-indol-5-yl)oxy)phenyl)hydrazinylidene)acetyl)carbamate, as a red solid substance. To a stirred solution of ethyl N-[(Z)-cyano[2-(3,5-dichloro-4-[[3-isopropyl-1-(4- methylbenzenesulfonyl)indol-5-yl]-oxy]phenyl)hydrazin-1-ylidene]-carbonyl]carbamate, which is also can be called ethyl (Z)-(2-cyano-2-(2-(3,5-dichloro-4-((3-isopropyl-1-tosyl-1H-indole-5- (( KOAc (0.35 g, 3.546 mmol, 2 equiv.) was added portionwise at rt. The resulting mixture was stirred for 2 h at 120 °C under nitrogen. The reaction mixture was quenched by adding water (10 ml) at r.t. The solid precipitate was collected by filtration and washed with water (3 × 10 mL). The solid was dried overnight at rt to give 2-(3,5-dichloro-4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indole-5- yl]oxy]-phenyl)-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (521.2 mg, 45%) as a red solid substances. To a stirred solution of 2-(3,5-dichloro-4-[[3-isopropyl-1-(4-methyl-benzenesulfonyl)indol-5- yl]oxy]phenyl)-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (521.20 mg, 0.854 mmol, 1.00 equiv.) in THF (20.00 ml) was added to TBAF (20 ml) in portions at rt under nitrogen atmosphere. The resulting mixture was stirred for 20 h at 65 °C under nitrogen. The reaction mixture was quenched with H2O. The resulting mixture was extracted with EA, washed with brine, and dried over anhydrous Na2SO4. After After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC. (DCM:MeOH 16:1) to give crude product (200 mg). Crude product (200 mg) was purified by preparative HPLC to give 2-[3,5-dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-phenyl]- 3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (11.5 mg, 3%, compound 1) as a yellow solid. 1H-NMR: (300 MHz, DMSO-d6) δ ppm: 10.67 - 10.60 (m, 1H), 7.77 (s, 2H), 7.30 (d, J=8.7 Hz, 1H), 7.07 (s, 1H), 6.82 (d, J=2.5 Hz, 1H), 6.67 (dd, J=8.9, 2.5 Hz, 1H), 2.94 (n, J=7.0 Hz, 1H), 1.18 (d, J=6.8 Hz, 6H). Example 2: Synthesis of compound 2 N About NH 2 Ts N About N H Ts N About NH About About CN About N H About About 1) NaNO2, HClAcOH, H2O 2) Py, H2O KOAc DMA NC N About N Ts N H N About About CN N H About CN N N N H About About THF TBAF (1M in THE) 2 In a 100 ml 3-neck round-bottom flask, where an inert nitrogen atmosphere is maintained, 4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indol-5-yl]oxy]-3,5-dimethylaniline (450.00 mg, 1.003 mmol, 1.00 equiv.) in conc. HCl (9.60 mL), AcOH (27.40 mL), and H2O (20.9 mL). To the stirred NaNO2 (145.35 mg, 2.107 mmol, 2.1 equiv.) in H2O (1.8 mL) was added dropwise to the solution over 45 min. at 0 °C. The second reaction flask was charged with methyl N-(2-cyanoacetyl)carbamate (213.85 mg, 1.505 mmol, 1.50 equiv.) in H2O (25.6 mL) and pyridine (9.80 mL) for 10 min at 0 °C. The above The solution was quickly poured into a second reaction flask for 30 min at 0 °C. The solid precipitate was collected by filtration and washed with water and PE. The resulting mixture was concentrated in vacuo. This resulted in preparation of ethyl N-[(Z)-cyano[2-(4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indol-5-yl]oxy]-3,5- dimethylphenyl)hydrazin-1-ylidene]-carbonyl]carbamate, which can also be called ethyl (Z)-(2-cyano-2-(2- (4-((3-isopropyl-1-tosyl-1H-indol-5-yl)oxy)-3,5-dimethylphenyl)hydrazinylidene)acetyl)carbamate, in in the form of a red solid. To a stirred solution of ethyl N-[(Z)-cyano[2-(4-[[3-isopropyl-1-(4-methyl-benzenesulfonyl)indole-5- yl]oxy]-3,5-dimethylphenyl)hydrazin-1-ylidene]-carbonyl]carbamate, which can also be called ethyl (Z)- (2-cyano-2-(2-(4-((3-isopropyl-1-tosyl-1H-indol-5-yl)oxy)-3,5- dimethylphenyl)hydrazinylidene)acetyl)carbamate (name created by Chemdraw) (560.0 mg, 0.910 mmol, 1.00 equiv.) in DMA (10.00 mL) was added KOAc (178.52 mg, 1.819 mmol, 2.0 equiv.) in portions at r.t. The resulting mixture was stirred for 2 h at 120 °C under nitrogen. The reaction mixture was quenched by adding water (10 mL) at rt. The resulting mixture was extracted with EA (3 × 100 mL). The combined The organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4. After filtration, The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gels to obtain 2-(4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indol-5-yl]oxy]-3,5- dimethylphenyl)-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (350 mg, 56%) as a red solid substances. To a stirred solution of 2-(4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)-indol-5-yl]oxy]-3,5- dimethylphenyl)-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (330.00 mg, 1 equiv.) in THF was added TBAF(1 M in THF) (8.00 ml) at rt. The resulting mixture was stirred for 48 h at 65 °C. The resulting The mixture was diluted with water (100 mL). The resulting mixture was extracted with EA (3 × 100 mL). The combined organic The layers were washed with brine (100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate concentrated under reduced pressure. Purification gave 2-[4-[(3-isopropyl-1H-indole-5- yl)oxy]-3,5-dimethyl-phenyl]-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (132.3 mg, 54%) as yellow solid. 1H-NMR: (300 MHz, DMSO-d6) δ ppm: 10.66 (s, 1H), 7.29-7.20 (m, 3H), 7.04 (d, J=2.2 Hz, 1H), 6.77 (d, J=2.4 Hz, 1H), 6.60 (dd, J=8.8, 2.5 Hz, 1H), 2.94 (n, J=6.9 Hz, 1H), 2.10 (s, 6H), 1.19 (d, J=6.8 Hz, 6H). Example 3: Synthesis of compound 3 N NH2 Ts N N H Ts N About NH About About CN About N H About About 1) NaNO2, HCl, 0 oC, HOAc Py, H2O, 0 oC NC N N Ts N H N About About CN N H N N NH About CN About THF, 65 °C, 3 days TBAF (1M in THE) 3 KOAc, DMA 120 oC, overnight In the first reaction flask, to a stirred solution of 4-[[3-isopropyl-1-(4-methyl- benzenesulfonyl)indol-5-yl]methyl]-3,5-dimethylaniline (480.00 mg, 1.075 mmol, 1.00 equiv.) in concentrated HCl (9.60 mL), HOAc (28.80 mL), and H2O (22.4 mL) under nitrogen at 0 °C NaNO2 (155.72 mg, 2.257 mmol, 2.1 equiv) in H2O (22.4 mL) was added. The reaction mixture was stirred for 45 min at 0 °C. In a second reaction flask, a solution of ethyl N-(2- cyanoacetyl)carbamate (251.72 mg, 1.612 mmol, 1.50 equiv.) in H2O (27.2 mL) and pyridine (9.60 mL) at 0 °C for 10 min. The contents of the first reaction flask were quickly poured into the second reaction flask, the reaction The mixture was stirred at 0 °C for 30 min. The solid precipitate was collected by filtration and washed with water (3 × 50 mL) and PE (3 × 50 mL). The resulting mixture was concentrated in vacuo. The crude product isolated as a yellow solid, 520 mg, purity 80%, yield 63%. To a stirred solution of ethyl N-[(Z)-cyano[2-(4-[[3-isopropyl-1-(4-methyl-benzenesulfonyl)indole-5- yl]methyl]-3,5-dimethylphenyl)hydrazin-1-ylidene]-carbonyl]carbamate, which can also be called ethyl (Z)- (2-cyano-2-(2-(4-((3-isopropyl-1-tosyl-1H-indol-5-yl)methyl)-3,5- dimethylphenyl)hydrazinylidene)acetyl)carbamate, (350.00 mg, 0.570 mmol, 1.0 equiv.) in DMA (8.0 mL) at rt. KOAc (111.94 mg, 1.141 mmol, 2.0 equiv.) was added. The reaction mixture was stirred at 120 °C. for 3 h. The reaction mixture was quenched by adding water (10 ml) at rt. The solid precipitate was collected by filtration and washed with water (3 × 10 mL). The solids were dried in vacuo for over 2 h at 60 °C to give 2-(4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indol-5-yl]methyl]-3,5- dimethylphenyl)-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile. The desired product was isolated as dark orange solid, 250 mg, purity 80%, yield 62%. To a stirred solution of 2-(4-[[3-isopropyl-1-(4-methylbenzenesulfonyl)indol-5-yl]methyl]-3,5- dimethylphenyl)-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (200.00 mg, 0.352 mmol, 1.00 equiv.) in THF (5.00 mL) under nitrogen at 0 °C was added TBAF (10.57 mL, 10.570 mmol, 30.00 equiv., 1 M in THF). The reaction mixture was stirred at 65 °C for 3 days. The reaction mixture was concentrated at under reduced pressure to give the crude product. The sample was purified to give 2-(4-((3- isopropyl-1H-indol-5-yl)methyl)-3,5-dimethylphenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6- carbonitrile as a yellow solid (compound 3, 29.7 mg, purity 99%, yield 20%). 1H NMR (400 MHz, DMSO-d6) δ ppm: 13.00 (w, 1H), 10.63 (s, 1H), 7.19-7.22 (m, 2H), 7.14 (s, 2H), 7.01 (d, J=2.0 Hz, 1H), 6.68-6.71 (m, 1H), 4.11 (s, 2H), 3.00-3.04 (m, 1H), 2.27 (s, 6H), 1.24-1.25 (m, 6H). Example 4: Synthesis of compound 4 N Cl About Cl N I Ts N NH About About CN N Cl About Cl About About N N NH About Ts About CN 90 oC, overnight CO, Pd(dppf)Cl2, Et3N, MeOH N HCl About Cl About About N N NH About About CN 65 oC, overnight TBAF,THF A 50 ml autoclave was charged with 2-(3,5-dichloro-4-[[3-iodo-1-(4- methylbenzenesulfonyl)indol-5-yl]oxy]phenyl)-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (1.00 g, 1.44 mmol, 1.00 equiv.), dichloro[1,1'-bis(diphenylphosphine)-ferrocene]-palladium (II) (0.11 g, 0.144 mmol, 0.10 equiv.), triethylamine (0.44 g, 4.32 mmol, 3.00 equiv.), methanol (10 ml). The contents of the autoclave were placed in carbon monoxide atmosphere (30 atm). The reaction mixture was stirred overnight at 90 °C. The catalysts were filtered off. The filtrate was concentrated under reduced pressure. The residue was purified with obtaining 500 mg (yield 67%) of methyl 5-[2,6-dichloro-4-(6-cyano-3,5-dioxo-4H-1,2,4-triazine-2- yl)phenoxy]-1-(4-methylbenzenesulfonyl)-indole-3-carboxylate as a brown solid. Methyl 5-[2,6-dichloro-4-(6-cyano-3,5-dioxo-4H-1,2,4- triazin-2-yl)phenoxy]-1-(4-methylbenzenesulfonyl)indole-3-carboxylate (400 mg, 0.639 mmol, 1.00 equiv.), tetrahydrofuran (5 ml), tetrabutylammonium fluoride (6.39 ml, 1 M in tetrahydrofuran, 6.39 mmol, 10.0 equiv.). The reaction mixture was stirred overnight at 65 °C and quenched with water (10 mL). The resulting solution was extracted with dichloromethane (3 × 20 mL) and the organic layers were combined, washed brine (2 × 10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated at The residue was purified to give 30.4 mg (15% yield) of methyl 5-[2,6-dichloro-4-(6-cyano- 3,5-dioxo-4H-1,2,4-triazin-2-yl)phenoxy]-1H-indole-3-carboxylate as a yellow solid. 1H NMR (300 MHz, Methanol-d4) δ ppm: 7.97 (s, 1H), 7.80 (s, 2H), 7.41-7.44 (m, 2H), 6.88-6.92 (m, 1H), 3.84 (s, 3H). Example 5: Synthesis of compound 5 N Cl About Cl N N NH About CN About Ts N H Cl About Cl N N NH About CN About TBAF, THF 65 oC, overnight N H Cl About Cl N N NH About CN About About 100 oC, overnight 5 CCl3COOH, Et3SiH, toluene A 250 ml round-bottom flask was charged with 2-(3,5-dichloro-4-[[1-(4- methylbenzenesulfonyl)indol-5-yl]oxy]phenyl)-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (1.00 g, 1.759 mmol, 1.00 equiv.), tetrahydrofuran (20 ml), tetrabutylammonium fluoride (52.78 ml, 1 M in tetrahydrofuran, 52.78 mmol, 30.00 equiv.). The resulting solution was stirred overnight at 65 °C and then quenched with water (150 mL). The resulting mixture was extracted with ethyl acetate (3 × 200 mL) and the organic The layers were combined, washed with brine (3 × 200 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified to give 500 mg (yield 69 %) 2-[3,5-dichloro-4-(1H-indol-5-yloxy)phenyl]-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile in the form yellow solid. To a stirred solution of 2-[3,5-dichloro-4-(1H-indol-5-yloxy)phenyl]-3,5-dioxo-4H-1,2,4-triazine- 6-carbonitrile (300 mg, 0.724 mmol, 1.00 equiv.), trichloroacetic acid (355 mg, 2.17 mmol, 3.00 equiv.) and triethylsilane (337 mg, 2.90 mmol, 4.0 equiv.) in toluene (10 mL) under nitrogen at 100 °C Cyclopentanone (366 mg, 4.35 mmol, 6.00 equiv.) was added. The reaction mixture was stirred overnight. at 100 °C and concentrated under reduced pressure. Purification gave 20.2 mg (6% yield) 2-[3,5-dichloro-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]phenyl]-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ ppm: 10.77 (s, 1H), 7.81 (s, 2H), 7.30-7.34 (m, 1H), 7.13 (d, J=1.8 Hz, 1H), 6.90 (d, J=2.4 Hz, 1H), 6.64-6.68 (m, 1H), 3.06-3.14 (m, 1H), 1.99-2.03 (m, 2H), 1.60-1.78 (m, 6H). Example 6: Synthesis of compound 6 N HCl About Cl N N NH About About CN N HCl About Cl N N NH About About CN About 100 oC, overnight CCl3COOH, Et3SiH, toluene In a 50 ml round-bottom flask charged with 2-[3,5-dichloro-4-(1H-indol-5-yloxy)phenyl]-3,5- dioxo-4H-1,2,4-triazine-6-carbonitrile (300 mg, 0.724 mmol, 1.00 equiv.), trichloroacetic acid (355 mg, 2.17 mmol, 3.00 equiv.), toluene (10.00 mL), triethylsilane (504.10 mg, 4.35 mmol, 6.00 equiv.) under nitrogen atmosphere, acetophenone (261 mg, 2.17 mmol, 3.00 equiv.) was added at 100 °C. The resulting The solution was stirred overnight at 100 °C and concentrated under reduced pressure. The residue was dissolved in water (20 mL) and extracted with dichloromethane (3 × 50 mL). The organic layers were combined, washed with brine (2 × 10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification gave 63.2 mg (17% yield) of 2-(3,5-dichloro-4-[[3-(1- phenylethyl)-1H-indol-5-yl]oxy]phenyl)-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile as a yellow solid substance. 1H NMR (300 MHz, DMSO-d6) δ ppm: 10.88 (s, 1H), 7.75 (s, 2H), 7.21-7.29 (m, 2H), 7.13-7.21 (m, 4H), 7.06-7.11 (m, 1H), 6.63-6.67 (m, 1H), 6.38-6.39 (m, 1H), 4.11-4.18 (m, 1H), 1.56-1.59 (m, 3H). Example 7: Synthesis of compound 7 N Cl About Cl N I Ts N NH About About CN N Cl About Cl N N NH About Ts About CN B OH OH 90 oC, overnight Pd(dppf)2Cl2, K2CO3 dioxane, water TBAF, THF 65 oC, overnight N HCl About Cl N N NH About About CN 7 To a stirred solution of 2-(3,5-dichloro-4-[[3-iodo-1-(4-methylbenzenesulfonyl)indole-5- yl]oxy]phenyl)-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (400 mg, 0.576 mmol, 1.00 equiv.) and phenylboronic acid (91.3 mg, 0.749 mmol, 1.30 equiv.) and dioxane (4 mL) and water (0.8 mL) were added dichloro[1,1'-bis(diphenylphosphine)-ferrocene]palladium(II) (42.2 mg, 0.0580 mmol, 0.10 equiv) and carbonate potassium (238.88 mg, 1.728 mmol, 3.00 equiv.) at rt under nitrogen. The reaction mixture was stirred overnight at 90 °C and concentrated under reduced pressure. The residue was purified to give 170 mg (yield 42%) 2-(3,5-dichloro-4-[[1-(4-methyl-benzenesulfonyl)-3-phenylindol-5-yl]oxy]phenyl)-3,5-dioxo- 4H-1,2,4-triazine-6-carbonitrile as a light brown solid. To a stirred solution of 2-(3,5-dichloro-4-[[1-(4-methylbenzenesulfonyl)-3-phenylindole-5- yl]oxy]phenyl)-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (160 mg, 0.248 mmol, 1.00 equiv.) in tetrahydrofuran (4 ml) was added tert-butyl ammonium fluoride (4.96 ml, 1 M in tetrahydrofuran, 4.96 mmol, 20.00 equiv.) at rt under nitrogen. The reaction mixture was then stirred overnight. at 65 °C and quenched with water (10 mL). The resulting mixture was extracted with ethyl acetate (3 × 10 mL) and combined. The organic layers were combined, washed with brine (3 × 20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification gave 2-[3,5-dichloro-4-[(3-phenyl-1H- indol-5-yl)oxy]phenyl]-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (compound 7, 39 mg, 32%) in the form light orange solid. 1H NMR (300 MHz, Methanol-d4) δ ppm: 7.78 (s, 2H), 7.50-7.56 (m, 2H), 7.49 (s, 1H), 7.35-7.41 (m, 3H), 7.18-7.23 (m, 2H), 681-6.84 (m, 1H). Example 8: Synthesis of compound 8 To a solution of 2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-4H-1,2,4- triazine-6-carbonitrile (200.00 mg, 0.460 mmol, 1.00 equiv.) in HOAc (4.43 mL, 0.074 mmol, 0.16 equiv.) HCl (2.00 mL, 0.055 mmol, 0.12 equiv.) was added portionwise at rt. The resulting mixture was stirred overnight at 120 °C under nitrogen. The crude product (160 mg) was purified to give 2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-4H-1,2,4-triazine-6- carboxylic acid (78.3 mg, 38%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): δ ppm: 13.82 (s, 1H), 12.70 (s, 1H), 12.19 (s, 1H), 7.82 (s, 2H), 7.44 (s, 1H), 3.05 (n, J=6.8 Hz, 1H), 1.20 (d, J=6.9 Hz, 6H). Example 9: Synthesis of compound 9 To a solution of 2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-4H-1,2,4- To a solution of triazine-6-carbonitrile (200.00 mg, 0.460 mmol, 1.00 equiv.) in DMSO (5 mL) was added K2CO3 (190.53 mg, 1.379 mmol, 3.00 equiv.) and H2O2 (2 mL, 30% in water) in portions at 0 °C. The resulting mixture was stirred for 5 h at rt. The reaction mixture was quenched with saturated Na2S2O3 solution at rt. and concentrated under reduced pressure. The residue was purified by reverse flash chromatography with the following conditions (column, C18; mobile phase, ACN in water, gradient from 10% to 80% in 30 min) to obtain of crude product (150 mg), which was then purified by preparative HPLC (Column: XBridge Prep OBD C18 Column, Mobile Phase A: Water (10 mM NH4HCO3), Mobile Phase B: ACN; Flow Rate: 60 mL / min; Gradient: from 20% B to 33% B in 9 min;) to give 2-[3,5-dichloro-4-[(5-isopropyl-6-oxo- 1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-4H-1,2,4-triazine-6-carboxamide (112.1 mg, 54%) as white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm: 12.76 (s, 1H), 12.20 (s, 1H), 8.14 (w, 1H), 7.85-7.90 (m, 3H), 7.44 (c, 1H), 3.05 (n, J=6.8 Hz, 1H), 1.20 (d, J=6.8 Hz, 6H). Example 10: Synthesis of compound 10 N H N Cl About Cl N N N H About About About OH About N H N Cl About Cl N N N H About About About N H DPPA, Et, t-BuOH Boc N H N Cl About Cl N N N H About About About NH 2 HCl in dioxane 10 To a solution of 2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-4H-1,2,4- triazine-6-carboxylic acid (200.00 mg, 0.440 mmol, 1.00 equiv.) in tert-BuOH (20.00 mL, 210.465 mmol) was added DPPA (375.64 mg, 1.365 mmol, 3.10 equiv.) and Et3N (138.12 mg, 1.365 mmol, 3.10 equiv.) in portions at rt. The resulting mixture was stirred for 24 h at 85 °C in a nitrogen atmosphere. The resulting mixture was concentrated. The residue was dissolved in CH2Cl2 (100 mL), and then washed with NH4Cl (4 × 200 ml), NaHCO3 and brine. The combined organic layers were dried over anhydrous Na2SO4. After After filtration, the filtrate was concentrated. The residue was purified by column chromatography on silica gel, eluted with CH2Cl2:MeOH (50:1), to give tert-butyl N-(2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H- pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-4H-1,2,4-triazin-6-yl)-carbamate (110 mg, 48%) as a white solid substance. LCMS (ESI, m / z): 525 [M+H]+. Solution of tert-butyl N-(2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo- 4H-1,2,4-triazin-6-yl)carbamate (90.0 mg, 1 equiv.) in 4 N HCl in 1,4-dioxane (5.00 mL) was stirred overnight at rt. The resulting mixture was concentrated. The crude product (70 mg) was purified preparative HPLC (Column: XBridge Prep OBD C18, Mobile phase A: Water (10 mmol / L NH4HCO3+0.1%NH3·H2O), Mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 10 B to 40 B in 8 min) to give 6-amino-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-4H- 1,2,4-triazine-3,5-dione (18.8 mg, 26%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm: 12.26 (s, 1H), 12.18 (s, 1H), 7.85 (s, 2H), 7.41 (s, 1H), 6.45 (s, 2H), 2.95-3.10 (m, 1H), 1.19 (d, J=6.9 Hz, 6H). Example 11: Synthesis of compound 11 N H N Cl About Cl N N N About About About Br About N H N Cl About Cl N N N About About About About TMS Gul, Pd(dppf)Cl2, Et3N, DMF TMS 80 oC, overnight N H N Cl About Cl N N N H About About About N H N Cl About Cl N N N H About About About TMS 0 oC to kt, 4 h BBr3, DCM K2CO3, MeOH kt, during the night 11 To a stirred solution of 4-[(benzyloxy)methyl]-6-bromo-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H- pyridazin-3-yl)oxy]phenyl]-1,2,4-triazine-3,5-dione (430.00 mg, 0.706 mmol, 1.00 equiv.) and To trimethylsilylacetylene (207.96 mg, 2.117 mmol, 3.0 equiv.) in DMF (10 mL) was added CuI (26.88 mg, 0.141 mmol, 0.20 equiv.), Et3N (214.25 mg, 2.117 mmol, 3.00 equiv.) and Pd(dppf)Cl2 (103.28 mg, 0.141 mmol, 0.20 equiv.) in portions at rt under nitrogen. The reaction mixture was stirred overnight at 80 °C and quenched with water (10 mL). The resulting mixture was extracted with EA (3 × 40 mL). The combined organic layers washed with water (1 × 100 ml), dried over anhydrous Na2SO4. After filtration, the filtrate concentrated under reduced pressure. The residue was purified by column chromatography on silica gel with obtaining 4-[(benzyloxy)methyl]-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]- 6-[2-(trimethylsilyl)ethynyl]-1,2,4-triazine-3,5-dione (260 mg, 52%) as an off-white solid substances. To a stirred solution of 4-[(benzyloxy)methyl]-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H- pyridazin-3-yl)oxy]phenyl]-6-[2-(trimethylsilyl)ethynyl]-1,2,4-triazine-3,5-dione (240.00 mg, 0.383 mmol, 1.00 equiv.) in DCM (5 mL) was added BBr3 (383.84 mg, 1.532 mmol, 4.00 equiv.) dropwise at 0 °C in under nitrogen atmosphere. The reaction mixture was stirred for 4 h at rt and quenched with MeOH (5 The resulting mixture was concentrated under reduced pressure to give 100 mg (crude) of 2-[3,5- dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-6-[2-(trimethylsilyl)-ethynyl]-4H-1,2,4- triazine-3,5-dione as a light brown solid. To a stirred solution of 2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-6-[2- (trimethylsilyl)ethynyl]-4H-1,2,4-triazine-3,5-dione (100.00 mg, 0.197 mmol, 1.00 equiv.) in MeOH (10 mL) K2CO3 (109.16 mg, 0.790 mmol, 4.00 equiv.) was added at rt. The reaction mixture was stirred for overnight at rt and concentrated under reduced pressure to give a residue. Purification led to obtaining 19.4 mg (yield 22%) of 2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-6- ethynyl-4H-1,2,4-triazine-3,5-dione as a white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm: 12.75 (s, 1H), 12.23 (s, 1H), 7.77 (s, 2H), 7.44 (s, 1H), 4.70 (s, 1H), 3.03-3.10 (m, 1H), 1.20 (d, J=6.8 Hz, 6H). Example 12: Synthesis of compound 12 N H N Cl About Cl N N N About O.O. About Br N H N Cl About Cl N N About ON About About About About NC About About CN K2CO3, DMF 90 oC, overnight N H N Cl About Cl N N N About O.O. About NC N H N Cl About Cl N N About OH NH About N -78 oC to kt, 4 hours TsOH, toluene 90 °C, 4 h BBr3, DCM 12 To a stirred solution of 4-[(benzyloxy)methyl]-6-bromo-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H- pyridazin-3-yl)oxy]phenyl]-1,2,4-triazine-3,5-dione (300.00 mg, 0.492 mmol, 1.00 equiv.) and tert-butyl 2- cyanoacetate (208.54 mg, 1.477 mmol, 3.0 equiv.) in DMF (5.00 mg) at rt was added K2CO3 (272.21 mg, 1.970 mmol, 4.0 equiv.). The reaction mixture was stirred overnight at 90 °C. The reaction mixture was quenched with water (30 mL). The resulting mixture was extracted with dichloromethane (3 × 50 mL) and the organic layers were combined, washed with brine (2 × 50 mL), dried over anhydrous sodium sulfate, filtered, and The residue was purified to give 190 mg (95% purity) of tert- butyl2-[4-[(benzyloxy)methyl]-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-3,5- dioxo-1,2,4-triazin-6-yl]-2-cyanoacetate (190 mg, 58%) as a yellow solid. A 50 ml round-bottom flask was charged with tert-butyl 2-[4-[(benzyloxy)methyl]-2-[3,5- dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]-phenyl]-3,5-dioxo-1,2,4-triazin-6-yl]-2- cyanoacetate (190.00 mg, 0.284 mmol, 1.00 equiv), TsOH (24.43 mg, 0.142 mmol, 0.5 equiv), and toluene (5 mL). The resulting solution was stirred for 4 h at 90 °C and quenched with water (10 mL). The resulting mixture extracted with dichloromethane (3 × 50 mL) and the organic layers were combined, washed with brine (2 × 30 ml), dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure with obtaining 190 mg of crude (70% purity) 2-[4-[(benzyloxy)methyl]-2-[3,5-dichloro-4-[(5- isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]-phenyl]-3,5-dioxo-1,2,4-triazin-6-yl]acetonitrile (190 mg, yield 82%) as a yellow oil. To a stirred solution of 2-[4-[(benzyloxy)methyl]-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H- pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazin-6-yl]acetonitrile (190.00 mg, 0.334 mmol, 1.00 equiv.) in DCM (3 mL) under nitrogen at -78 °C was added BBr3 (501.57 mg, 2.002 mmol, 6.0 equiv.). The reaction mixture was stirred at rt for 4 h. The reaction mixture was quenched with water (10 ml). The resulting solution was extracted with dichloromethane (3 × 20 mL) and the organic layers were combined, washed brine (2 × 10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated at under reduced pressure to give the crude product. Purification gave 24.9 mg. (yield 16%) 2-(2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-4H-1,2,4- triazin-6-yl)acetonitrile as a white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm: 12.71 (s, 1H), 12.20 (s, 1H), 7.81 (s, 2H), 7.46 (s, 1H), 4.05 (s, 2H), 3.03-3.07 (m, 1H), 1.11-1.31 (m, 6H). Example 13: Synthesis of compound 13 N H N Cl About Cl N N N About O.O. About Br N H N Cl About Cl N N About ON About About About O.O. About About About About About 110 oC, 1 hour CsCO3, DMSO N N Cl About Cl N N NH About About About About O.O. About N H N Cl About Cl N N N H About About About OH About 60 oC, 4 hours 13 NaOH, MeOH, H2O BBr3, DCM CT, 3 hours N To a stirred solution of 4-[(benzyloxy)methyl]-6-bromo-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H- pyridazin-3-yl)oxy]phenyl]-1,2,4-triazine-3,5-dione (350.00 mg, 0.574 mmol, 1.00 equiv.) and diethyl malonate (184.02 mg, 1.149 mmol, 2.00 equiv.) in DMSO (5 mL) under nitrogen at rt was added Cs2CO3 (561.52 mg, 1.723 mmol, 3.0 equiv.). The reaction mixture was stirred at 110 °C for 1 h. The reaction mixture The mixture was quenched with water (20 mL). The resulting solution was extracted with dichloromethane (3 × 50 mL) and the organic The layers were combined, washed with brine (2 × 30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. Crude the product was diluted with dichloromethane (50 ml) and a suspension was prepared with silica gel of 100~200 mesh size (2 g). The sample was purified and the desired product was isolated as a yellow oil. 270 mg, purity 90%, yield 61%. To a stirred solution of 1,3-diethyl 2-[4-[(benzyloxy)methyl]-2-[3,5-dichloro-4-[(5-isopropyl-6- oxo-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazin-6-yl]-propanedioate (250.00 mg, 0.363 To BBr3 (363.86 mg, 1.452 mmol, 1.00 equiv.) in DCM (5.00 mL) under nitrogen at 0 °C was added BBr3 (363.86 mg, 1.452 mmol, 4.00 equiv.). The reaction mixture was stirred at rt for 3 h. The reaction mixture was quenched with water (15 mL). The resulting solution was extracted with dichloromethane (3 × 30 mL) and the organic layers were combined, washed with brine (2 × 15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. No further purification of this material was required. The crude product was isolated as a yellow solid, 210 mg, purity 70%, yield 71%. To a stirred solution of 1,3-diethyl 2-(2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazine-3- yl)oxy]phenyl]-3,5-dioxo-4H-1,2,4-triazin-6-yl)propanedioate (210.00 mg, 0.369 mmol, 1.00 equiv.) in MeOH (5.00 mL) and H2O (1.00 mL) at rt were added NaOH (147.78 mg, 3.695 mmol, 10.00 equiv.). The reaction The mixture was stirred at 60 °C for 4 h. The pH of the mixture was adjusted to ~5-6 with hydrochloric acid. acid (1 M). The resulting solution was extracted with dichloromethane (3 × 30 mL) and the organic layers were combined, washed with brine (2 × 10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was purified to give 2-(2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)- 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)acetic acid. The desired product was isolated as white solid (54.0 mg, purity 99.5%, yield 31%). 1H NMR (300 MHz, DMSO-d6) δ ppm: 7.82 (s, 1H), 7.44 (s, 1H), 3.44 (s, 2H), 3.01-3.10 (m, 1H), 1.19- 1.24 (m, 6H). Example 14: Synthesis of compound 14 N N Cl About Cl N N N About About About Br About NH 2 110 oC, overnight N n-BuOH N N Cl About Cl N N N About About About NH About N H N Cl About Cl N About OH NH N About NH -78 oC to kt, 4h 14 N BBr3, DCM To a stirred solution of 4-[(benzyloxy)methyl]-6-bromo-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H- pyridazin-3-yl)oxy]phenyl]-1,2,4-triazine-3,5-dione (400.00 mg, 0.657 mmol, 1.00 equiv.) in n-BuOH (5 mL) methylamine (3.3 mL, 6.565 mmol, 10.00 equiv., 2 M in THF) was added at rt. The reaction mixture was stirred overnight at 110 °C. The reaction mixture was concentrated under reduced pressure with The residue was purified to give 220 mg (53% yield) of 4-[(benzyloxy)methyl]-2- [3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]-phenyl]-6-(dimethylamino)-1,2,4-triazine-3,5- dione as a light yellow solid. To a stirred solution of 4-[(benzyloxy)methyl]-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H- pyridazin-3-yl)oxy]phenyl]-6-(methylamino)-1,2,4-triazine-3,5-dione (400.00 mg, 0.715 mmol, 1.00 equiv.) in BBr3 (716.55 mg, 2.860 mmol, 4.00 equiv) was added to DCM at -78 °C. The resulting solution was stirred for 4 h at rt. The reaction mixture was concentrated under reduced pressure to give of crude product. Purification afforded 86.9 mg (54% yield) of 2-[3,5-dichloro-4-[(5- isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-6-(methylamino)-4H-1,2,4-triazine-3,5-dione as a white solid substance. 1H NMR (300 MHz, DMSO-d6) δ ppm: 12.99 (s, 1H), 12.23 (s, 1H), 8.82 (d, J=4.8 Hz, 1H), 8.16 (s, 2H), 7.42 (s, 1H), 3.03-3.08 (m, 1H), 2.79 (d, J=4.8 Hz, 3H), 1.20 (d, J=6.9 Hz, 6H). Example 15: Synthesis of compound 15 N N Cl About Cl N N N About About About Br About N H 110 oC, overnight N n-BuOH N N Cl About Cl N N N About About About N About N H N Cl About Cl N About OH NH N About N -78 oC to kt, 4 hours 15 N BBr3, DCM 4-[(benzyloxy)methyl]-6-bromo-2-[3,5-dichloro-4-[(5- isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-1,2,4-triazine-3,5-dione (400.00 mg, 0.657 mmol, 1.00 equiv.) in n-BuOH (8 mL) and dimethylamine (3.3 mL, 6.565 mmol, 10.00 equiv., 2 M in THF) at rt. Reaction The mixture was stirred overnight at 110 °C. The reaction mixture was concentrated under reduced pressure with The residue was purified to give 170 mg (yield 41%) of 4-[(benzyloxy)methyl]-2- [3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)-oxy]phenyl]-6-(dimethylamino)-1,2,4-triazine-3,5- dione as a light pink solid. A 50 ml round-bottom flask was charged with 4-[(benzyloxy)methyl]-2-[3,5-dichloro-4-[(5- isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-6-(dimethyl-amino)-1,2,4-triazine-3,5-dione (160.00 mg, 0.279 mmol, 1.00 equiv.), DCM (10.00 mL). BBr3 (279.61 mg, 1.116 mmol, 4.00 equiv.) was added at -78 °C. The resulting solution was stirred for 4 h at room temperature. The reaction mixture was concentrated under reduced pressure. to obtain the crude product. Purification led to the preparation of 54.3 mg (yield 42%) of 2-[3,5- dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-6-(dimethylamine)-4H-1,2,4-triazine-3,5- dione. 1H NMR (300 MHz, DMSO-d6) δ ppm: 7.91 (s, 2H), 7.43 (s, 1H), 3.03-3.10 (m, 1H), 2.99 (d, J=8.1Hz, 6H), 1.20 (d, J=6.9 Hz, 6H). Example 16: Synthesis of compounds 16 and 23 Compound 16 N N Cl About Cl OH BO OH N H N Cl About Cl NO OH NH N About N N NH Br About About 90 oC, overnight 16 Н Pd(PPh3)4, K2CO3, dioxane H2O To a stirred mixture of 3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenylboronic acid acid (250.00 mg, 0.729 mmol, 1.00 equiv.), 6-bromo-2-methyl-4H-1,2,4-triazine-3,5-dione (180.19 mg, 0.875 mmol, 1.20 equiv.), K2CO3 (201.48 mg, 1.458 mmol, 2.00 equiv.) in dioxane (10 mL) and H2O (1 mL) Pd(PPh3)4 (168.46 mg, 0.146 mmol, 0.20 equiv.) was added under nitrogen atmosphere. The resulting mixture was stirred overnight at 90 °C under nitrogen. The reaction mixture was quenched with water (15 mL) and extracted with EA (3 × 15 mL). The combined organic layers were washed with brine (2 × 15 mL), dried anhydrous sodium sulfate was filtered and concentrated under reduced pressure. The crude The product was triturated with EA:PE 1:5 and MeCN (5 mL), washed with ether (5 mL) to give the desired of the product 6-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-2-methyl-4H-1,2,4-triazine- 3,5-dione (103.8 mg, 34%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm: 12.45 (w, 1H), 12.21 (s, 1H), 8.10 (s, 2H), 7.43 (s, 1H), 3.58 (s, 3H), 3.11-2.97 (m, 1H), 1.20 (d, J=6.9 Hz, 6H). Compound 23 Compound 23 was prepared in the same manner as described for compound 16, using 6-bromo-2-ethyl-4H- 1,2,4-triazine-3,5-dione instead of 6-bromo-2-methyl-4H-1,2,4-triazine-3,5-dione. 1H NMR (300 MHz, DMSO-d6) δ: 12.39 (s, 1H), 12.18 (s, 1H), 8.09 (s, 2H), 7.40-7.41 (m, 1H), 3.95-4.03 (m, 2H), 3.00-3.07 (m, 1H), 1.28 (t, J=7.0 Hz, 3H), 1.28 (t, J=6.9 Hz, 6H). LCMS (ESI, m / z): 438 [M+H]+. Example 17: Synthesis of compound 17 Cl About Cl N N NH About About CN N HCl About Cl N N NH About About CN N H NC ClS About About NCO -45 oC to kt, 2 hours CH3CN, DMF 17 To a solution of 2-[3,5-dichloro-4-(1H-indol-5-yloxy)phenyl]-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (250.0 mg, 0.604 mmol, 1.00 equiv.) in acetonitrile (4 mL) was added dropwise to chlorosulfonyl isocyanate (102.5 mg, 0.724 mmol, 1.2 equiv.) in acetonitrile (0.4 mL) at -45 °C under nitrogen. During A fine precipitate formed upon addition. The mixture was stirred at -45 °C under nitrogen. for 10 min. N,N-dimethylformamide (4 mL) was then slowly added and the mixture was allowed to warm to rt and stirred for 2 h. The reaction mixture was quenched by addition of water / ice (10 mL) at 0 °C. The resulting mixture was extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with water. (3 × 10 mL), saturated NaHCO3, and brine, dried over anhydrous sodium sulfate, filtered, and The residue was purified by preparative TLC with dichloromethane:methanol (12:1) to give of crude product (160 mg). The crude product (160 mg) was purified by preparative HPLC with following conditions (Column: Kinetex EVO C 18 Column, 30*150, 5 μm; Mobile phase A: Water (0.05% TFA), Mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 50% B to 50% B in 8 min) to obtain 5-[2,6-dichloro-4-(6-cyano-3,5-dioxo-4H-1,2,4-triazin-2-yl)phenoxy]-1H-indol-3- carbonitrile (75.9 mg, 29% yield) as a light yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 13.30 (s, 1H), 12.28 (s, 1H), 8.28 (d, J=3.0 Hz, 1H), 7.84 (s, 2H), 7.58 (d, J=9.0 Hz, 1H), 6.97-7.01 (m, 1H), 6.86 (d, J=2.4 Hz, 1H). Example 18: Synthesis of compounds 18 and 19 N Cl About Cl NH 2 N H N Cl About Cl N H N N HN H About N About About ON H O.O. N 0 oC, 30min HCl, AcOH, NaNO2 pyridine, H2O N Cl About Cl N N H NH N About About N N Cl About Cl N N H NH N About About N 120 oC, overnight 18 KOAc, DMA 19 NaNO2 (150.8 mg, 2.19 mmol, 2.1 equiv.) in H2O (12 mL) was added dropwise to a solution of 3,5-dichloro- 4-([3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl]oxy)aniline (350.0 mg, 1.04 mmol, 1.0 equiv.) in HCl (5.5 mL, conc.), AcOH (16 mL) and H2O (12 mL). The mixture was stirred for 30 min at 0 °C. Then the reaction mixture was The mixture was quickly poured into a solution of ethyl N-(2-cyanoacetyl)carbamate (243.8 mg, 1.56 mmol, 1.5 equiv.) in H2O (16 mL) and pyridine (5.5 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 30 min and The filter residue was washed with water (2 × 15 ml) and petroleum ether (2 × 15 ml) was dried under reduced pressure to give (350 mg, crude) ethyl N-[(E)-cyano([2-[3,5-dichloro-4-([3- isopropyl-1H-pyrrol[3,2-b]pyridin-5-yl]oxy)phenyl]hydrazin-1-ylidene])carbonyl]carbamate in the form of a yellow solid substance. LCMS (ESI, m / z): 503 [M+H]+. To the solution of ethyl N-[(E)-cyano([2-[3,5-dichloro-4-([3-isopropyl-1H-pyrrolo[3,2-b]pyridine-5- yl]oxy)phenyl]hydrazin-1-ylidene])carbonyl]carbamate (350.00 mg, 0.695 mmol, 1.00 equiv.) in DMA (20 mL) KOAc (341.22 mg, 3.477 mmol, 5.00 equiv.) was added. The resulting mixture was stirred overnight at 120 °C and quenched with water (30 mL). The resulting mixture was extracted with EA (3 × 40 mL) and the organic layers were combined, washed with brine (2 × 30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was purified by TLC (Mobile phase: MeOH / DCM=1:7; Ku = 0.4; detection: UV) to give the crude product (180 mg). The product was separated by preparative chiral HPLC, Column: CHIRALPAK IE, 2*25 cm, 5 μm; Mobile phase A: Hexane (0.1 % FA)--HPLC, Mobile phase B: EtOH--HPLC; Speed Flow: 20 mL / min; Gradient: 10% B to 10% B in 21 min. Purification resulted in the desired of the product 2-[3,5-dichloro-4-([3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl]oxy)phenyl]-3,5-dioxo-4H-1,2,4- triazine-6-carbonitrile (86.3 mg, 26%) as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 13.25 (w, 1H), 11.00 (s, 1H), 7.82 (d, J=8.7 Hz, 1H), 7.76 (s, 2H), 7.28 (d, J=2.4 Hz, 1H), 6.89 (d, J=8.7 Hz, 1H), 2.78-2.95 (m, 1H), 1.13 (d, J=6.6 Hz, 6H). LCMS (ESI, m / z): 457.0 [M+H]+. The reaction also produces a by-product 2-[3,5-dichloro-4-([3-propyl-1H-pyrrolo[3,2-b]- pyridin-5-yl]oxy)phenyl]-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (20.8 mg, 6%) as a yellow solid substance. 1H NMR (300 MHz, DMSO-d6) δ 13.26 (w, 1H), 11.03 (s, 1H), 7.82 (d, J=8.4 Hz, 1H), 7.76 (s, 2H), 7.33 (d, J=2.4 Hz, 1H), 6.87 (d, J=8.7 Hz, 1H), 2.42 (t, J=7.5 Hz, 2H), 1.45-1.58 (m, 2H), 0.77 (t, J=7.5 Hz, 3H). LCMS (ESI, m / z): 457.0 [M+H]+. Example 19: Synthesis of compounds 20, 21 and 22 Compound 21 Cl About Cl NN I N NH About Ts About CN Cl About Cl N N N N NH About About Ts About CN NH 100 oC, overnight Et3N, toluene CO, Pd(MeCN)2Cl2, dppf TBAF, THF 65 oC, overnight Cl About Cl N N H N N NH About About About CN21 2-(3,5-dichloro-4-[[3-iodo-1-(4- methylbenzenesulfonyl)indol-5-yl]oxy]phenyl)-3,5-dioxo-4H-1,2,4-triazine-6-carbonitrile (600.00 mg, 0.864 mmol, 1.00 equiv.), dimethylamine (2.59 mL, 2 M in tetrahydrofuran, 5.185 mmol, 6.00 equiv.), 1,1'- bis(diphenylphosphine)ferrocene (95.47 mg, 0.173 mmol, 0.20 equiv), bis(acetonitrile)palladium(II) chloride (22.42 mg, 0.0864 mmol, 0.10 eq.), triethylamine (262.35 mg, 2.593 mmol, 3.00 eq.), toluene (15 mL). The contents of the autoclave were placed in a carbon monoxide atmosphere (20 atm). The reaction mixture was stirred overnight at 100 °C and quenched with water (10 mL). The resulting mixture was extracted with ethyl acetate (3 × 15 mL) and the organic layers were combined, washed with brine (3 × 15 mL), dried over anhydrous sulfate sodium. After filtration, the filtrate was concentrated under reduced pressure. The residue was chromatographed on a C18 chromatography column CH3CN:water (3:2) to give 300 mg (yield 49%) 5-[2,6-dichloro-4-(6-cyano-3,5-dioxo-4H-1,2,4-triazin-2-yl)phenoxy]-N,N-dimethyl-1-(4- methylbenzenesulfonyl)indole-3-carboxamide as a light brown solid. LCMS (ESI, m / z): 637 [MH]-. To a stirred solution of 5-[2,6-dichloro-4-(6-cyano-3,5-dioxo-4H-1,2,4-triazin-2-yl)phenoxy]-N, N-dimethyl-1-(4-methylbenzenesulfonyl)indole-3-carboxamide (200.00 mg, 0.313 mmol, 1.00 equiv.) in tetrahydrofuran (10 ml) was added tetrabutylammonium fluoride (1.25 ml, 1 M in tetrahydrofuran, 1.251 mmol, 4.00 equiv.) at room temperature under nitrogen. The reaction mixture was stirred overnight at 65 °C and quenched with water (5 mL). The resulting mixture was extracted dichloromethane (3 × 20 mL) and the organic layers were combined, washed with brine (5 × 10 mL) and hydrochloric acid (1 M), dried over anhydrous sodium sulfate. After filtration, the filtrate concentrated under reduced pressure. The crude product (150 mg) was purified by preparative HPLC with following conditions (Column: XBridge Shield RP18 OBD Column, 19*250 mm, 10 μm; Mobile phase A: Water (10 mM NH4HCO3), Mobile phase B: ACN; Flow rate: 25 mL / min; Gradient: From 27% B to 47% B in 7 min) to give 52 mg (34% yield) of 5-[2,6-dichloro-4-(6-cyano-3,5-dioxo-4H-1,2,4-triazine-2- yl)phenoxy]-N, N-dimethyl-1H-indole-3-carboxamide as a light yellow solid. 1H NMR (300 MHz, methanol-d4) δ 7.76 (s, 1H),7.68 (s, 2H), 7.41 (d, J=9.0 Hz, 1H), 7.08 (d, J=2.1 Hz, 1H), 6.90-6.94 (m, 1H), 3.13 (s, 6H). LCMS (ESI, m / z): 485 [M+H]+. Compound 20 Compound 20 was prepared in the same manner as described for compound 21, using 2 equiv. of isopropylamine instead of 6 equiv. of dimethylamine and leaving to react overnight at 80 °C. 1H NMR (300 MHz, methanol-d4) δ 7.89 (s, 1H),7.77 (s, 2H), 7.50 (d, J=2.4 Hz, 1H), 7.38 (d, J=9.3 Hz, 1H), 6.87-6.91(m, 1H), 4.12-4.16 (m, 1H), 1.21(d, J=6.6 Hz, 6H). LCMS (ESI, m / z): 499 [M+H]+. Compound 22 Compound 22 was prepared in the same manner as described for compound 21, using 1.5 equiv. of tetrahydroisoquinoline instead of 6 equiv. of dimethylamine. 1H NMR (400 MHz, methanol-d4) δ 7.70 (d, J=8.4 Hz, 3H), 7.45 (d, J=8.8 Hz, 1H), 7.15-7.17 (m, 3H), 7.07 (w, 1H), 6.93-6.99 (m, 1H), 6.91-6.92 (m, 1H), 4.78 (s, 2H), 3.86 (t, J=6.0 Hz, 2H), 2.87 (t, J=5.8 Hz, 2H). LCMS: 573 [M+H]+. Example 20: Synthesis of compounds 24, 25 and 26 Compound 25 N H N Cl About Cl N N NH About About About OH O N H N Cl About Cl N N NH About About About OH ClO About kt, during the night 25 DIEA, NaBH4,THF To a solution of 2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-4H-1,2,4- triazine-6-carboxylic acid (500 mg, 1.101 mmol, 1.00 equiv.) and N,N-diisopropylmethylamine (298.77 mg, 2.312 mmol, 2.10 equiv.) in tetrahydrofuran (30 mL) at 0 °C under nitrogen was added ethyl chloroformate (126.62 mg, 1.167 mmol, 1.06 equiv.) was added dropwise. The mixture was stirred for 1 h. at room temperature and treated dropwise with sodium borohydride solution (124.94 mg, 3.302 mmol, 3.00 equiv.) in water (2 mL) at 0 °C. The resulting solution was stirred overnight at room temperature. temperature and then slowly quenched with saturated NaHCO3 solution (10 mL). The resulting mixture extracted with chloroform / isopropanol (3 / 1) (5 × 30 mL) and the organic layers were combined, dried anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give of crude product. The crude product (400 mg) was purified by preparative HPLC using following gradient conditions: Column: XSelect CSH Prep C18 OBD Column, 5 μm, 19*150 mm; Mobile Phase A: Water (10 mM NH4HCO3+0.1 % NH3·H2O), Mobile phase B: ACN; Flow rate: 25 mL / min; Gradient: From 19% B to 31% B in 8 min), which led to the preparation of 2-[3,5-dichloro-4-[(5-isopropyl-6- oxo-1H-pyridazin-3-yl)oxy]phenyl]-6-(hydroxymethyl)-4H-1,2,4-triazine-3,5-dione (100.6 mg, yield 21%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 12.48 (w, 1H), 12.22 (w, 1H), 7.86 (s, 2H), 7.44 (s, 1H), 5.30 (t, J=6.0 Hz, 1H), 4.40 (d, J=6.0 Hz, 2H), 3.02-3.11 (m, 1H), 1.20 (d, J=6.9 Hz, 6H). LCMS (ESI, m / z): 440 [M+H]+. Compound 24 N H N Cl About Cl N N NH About About About OH N H N Cl About Cl N N NH About About About Br 75 °C, 1 hour 25 PBr3, CH3CN N H N Cl About Cl N N NH About About About NH NH 2 DMF, 70 °C, 1 h 24 A 50 ml round-bottom flask was charged with 2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H- pyridazin-3-yl)oxy]phenyl]-6-(hydroxymethyl)-4H-1,2,4-triazine-3,5-dione (1.60 g, 3.634 mmol, 1.00 equiv.), acetonitrile (15 mL). Phosphorus tribromide (0.3 mL) was added at 0 °C under nitrogen. The resulting solution was stirred for 1 h at 75 °C. The mixture was cooled to room temperature. temperature and then quenched with saturated aqueous NaHCO3 (10 mL). The resulting mixture was extracted ethyl acetate (3 × 15 mL) and the organic layers were combined, washed with brine (1 × 30 mL), dried anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 1.1 g (yield 39%) 6-(bromomethyl)-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-4H- 1,2,4-triazine-3,5-dione as a yellow solid. LCMS (ESI, m / z): 502 [M+H]+. A 50 ml round-bottom flask was charged with 6-(bromomethyl)-2-[3,5-dichloro-4-[(5-isopropyl-6- oxo-1H-pyridazin-3-yl)oxy]phenyl]-4H-1,2,4-triazine-3,5-dione (400 mg, 0.795 mmol, 1.00 equiv.), methylamine (1.2 mL, 2 M in tetrahydrofuran, 2.385 mmol, 3.00 equiv.) and N,N-dimethylformamide (8 mL). The mixture was stirred for 1 h at 70 °C. The mixture was cooled to room temperature and was diluted with water (5 ml). At this time, it was acidified by adding 1 N. hydrochloric acid (5 ml) and extracted with ethyl acetate (3 × 10 mL). The organic layer was removed. The aqueous layer was basified by adding saturated NaHCO3 solution (15 ml) and extracted with a mixed solution chloroform:isopropanol 3:1 (5 × 30 mL) and the organic layers were combined, dried over anhydrous sulfate sodium, filtered and concentrated under reduced pressure to give the crude product. The crude product (300 mg) was purified by preparative HPLC using the following conditions: gradient: Column: XBridge Prep OBD C18 Column, 30×150 mm 5 μm; Mobile phase A: Water (10 mM NH4HCO3+0.1 % NH3·H2O), Mobile phase B: ACN; Flow rate: 60 ml / min; Gradient: From 17 % B to 35% B in 8 min. Purification gave 2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazine-3- yl)oxy]phenyl]-6-[(methylamino)methyl]-4H-1,2,4-triazine-3,5-dione (64.8 mg, yield 18%) as a white solid solid. 1H NMR (300 MHz, DMSO-d6) δ 12.23 (br, 1H), 7.88 (s, 2H), 7.43 (s, 1H), 3.83 (s, 2H), 3.01-3.19 (m, 1H), 2.51 (s, 3H), 1.20 (d, J=6.9 Hz, 6H). LCMS (ESI, m / z): 453 [M+H]+. Compound 26 Compound 26 was prepared in the same manner as described for compound 24, using dimethylamine. instead of methylamine and left to react at 60 °C for 1 h. 1H NMR (300 MHz, DMSO-d6) δ 12.21 (w, 1H), 7.80 (s, 2H), 7.45 (s, 1H), 3.37 (w, 2H), 3.03-3.08 (m, 1H), 2.25 (s, 6H), 1.20 (d, J=6.9 Hz, 6H). LCMS (ESI, m / z): 467 [M+H]+. Example 21: Synthesis of compound 27 N H N Cl About Cl N N NH About About About N N N H N Cl About Cl N N NH About About About Br N NH 70°C, 1 hour 27 K2CO3, DMF A 100 ml round-bottom flask was charged with 6-(bromomethyl)-2-[3,5-dichloro-4-[(5-isopropyl-6- oxo-1H-pyridazin-3-yl)oxy]phenyl]-4H-1,2,4-triazine-3,5-dione (400.00 mg, 0.795 mmol, 1.00 equiv.), imidazole (64.95 mg, 0.954 mmol, 1.20 equiv.), potassium carbonate (219.75 mg, 1.590 mmol, 2.00 equiv.) and N,N- dimethylformamide (8 ml). The mixture was stirred for 1 h at 70 °C and cooled sequentially to room temperature and diluted with water (5 ml). At this time, it was acidified by adding 1 N. hydrochloric acid (5 mL) and extracted with ethyl acetate (3 × 10 mL). The organic layer was removed. The aqueous layer was basified by adding saturated NaHCO3 solution (15 mL) and extracted with a mixture chloroform:isopropanol 3:1 (5 × 30 mL) and the organic layers were combined, dried over anhydrous sulfate sodium, filtered and concentrated under reduced pressure to give the crude product. The crude product (150 mg) was purified by preparative HPLC using the following conditions: gradient: Column: XBridge Prep OBD C18 Column, 30×150 mm, 5 μm; Mobile phase A: Water (10 mM NH4HCO3+0.1 % NH3·H2O), Mobile phase B: ACN; Flow rate: 60 ml / min; Gradient: From 19 % B to 37% B in 8 min; Purification gave 2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazine-3- yl)oxy]phenyl]-6-(imidazol-1-ylmethyl)-4H-1,2,4-triazine-3,5-dione (14.5 mg, yield 4%) as a white solid substance. 1H NMR (300 MHz, DMSO-d6) δ 12.19 (s, 1H), 7.74 (s, 2H), 7.69 (s, 1H), 7.43 (s, 1H), 7.21 (s, 1H), 6.90 (s, 1H), 5.15 (s, 2H), 3.02-3.09 (m, 1H), 1.19 (d, J=6.9 Hz, 6H). LCMS (ESI, m / z): 490 [M+H]+. Example 22. Synthesis of compound 28 N N Cl About Cl N N N About About About F About F N N Cl About Cl N N H N About About O.O. 50 °C, 5 hours DMF CH2Cl, K2CO3 N H N Cl About Cl N N NH About About About FF BBr3, DCM, ct, 45min 28 60 °C, 2 hours i) 4M HCl in 1,4-dioxane ii) A stirred mixture of 4-[(benzyloxy)methyl]-6-[3,5-dichloro-4-[(5-isopropyl-6-methoxypyridazine-3- yl)oxy]phenyl]-2H-1,2,4-triazine-3,5-dione (310 mg, 0.569 mmol, 1.00 equiv.) and K2CO3 (630 mg, 4.56 mmol, 8.00 equiv.) in DMF (20 mL) was bubbled with difluorochloromethane for 4 h and the mixture was stirred for 5 h at 50 °C. The reaction mixture was quenched by adding water (50 ml). The resulting mixture extracted with EA (3 × 30 mL). The combined organic layers were washed with water (150 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography. chromatography on silica gel (eluting with PE:EA 2:1) to give 230 mg (65% yield) of 4- [(benzyloxy)methyl]-6-[3,5-dichloro-4-[(5-isopropyl-6-methoxypyridazin-3-yl)oxy]phenyl]-2- (difluoromethyl)-1,2,4-triazine-3,5-dione as a light yellow solid. LCMS (ESI, m / z): 594 [M+H]+. 4-[(benzyloxy)methyl]-6-[3,5-dichloro-4-[(5-isopropyl-6-methoxy-pyridazine-3- yl)oxy]phenyl]-2-(difluoromethyl)-1,2,4-triazine-3,5-dione (230 mg, 0.387 mmol, 1.00 equiv.) in solution hydrogen chloride (4 ml, 4M in 1,4-dioxane) for 2 h at 60 °C. After cooling to 25 °C, The resulting mixture was concentrated in vacuo. The residue was then diluted with DCM (5 mL) and a solution of BBr3 (1.5 mL, 1 M in DCM) was added dropwise at 25 °C. The final reaction mixture was stirred for 45 min. at 25 °C. The reaction mixture was quenched by the addition of water (1 mL). The resulting mixture was concentrated at under reduced pressure. The residue was purified by reverse phase chromatography (column: silica gel C18; Mobile phase, A: water (containing 10 mM NH4HCO3) and B: ACN (from 0% to 50% over 15 min); Detector: UV 220 / 254 nm). The product fractions were lyophilized to give 113.4 mg (63% yield) of 6-[3,5-dichloro-4- [(5-isopropyl-6-oxo-1H-pyridazin-3-yl)oxy]phenyl]-2-(difluoromethyl)-4H-1,2,4-triazine-3,5-dione in as a white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm: 12.78 (w s, 1H), 12.22 (w s, 1H), 7.99 (s, 2H), 7.83 (t, J=57.2 Hz, 1H), 7.45 (s, 1H), 3.13-2.98 (m, 1H), 1.20 (d, J=7.2 Hz, 6H). LCMS (ESI, m / z): 460 [M+H]+. Example 23 Synthesis of compound 29 N H N Cl About Cl N N NH About About About Br N H N Cl About Cl N N NH About About About About 29 MeONa DMF, 0 oC, 1h A 50 ml round-bottom flask was charged with 6-(bromomethyl)-2-[3,5-dichloro-4-[(5-isopropyl-6- oxo-1H-pyridazin-3-yl)oxy]phenyl]-4H-1,2,4-triazine-3,5-dione (400 mg, 0.795 mmol, 1.00 equiv.), N, N- dimethylformamide (8 mL) under nitrogen. Sodium methylate (0.50 mL, 30% w / w in methanol) at 0 °C. The mixture was stirred for 1 h at 0 °C. The mixture was acidified by adding 1 n. hydrochloric acid (5 ml) and extracted with ethyl acetate (3 × 15 ml). The organic layer was washed with brine (2 × 30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated at under reduced pressure. The residue was chromatographed on a silica gel column with a solution dichloromethane / methanol (10 / 1) to give the crude product (150 mg) and then purified preparative HPLC using the following gradient conditions: Column: XSelect CSH Prep C18 OBD Column, 5 μm, 19*150 mm; Mobile phase A: Water (0.1 % FA), Mobile phase B: ACN; Speed Flow rate: 25 mL / min; Gradien...

Claims

1. Compound of formula (I'): TL-La-CE-HD, (I') or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein: i) TL is a fragment of formulae (IIa), (IIb), (IIIa), (IIIb), (IIIc) or (IIId): , (IIa) , (IIb) , (IIIa) , (IIIb) , (IIIc) , (IIId) where: each of Q1, Q2, Q3, Q4, Q5, Q6 and Q8, independently, represents nitrogen or -CRb-, where each Rb independently represents hydrogen, halogen or C1-C5alkyl; R1 represents hydrogen, -CN, C1-C6alkyl, cyclopentyl, phenyl, (cyclopropyl)C1-C6alkyl, benzyl or -C(O)-Rj; where Rj represents -NRmRn or -ORm; Rm represents hydrogen or C1- C6alkyl; Rn represents C1-C6alkyl; or Rm and Rn, together with the nitrogen to which they are attached, form 1,2,3,4-tetrahydroisoquinoline; and R1 is optionally substituted with 1-3 Rk, independently selected from phenyl and C1-C6haloalkyl; R2 represents hydrogen; R3 represents hydrogen or C1-C5alkyl; R4 represents C1-C6alkyl, C2-C10alkenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyridazin-3(2H)-one, phenyl, naphthyl, pyridinyl, cinnolinyl, isoquinolinyl, quinolinyl, pyrazolo[1,5-a]pyridinyl, imidazo[1,5- a]pyridinyl, benzo[b]thiophenyl, (cyclopropyl)C1-C6alkyl group, (cyclobutyl)C1- C6alkyl group, (cyclopentyl)C1-C6alkyl group, benzyl group, (tetrahydrofuranyl)C1-C6alkyl group or (tetrahydropyranyl)C1-C6alkyl group; and R4 optionally substituted with 1-5 Rg independently selected from the group consisting of hydroxy, halogen, CN, C1-C6alkyl, C6-C10aryl, C1-C6alkoxy, C1-C6haloalkoxy and C6-C10aralkoxy, or two Rg together with the atoms to which they are attached form an aromatic or a non-aromatic 3- to 6-membered ring, optionally containing one or two ring members heteroatoms independently selected from oxygen, sulfur, or nitrogen; and R5 represents hydroxy, NH2, C1-C6alkylamino, C1-C6alkanoylamino or C1- C6alkylsulfonylamino; or R4 and R5, taken together with the carbon atoms to which they are attached, form a 3- to 6- a membered heterocycloalkyl ring containing from one to four ring members heteroatoms independently selected from oxygen, sulfur or nitrogen; and where the 3- to 6-membered a heterocycloalkyl ring optionally substituted with 1-5 Rg independently selected from the group, consisting of -CN, C1-C6alkyl optionally substituted with phenyl or C3- C9cycloalkyl; C1-C6haloalkyl; C2-C6alkenyl; C-carboxy; C-amido; C3-C9cycloalkyl; phenyl; amino; and oxo, and / or optionally two Rg together with the atom(s) to which they are attached attached, form a 3- to 6-membered non-aromatic carbocyclic group; and R11 represents phenyl optionally substituted with C1-C5alkyl, C1-C5alkoxy, C1- C5haloalkoxy, halogen or C3-C9cycloalkyl; pyridine optionally substituted with C1- C5alkyl; cinnolinyl; isoquinolinyl; quinolinyl; pyrazolo[1,5-a]pyridinyl; imidazo[1,5- a]pyridinyl; benz[b]thiophenyl; chromanyl; 1,2,3,4-tetrahydronaphthyl; or naphthyl; ii) CE is a fragment of formula (IV): , (IV) where: each of R6 and R7 is independently selected from halogen; -CN; C1-C5alkyl, optionally substituted 1-5 substituents independently selected from hydroxy, halogen and C1-C6alkoxy; or cyclopropyl; R8 represents hydrogen, C1-C5alkyl, cyano or halogen; optionally R7 and R8, taken together, together with the carbon atoms to which they are attached, form a 4-, 5- or 6-membered non-aromatic carbocyclic ring; Q7 represents nitrogen or -CRc-, where Rc represents hydrogen, halogen or C1-C5alkyl; (TL) denotes the point where the moiety of formula (IV) is attached to TL-La-; and (HD) denotes the point where the moiety of formula (IV) is attached to -HD; iii) HD is a fragment of formula (V): , (V) where: R9 represents -(C(Rd)2)nN(Rd)2; where each Rd independently represents hydrogen or optionally substituted C1-C5alkyl; each n is independently selected from 0, 1, 2, 3, 4 or 5; and La independently represents a bond; -(C(Ra)2)z-; oxygen; sulfur; or -NRa-; where: each Ra independently represents hydrogen or C1-C5alkyl; and z represents 0, 1, 2, 3, 4 or 5.

2. The compound of claim 1 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, where: TL is a fragment of formula (IIIb): (IIIb).

3. The compound of claim 1 or 2 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable a salt where R9 is -(CH2)nN(Rd)2.

4. A compound according to any one of claims 1-3 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable an acceptable salt, wherein R9 is -(CH2)-N(Rd)2 or -N(Rd)2.

5. A compound according to any one of claims 1-4 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, where R9 is -NH2.

6. A compound according to any one of claims 1-5 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, where Q4 represents -CH-, and Q5 represents nitrogen.

7. A compound according to any one of claims 1-6 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable an acceptable salt, wherein R4 is C1-C6alkyl.

8. The compound of claim 1 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, where: TL represents a fragment of formula (IIIa): (IIIa).

9. The compound of claim 8 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, where R9 represents -(CH2)nN(Rd)2.

10. The compound of claim 8 or 9 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable a salt where R9 is -N(Rd)2.

11. A compound according to any one of claims 8-10 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, where R9 is -NH2.

12. A compound according to any one of claims 8-11 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt wherein R4 and R5, taken together with the carbon atoms to which they are attached, form pyrrolidine optionally substituted with 1-5 Rg independently selected from the group consisting of C1-C6alkyl and oxo, and / or, optionally, two Rg together with the atom(s) to which they are attached attached, form a 3- to 6-membered non-aromatic carbocyclic group.

13. The compound of claim 12 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, where TL represents a fragment of formula (IIIaa): , (IIIaa) where each Rg independently represents C1-C6alkyl or two Rg together with the atom(s) to which they are attached they are attached, forming a 3- to 6-membered non-aromatic carbocyclic group.

14. The compound of claim 13 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, where two Rg together with the atom to which they are attached form a cyclopropyl group, a cyclobutyl group, a cyclopentyl group or a cyclohexyl group.

15. A compound according to any one of claims 8-11 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, where TL represents a fragment of formula (IIIab): , (IIIab) where Rg represents C1-C6alkyl.

16. The compound of claim 15 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, where Rg represents isopropyl.

17. A compound according to any one of claims 8-11 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, where TL represents a fragment of formula (IIIac): , (IIIac) where Rg represents C1-C6alkyl.

18. The compound of claim 17 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, where Rg represents methyl.

19. A compound according to any one of claims 8-11 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, where TL represents a fragment of formula (IIIad): , (IIIad) where each Rg independently represents hydrogen or C1-C6alkyl.

20. A compound according to any one of claims 8-11 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, wherein R4 is C1-C3alkyl.

21. A compound according to any one of claims 8-20 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, where Q4, Q5, and Q6 are -CH-.

22. A compound according to any one of claims 8-20 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, where Q4 represents -CH-, and Q5 and Q6 represent nitrogen.

23. A compound according to any one of claims 8-20 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, where Q4 represents nitrogen, and Q5 and Q6 represent -CH-.

24. The compound of claim 1 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, where: TL is a fragment of formula (IIId): (IIId).

25. The compound of claim 24 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, where R9 represents -(CH2)nN(Rd)2.

26. The compound of claim 24 or 25 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, where R9 is -N(Rd)2.

27. A compound according to any one of claims 24-26 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, wherein R9 is -NH2.

28. A compound according to any one of claims 24-27 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, where Q8 represents -CH- and Q5 represents nitrogen.

29. The compound of claim 1 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, where: TL is a fragment of formula (IIa): (IIa).

30. The compound of claim 29 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, where R9 represents -(CH2)nN(Rd)2.

31. The compound of claim 29 or 30 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, where R9 is -N(Rd)2.

32. A compound according to any one of claims 29-31 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, wherein R9 is -NH2.

33. A compound according to any one of claims 29-32 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, wherein R3 represents hydrogen.

34. A compound according to any one of claims 29-32 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, wherein R3 is C1-C5alkyl.

35. A compound according to any one of claims 29-34 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, wherein Q1, Q2, and Q3 are -CH-.

36. A compound according to any one of claims 29-34 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, where Q1 represents -CH-, and Q2 and Q3 represent nitrogen.

37. A compound according to any one of claims 29-34 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, where Q2 represents -CH-, and Q1 and Q3 represent nitrogen.

38. A compound according to any one of claims 29-34 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, where Q1 represents nitrogen, and Q2 and Q3 represent -CH-.

39. A compound according to any one of claims 29-34 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, where Q2 represents nitrogen, and Q1 and Q3 represent -CH-.

40. The compound of claim 1 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, where: TL is a fragment of formula (IIb): (IIb).

41. The compound of claim 40 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, where R9 represents -(CH2)nN(Rd)2.

42. The compound of claim 40 or 41 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, where R9 is -N(Rd)2.

43. A compound according to any one of claims 40-42 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, wherein R9 is -NH2.

44. A compound according to any one of claims 40-43 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, wherein R1 is C1-C6alkyl.

45. A compound according to any one of claims 40-44 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, wherein R3 represents hydrogen.

46. ​​A compound according to any one of claims 40-44 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, wherein R3 is C1-C5alkyl.

47. A compound according to any one of claims 40-46 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, where Q1, Q2 and Q3 are -CH-.

48. A compound according to any one of claims 40-46 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof a pharmaceutically acceptable salt, where Q1 represents -CH-, and Q2 and Q3 represent nitrogen.

49. The compound of claim 1 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, where: TL is a fragment of formula (IIIc): (IIIc).

50. A compound according to any one of claims 1-49 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt where La represents oxygen.

51. A compound according to any one of claims 1-49 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt where La represents -CH2-.

52. A compound according to any one of claims 1-51 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, where Q7 represents -CH-.

53. A compound according to any one of claims 1-52 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. acceptable salt, where each of R6 and R7 independently represents halogen or C1-C5alkyl optionally substituted with 1-5 substituents independently selected from hydroxy, halogen and C1-C6alkoxy; and R8 is hydrogen; or R6 represents halogen or C1-C5alkyl optionally substituted with 1-5 substituents, independently selected from hydroxy, halogen and C1-C6alkoxy; and R7 and R8, taken together, together with the atoms The carbons to which they are attached form a 4-, 5-, or 6-membered carbocyclic ring.

54. A compound according to any one of claims 1-52 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt where R6 is Cl, R7 is Cl, and R8 is hydrogen.

55. A compound according to any one of claims 1-52 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt where R6 is Cl, R7 is Cl, and R8 is methyl.

56. A compound according to any one of claims 1-52 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. an acceptable salt, wherein R6 is halogen, and R7 and R8, taken together, together with the carbon atoms, to to which they are attached, form a 4-membered carbocyclic ring.

57. A compound selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and , or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

58. A pharmaceutical composition comprising a compound according to any one of claims 1-57 or its a stereoisomer, or a tautomer thereof, or a pharmaceutically acceptable salt thereof and at least one a pharmaceutically acceptable excipient.

59. A method of treating a disorder or disease in a subject in need thereof, a method comprising comprising administering to a subject a therapeutically effective amount of a compound according to any one of claims 1-57 or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the disorder or disease selected from nonalcoholic steatohepatitis (NASH), obesity, hyperlipidemia, hypercholesterolemia, diabetes mellitus, liver steatosis, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer.

60. A method of treating a disorder or disease in a subject in need thereof, a method comprising comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition by item 58, wherein the disorder or disease is selected from nonalcoholic steatohepatitis (NASH), obesity, hyperlipidemia, hypercholesterolemia, diabetes mellitus, hepatic steatosis, atherosclerosis, cardiovascular disease, hypothyroidism and thyroid cancer.

61. Use of a compound according to any one of claims 1-57 or a stereoisomer thereof, or a tautomer thereof, or a tautomer thereof pharmaceutically acceptable salt, for the manufacture of medicaments for the treatment of the disorder or a disease selected from nonalcoholic steatohepatitis (NASH), obesity, hyperlipidemia, hypercholesterolemia, diabetes mellitus, hepatic steatosis, atherosclerosis, cardiovascular disease, hypothyroidism and thyroid cancer.

62. Method for treating a thyroid hormone receptor disorder in patient, which includes the stages: identifying a patient who needs treatment for a hormone receptor-related disorder thyroid gland, and administering to a patient or contacting a patient with the compound in any which of claims 1-57 or its stereoisomer, or its tautomer, or its pharmaceutically acceptable salt.

63. Method for treating a thyroid hormone receptor disorder in patient, which includes the stages: identifying a patient who needs treatment for a hormone receptor-related disorder thyroid gland, and administering to the patient or contacting the patient with the pharmaceutical composition according to item 58.

64. The method of claim 62 or 63, wherein the thyroid hormone receptor disorder is selected from nonalcoholic steatohepatitis (NASH), obesity, hyperlipidemia, hypercholesterolemia, diabetes, fatty liver, atherosclerosis, cardiovascular disease, hypothyroidism and cancer thyroid gland.

65. Method for selective modulation of the activity of thyroid hormone beta receptors (THR-) in a patient suffering from a disease or disorder selected from non-alcoholic steatohepatitis (NASH), obesity, hyperlipidemia, hypercholesterolemia, diabetes mellitus, fatty liver, atherosclerosis, cardiovascular disease, hypothyroidism and cancer thyroid gland, a method comprising contacting a compound according to any one of claims 1-57 or its stereoisomer, or tautomer thereof, or pharmaceutically acceptable salt thereof with a hormone receptor thyroid gland.

Citation Information

Patent Citations

  • Pyridazinone derivatives as thyroid hormone receptor agonists

    WO2007009913A1

  • Prodrugs to thyroid hormone analogs

    WO2009037172A1

  • Method of synthesizing thyroid hormone analogs and polymorphs thereof

    WO2014043706A1

  • Thyroid hormone receptor agonists

    WO2020073974A1